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iABSTRACT
Satellite cells are muscle-specific progenitor cells involved in the routine maintenance
of skeletal muscle homeostasis, growth and regeneration. They are activated by
various stimuli (myotrauma, growth factors etc), undergo rounds of proliferation as
skeletal muscle myoblasts, to differentiate and fuse with each other to generate new
myotubes or onto existing myofibres to augment growth or repair damaged fibres.
Satellite cells contribute to hypertrophy by facilitating nuclear addition, which
maintains contractile protein synthetic capacity. Conversely, during atrophy the
dysregulation of satellite cells (e.g., via myogenic suppression), causes an opposing
deficit in nuclear supplementation/contractile protein synthesis. The activity status of
satellite cells, an important determinant of muscle regenerative capacity is not
routinely addressed in studies characterising mechanisms of muscle hypertrophy and
atrophy. Therefore, the investigations described within this thesis examined the
satellite cell specific signalling events that contribute to muscle loss or gain, in rodent
models experiencing non-mechanically-induced muscle hypertrophy or atrophy.
Chronic administration of an anabolic agent (BRL-47672, the pro-drug of clenbuterol)
increased the expression of early components of satellite cell myogenesis (pax7, ki-67,
myoD) but caused no alteration in myogenin expression, relative to control in rat
soleus muscle. Pro-drug administration increased myostatin expression, with no
concomitant change in follistation mRNA; this is likely a compensatory mechanism to
check excessive muscle growth. These results provided evidence of increase satellite
cell activity in hypertrophying muscle. In a lipopolysaccharide (LPS)-infusion model
of muscle atrophy, satellite cells were inhibited in an inflammatory-dependent manner.
LPS infusion caused early (<2hr) elevations inflammatory cytokines TNF-D, IL-6 and
NF-NB. LPS-induced elevation in cytokine transcript levels paralleled increased
myostatin and decreased pax7 and myoD mRNA and protein expression. The
differential increase in cytokines also paralleled the reduction in the number of pax7
+
and myoD
+
satellite cells. These results suggest that alterations in satellite cell activity
may contribute to the progression of muscle atrophy, due to the suppression of muscle
compensatory mechanisms, which include satellite cell activation, differentiation and
fusion for nuclear supplementation. Co-infusion with an anti-inflammatory agent,
dexamethasone (Dex), blunted LPS-induced increase in inflammatory cytokines but
had an additive effect on myogenic suppression. Dex+LPS infusion prevented LPS-
induced increase in myogenin and resulted in an additional suppression of pax7 and
myoD, greater than that elicited by either substance alone. Negative regulation of
satellite cells by glucocorticoids could impede their efficacy in the treatment of
inflammatory muscle disorders.
The research within this thesis emphasise satellites are important for maintenance of
muscle homeostasis and their activation/inhibition, may determine the magnitude of
muscle loss or gain. This was demonstrated by the pattern of pax7 and myoD
expression in hypertrophying muscle, where both markers were up-regulated and in
atrophying muscle, where they were down-regulated. Down-regulation of these
markers in atrophy could have implications for muscle regenerative capacity,
especially myoD, whose expression was continuously inhibited across all time-points
sampled in septic muscles. Satellite cells are a major source of compensatory action in
skeletal muscle, their activation and subsequent myogenesis represents an auxiliary
mechanism by which muscle responds to damaging stimuli; therefore their
dysregulation (through the alteration of key myogenic markers) results in an alteration
of normal function. Such dysregulation, as frequently reported in cases or progressive
muscle degeneration and sarcopenia, limits the efficacy of muscle compensatory
processes (i.e. satellite cell activation/proliferative or differentiation potential), thereby
contributing to the progression of muscle atrophy and myopathy
ii
TABLE OF CONTENTS
ABSTRACT ....................................................................................................... i
TABLE OF CONTENTS ................................................................................. ii
ACKNOWLEDGEMENTS ............................................................................ vi
ABBREVIATIONS........................................................................................viii
DECLARATION ...........................................................................................xiii
CHAPTER 1: General Introduction............................................................... 1
1.1 Introduction and aims ................................................................................ 2
1.2 Satellite cell biology .................................................................................... 6
1.2.1 Overview of skeletal muscle and satellite cell structure .................... 6
1.2.2 Developmental origins of satellite cells. .......................................... 10
1.2.3 Satellite cell identification................................................................ 12
1.2.4. Satellite cell markers ....................................................................... 14
1.2.4.1 Quiescence................................................................................. 14
1.2.4.2 Activation and proliferation....................................................... 17
1.2.4.3 Differentiation and fusion.......................................................... 21
1.2.4.4 Negative regulatory markers...................................................... 22
1.2.5 Sequential events regulating satellite cell myogenesis..................... 24
1.2.6 Satellite cell self-renewal ................................................................. 27
1.2.5 Mechanisms modulating satellite cell activation and regulation...... 28
1.3 Satellite cell response to skeletal muscle hypertrophy .......................... 30
1.3.1 Definition of muscle hypertrophy .................................................... 30
1.3.2 Satellite cells and muscle hypertrophy............................................. 31
1.3.3 Summary of satellite cell activity in non-mechanically induced
hypertrophy models................................................................................... 32
1.4 Satellite cells during muscle atrophy ...................................................... 34
1.4.1 Overview of muscle atrophy ............................................................ 34
1.4.2 Satellite cell response to atrophic stimuli......................................... 35
1.5 Summary and hypotheses ........................................................................ 36
CHAPTER 2: General Methods.................................................................... 37
2.1 In vivo techniques...................................................................................... 38
iii
2.1.1 Ethics statement................................................................................ 38
2.1.2 E2-agonist pro-drug BRL-47672 study............................................. 38
2.1.1.1 Background................................................................................ 38
2.1.1.2 Animals and tissue collection .................................................... 40
2.1.2 Lipopolysaccharide (LPS) study ...................................................... 41
2.1.2.1 Background................................................................................ 41
2.1.2.2 Animals and surgical preparation .............................................. 41
2.1.2.3 Lipopolysaccharide administration and tissue collection .......... 42
2.1.3 Dexamethasone (Dex) study ............................................................ 43
2.1.3.1 Background................................................................................ 43
2.1.3.2 Animals and tissue collection .................................................... 43
2.2Molecular biology techniques .................................................................. 45
2.2.1 Analysis of mRNA expression ......................................................... 45
Quantitative real-time polymerase chain reaction (qRT-PCR) ................. 45
2.2.2 Total RNA extraction ....................................................................... 54
2.2.2.1 Formaldehyde gel electrophoresis ............................................. 55
2.2.3 cDNA synthesis................................................................................ 57
2.2.4 Taqman analysis ............................................................................... 57
2.2.4.1 DNA electrophoresis ................................................................. 58
2.2.5 Analysis of protein expression (Western blotting)........................... 61
2.2.5.1 Muscle protein extraction .......................................................... 61
2.2.5.2 Muscle protein quantification (Lowry assay) ............................ 62
2.2.5.3 Sodium dodecyl sulphate polyacrylamide gel electrophoresis
(SDS-PAGE).......................................................................................... 63
2.2.5.4 Western blotting......................................................................... 65
2.2.6 Histological analyses........................................................................ 67
2.2.6.1 Immunohistochemistry .............................................................. 67
2.2.6.2 Immunofluorescence.................................................................. 69
2.2.6.3 Duolink
®
Bright-field Proximity Ligation Assay (PLA)........... 70
2.2.6.4 Muscle Fibre Diameter Determination ...................................... 73
2.2.6.4.1 Image acquisition and analyses ...................................... 73
2.2.6.5 Stereology .................................................................................. 78
CHAPTER 3: Chronic administration of the clenbuterol pro-drug BRL-
4767 increases satellite cell activity ............................................................... 81
3.1 Summary ................................................................................................... 82
3.2 Introduction .............................................................................................. 84
iv
3.3 Methods ..................................................................................................... 90
3.3.1 Animals and tissue collection........................................................... 90
3.3.2 Analysis of muscle fibre hypertrophy .............................................. 90
3.3.3 mRNA Measurements (Real Time PCR .......................................... 90
3.3.4 Protein measurements (Western blotting) ........................................ 92
3.3.5 Statistical Analyses........................................................................... 96
3.4 Results ........................................................................................................ 97
3.4.1 Analysis of muscle fibre diameter.................................................... 97
3.4.2 mRNA and protein expression of muscle specific markers ............. 97
3.4.2 Myostatin Protein Expression ........................................................ 103
3.5 Discussion ................................................................................................ 109
CHAPTER 4: Continuous lipopolysaccharide infusion suppresses
components of the satellite cell myogenic program ................................... 117
4.1 Summary ................................................................................................. 118
4.2 Introduction ............................................................................................ 120
4.3 Methods ................................................................................................... 128
4.3.1 Animals and tissue collection......................................................... 128
4.3.2 mRNA measurements (real-time PCR).......................................... 129
4.3.3 Protein measurements (Western Blotting) ..................................... 131
4.3.4 Histology ........................................................................................ 131
4.3.4.1 Immunohistochemistry ............................................................ 131
4.3.4.2 Immunofluorescence................................................................ 133
4.3.4.3 Duolink
®
Bright-field Proximity Ligation Assay (PLA)......... 134
4.3.4.4 Stereology ................................................................................ 135
4.3.5 Statistical analyses.......................................................................... 137
4.4 Results ...................................................................................................... 138
4.4.1 Inflammatory Cytokines................................................................. 138
4.4.2 Macrophage Infiltration.................................................................. 147
4.4.3 TNF-D/macrophage co-localisation ............................................... 154
4.4.4 Myogenic Regulatory Factors (MRFs)........................................... 158
4.4.5. Myostatin....................................................................................... 169
4.5 Discussion ................................................................................................ 175
CHAPTER 5: Co-infusion of low dose dexamethasone is additive to
lipopolysaccharide-induced myogenic suppression ................................... 185
v5.1 Summary ................................................................................................. 186
5.2 Introduction ............................................................................................ 188
5.3 Methods ................................................................................................... 191
5.3.1 Animals and tissue collection......................................................... 191
5.3.2 mRNA measurements (real-time PCR).......................................... 192
5.3.3 Protein Measurements (Western Blotting) ..................................... 192
5.3.4 Statistical Analyses......................................................................... 195
5.4 Results ...................................................................................................... 196
5.4.1 Cytokines........................................................................................ 196
5.4.2 Myogenic Regulatory Factors (MRFs)........................................... 203
5.4.3 Myostatin........................................................................................ 208
5.5 Discussion ................................................................................................ 210
CHAPTER 6: General Discussion............................................................... 220
6.1 Overview of thesis ................................................................................... 221
6.2 Conclusions.............................................................................................. 224
6.3 Limitations and future directions ......................................................... 226
METHOD DEVELOPMENT APPENDICES ........................................... 230
Appendix I ..................................................................................................... 231
1. Rationale.............................................................................................. 232
2. Methods ............................................................................................... 233
2.1 Myostatin competitive blocking studies ........................................ 233
2.2 Minimum myostatin protein concentration for western blotting... 234
3. Observations and conclusions ............................................................. 234
Appendix II ................................................................................................... 240
1. Summary ............................................................................................. 241
2. Background ......................................................................................... 243
3. Methods ............................................................................................... 246
4. Results ................................................................................................. 248
5. Discussion ........................................................................................... 251
REFERENCES ............................................................................................. 257
vi
ACKNOWLEDGEMENTS
Firstly, I would like to thank my supervisors, Dr Rudi Billeter-Clark and
Professor Paul Greenhaff for their guidance and support during my PhD. Id
especially like t thank Rudi for all his time, effort and guidance over the last
four years. I could not have wished for a better primary supervisor, his
expertise, enthusiasm for the project, and willingness to help have had an
immeasurable influence on my scientific development.
Id also like to thank Dr Rob Layfield and the members of lab D45, for the use
of his lab facilities, the occasional pinching of reagents and helpful advice on
protein biochemistry. I am grateful to Dr Peter Wigmore, not only for his kind
donation of Ki-67 antibodies but also for his helpful assessments of my annual
reports. I would also like to thank Professor Terry Mayhew for his useful
advice of stereology. I must also thank Drs Andy Bennett (for the kind
donation of a thermal cycler) and Lynn Bedford, and the members of their labs,
for allowing me free use of their equipment and facilities. I owe a huge debt of
gratitude to Dr Emma King and the members of the AMU (Denise Christie,
Marie Smith and Ian Ward), whose friendship, support and advice has been of
tremendous value to me during the course of my PhD.
Secondly, Id like to thank all the people in and around Nottingham who
helped me not only with my research, but have also been a social outlet during
the years; particularly the lunch bunch (Barry Shaw, Alice Goode, Ryan
Atkins, Laura Lyons, Katherine Bridge, Dan Foxler, Vicky James, Donna
Bentley  I am sorry if Ive omitted anyone) and the D83 office crew (Ricardo
Samms, Chris Shannon, Chris Gaffney and Kevin Bailey). Id also like to
thank Sarah Skirrow for her friendship, the proof reading service (I liked the
smiley faces) and interesting office conversations. I am eternally indebted to Jo
Strachan, I am not sure the last four years would have gone as smoothly
without her influence. As well as being a brilliant work colleague, her
friendship has been of tremendous value to me  thanks so much for letting me
bend your ear a few times (well, a lot actually!), stay at your place so often and
just generally being a social relief from thesisness.
vii
Thirdly, for their support and camaraderie, Id like to thanks all my friends in
Nottingham, especially Chris McHugh, James Henstock, Alex Hulse, Benjamin
Whitehead, Jonathan Alldis, John Boden and Gary Patmore, who ensured I
took occasional breaks from my studies. I realise this is probably
unprecedented but must also thank my haematologist, Dr Marie Donohue and
the members of staff at the Centre for Clinical Heamatology, particularly,
Maxine, Emma, Fay, Cath, Kay and the two Anges  thank you so much for
putting up with my veins and for making the Day Unit feel like a second home
over the last seven years.
My special and genuine thanks to Marion Adair, who always ensured I was
fed, watered and generally well-looked after during the writing of this thesis.
Id also like to thank my family for all their support during the course of my
education, especially my sister Aminata, who has been a rock during these last
three years. Lastly, but certainly not the least, Id like to dedicate this thesis to
Kevin T. Adair, without whom, the last four and a half years would have
simply been impossible  thank you for putting up with me, especially during
the production of this thesis.
viii
ABBREVIATIONS
ABC Avidin biotin complex
ACTH Adrenocorticotrophic hormone
ADAM12 A disintegrin and metalloproteinase-domain-containing protein 12
ADAM12 A disintegrin and metalloproteinase-domain-containing protein 17
ALK-4/5 Activin receptor-like kinase-4/5
ANOVA Analysis of variance
APS Ammonium persulphate
ATP Adenosine triphosphate
bHLH basic helix-loop-helix
BMP Bone morphogentic protein
BSA Bovine serum albumin
cAMP Cyclic adenosine monophosphate
CD14 Monocyte differentiation antigen CD14
CD34 hematopoietic progenitor cell antigen CD34
CD45 Receptor-type tyrosine-protein phosphatase C
cDNA complementary DNA
CLP Caecal ligation and puncture
c-met Hepatocyte growth factor receptor
c-Myc Myc proto-oncogene protein
COX Cytochrome-c oxidase
Ct Cycle threshold
DAB 3, 3-diaminobenzidine
DAPI 4',6-diamidino-2-phenylindole
dATP deoxyadenosine tri-phosphate
dCTP deoxycytidine tri-phosphate
Dex Dexamethason
dGTP deoxyguanosine tri-phosphate
ix
DMD Duchenne muscular dystrophy
DNA Deoxyribonucleic acid
DTT Dithiothreitol
dTTP deoxythymidine tri-phosphate
dUTP deoxyuridine tri-phosphate
E3 Ubiquitin ligase
ECL Enhanced Chemiluminescence
EGF Endothelial-derived growth factor
EDL Extensor digitorum longus
EDTA Ethylenediaminetetraacetic acid
EGTA Ethylene glycol tetraacetic acid
eIF Eukaryotic initiation factor
eIF2B Eukaryotic initiation factor 2B
ERK Extracellular regulated kinase
FAM 6-carboxyl-fluorescein
FGF Fibroblast growth factor
flk Vascular endothelial growth factor receptor 2
FRET Fluorescent resonance energy transfer
GAB Gel application buffer
GDF8 Growth and differentiation factor 8 (myostatin)
GFP Green fluorescent protein
GILZ Glucocoticoid-induced leucine zipper
GRE Glucocorticoid response element
GSEA Gene Set Enrichment Analysis
GSK3 Glycogen synthase kinase 3
GTG Genetic technology grade
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
HGF Hepatocyte growth factor
HLH Helix-loop-helix
xHMBS Hydroxymethylbilane synthase
HRP Hydrogen peroxide
HPA Hypothalamic-pitituary-adrenal axis
i.p. intraperitoneal
i.v. intravenous
Iba-1 Ionised calcium binding adaptor molecule-1
IHC Immunohistochemistry
IGF-I/II Insulin-like growth factor I/II
INB Inhibitory proteins of kB family
IKK INB kinase
IL-1 Interleukin-1
IL-6 Interleukin-6
IL-10 Interleukin-10
IL-10R Interleukin-10 receptor
IRAK IL-1 receptor-associated kinase
Ki-67 antigen identified by monoclonal antibody Ki-67
LAP Latency associated peptide
LIF Leukaemia inhibitory factor
LPS Lipopolysaccharide
MAFbx Muscle atrophy F-box
MAPK Mitogen-activated protein kinase
MD2 Myeloid differentiation protein-2
MEF2 Myocyte enhancer factor 2
MGB Minor groove binder
MHC Myosin heavy chain
MMLV Maloney murine leukaemia virus
MOPS 3-(N-morpholino) propanesulfonic acid
mRNA messenger RNA
mTOR mammalian target of rapamycin
xi
MuRF1 Muscle RING-finger 1
MyD88 Myeloid differentiation primary gene 88
Myf5 Myogenic factor 5
MyoD Myogenic determination factor 1
NCAM Neural cell adhesion molecule
NF-NB Nuclear factor kappa B
NFQ Non-fluorescent quencher
NLS Nuclear localisation signal
NO Nitric oxide
NOS Nitric oxide synthase
NSAID Non-steroidal anti-inflammatory drug
OCT Optimal cutting temperature
p38 MAPK p38 mitogen-activated protein kinase
Pax3 Paired box 3 transcription factor
Pax7 Paired box 7 transcription factor
PBGB Porphobilinogen deaminase
PBS Phosphate-buffered saline
PCR Polymerase chain reaction
PDGF Platelet-derived growth factor
PFA Paraformaldehyde
PI3K Phosphatidylinositol 3-kinase
PKA Protein kinase A
PLA Proximity ligation assay
qRT-PCR Quantitative real-time PCR
RHD Rel homology domain
RNA Ribonucleic acid
ROS Reactive oxygen species
RT Reverse transcriptase
s.c. subcutaneous
xii
sca-1 Putative surface cell antigen sca1
SDS Sodium Dodecyl Sulphate
SDS Sequence detection system
SDS-PAGE Sodium Dodecyl Sulphate polyacrylamide gel electrophoresis
SEM Standard error of the mean
siRNA Short-interfering ribonucleic acid
SMAD Mothers against decapentaplegic homolog
STAT3 Signal transducer and activator of transcription 3
TA Tibialis anteroir
TBE Tris-Borate-EDTA
TBS Tris-Buffered-Saline
TEMED Tetramethylethylenediamine
TGF-E Transforming growth factor beta
TLR4 Toll-like receptor 4
TNF-D Tumour necrosis factor alpha
TRAF6 TNF-receptor associated factor 6
TUNEL Terminal deoxynucleotidyl transferase dUTP nick end labelling
UV Ultraviolet
VCAM-1 Vascular cell adhesion molecule 1
xiii
DECLARATION
I hereby confirm the work contained within this thesis was the result of
experimental work done by me, with a few exceptions noted below:
Chapter 3  Animal work and tissue collection was carried out by David Baker
and Simon Jones.
Chapters 4 and 5  Animal work and tissue collection was conducted by Julie
March and Phillip Kemp.
In chapter 5, cDNA synthesis and protein extraction was carried out by Hannah
Crossland
1CHAPTER 1
General Introduction
21.1 INTRODUCTION AND AIMS
Satellite cells are muscle-specific progenitor cells found in adult skeletal
muscle fibres between the basal lamina and the sarcolema. They are activated
by various stimuli (exercise, myotrauma, or trophic factors, e.g. HGF) to
undergo rounds of proliferation and may commit to myogenic lineage. This
usually includes differentiation into skeletal muscle myoblasts, and the lining
up and fusion of these myoblasts to form myotubes; these eventually mature
into myofibres (summarised in figure 1.1). Myoblasts can also fuse into
existing muscle fibres, to support growth or fuse to damaged muscle fibres to
facilitate repair following injury.
Skeletal muscle is the most abundant tissue in mammals with the capacity to
adapt to physiological demands such as postnatal growth, training or injury.
However, adult skeletal muscle fibres are terminally differentiated cellular
entities, with each fibre nucleus serving a limited cytoplasmic domain and thus
providing limited synthetic capacity. Therefore, a muscles remarkable ability
for self-repair and physiological adaptation is dependent on its satellite cells, as
a source of new nuclei. Adult skeletal muscle homeostasis is precisely adjusted
between (contractile) protein synthesis and degradation, their balance is
deterministic for muscle hypertrophy or atrophy. Activation, proliferation,
differentiation and fusion of satellite cells may ultimately be required for
muscle hypertrophy  via reducing nuclear domain size and increasing
synthetic capacity. Conversely, the opposing phenomenon is the loss of nuclei
(e.g. by apoptosis of myonuclei and satellite cells during muscle atrophy),
3Figure 1.1: Schematic representation of Skeletal Muscle Satellite Cell
Myogenesis. Mitotically quiescent satellite cells in adult muscle express the
canonical specification marker pax7; activated satellite cells are denoted by
cytoplasmic expansion and increased expression of myoD and myogenin is up-
regulated during differentiation.
4which causes an increase in the nuclear domain size and a reduction in protein
synthetic capacity. The activity status of satellite cells, denoted by expression
of certain myogenic markers (e.g., myogenic determination factor 1, (myoD)
for activation), is a major determinant of skeletal muscle regenerative capacity
and growth. Therefore an impairment or inhibition of satellite cell
activity/function (e.g., via alteration of key myogenic regulatory factors,
MRFs) could result in attenuation of muscle growth or lead to a reduction in
muscle regenerative potential, which could contribute to progressive muscle
degeneration.
The mechanisms of satellite cell regulation are not fully understood; activated
satellite cells do not always commit to differentiation, but can return to a
quiescent, undifferentiated state. For example, satellite cells activated during
mild exercise soon return to quiescence upon cessation of training. It is thought
this ability of some activated satellite cells to return to quiescence is likely a
mechanism for self renewal; however it is still undetermined what dictates
which satellite cells undergo self-renewal and which ones ultimately
differentiate. The process of activation or maintenance of quiescence is
complex, it appears linked to a balance between intrinsic (e.g. myogenic
regulatory factors) and extrinsic factors (stretch, trauma, growth factors, etc),
whose activity and/ or frequency provides impetus for satellite cell
myogenesis. Given the crucial role of satellite cells in the maintenance of
muscle homeostasis, a more comprehensive understanding of satellite cell
activity in rodent models characterised by muscle hypertrophy and atrophy
should further illuminate our knowledge of muscle biology, which could
5facilitate the development of novel techniques and therapies for affected
muscles.
The experiments described within this thesis aim to elucidate satellite cell
specific signalling events in rodent models associated with muscle hypertrophy
and atrophy. More specifically, the aims of the present investigations are;
i) To examine myogenic signalling events in hypertrophying muscle
induced by chronic administration of an anabolic agent; the clenbuterol
pro-drug BRL-47672.
ii) To examine the temporal aspects of inflammatory cytokine signalling
during endotoxaemia (by continuous infusion of lipopolysaccharide)
and the impact on components of the satellite cell myogenic program,
in order to determine factors that contribute to progressive
inflammation-induced muscle wasting.
iii) To determine whether a strategy aimed at reducing excessive
lipopolysaccharide-induced muscle inflammation (i.e., administration
of an anti-inflammatory agent dexamethasone) alters satellite cell
activity towards improvement of inflammation-induced muscle wasting.
61.2 SATELLITE CELL BIOLOGY
1.2.1 Overview of skeletal muscle and satellite cell structure
Skeletal muscle accounts for just over a third of adult body mass (reviewed by
Janssen et al. 2000); it is composed of bundles of repeated contractile units of
post-mitotic multi-nucleated muscle fibres. Individual myofibres are
surrounded by a basal lamina (called the basement membrane in light
microscopy), beneath which a population of muscle progenitor cells (satellite
cells) are located. These myofibres are syncytial cells stacked with an array of
myofibrils consisting of thick (myosin) and thin (actin) filaments organised
into contractile units called sarcomeres (summarised in figure 1.2). Sliding of
the two contractile filaments actin and myosin, in a ratchet-style motion whilst
utilising adenosine tri-phosphate (ATP) reduces the distance of opposing ends
of the sarcomere (Z-lines; consisting of D-actinin and titin, by which actin and
myosin filaments are attached to the Z-line), thus shortening the sarcomeres
and causing muscle contraction (reviewed by Jarosch 2000).
The contractile and metabolic properties vary between muscle fibres and are
categorised into two groups: slow-twitch (type 1  prevalent in rat soleus)
muscle fibres, which utilise mitochondrial respiration and fast-twitch muscle
fibres (prevalent in e.g. rat extensor digitorum longus). Fast-twitch muscle
fibres are further sub-divided into three main groups; type 2A, type 2B and
type 2X fibres, all of which favour glycolytic cellular metabolism and have a
faster contraction time and a more rapid relaxation compared to slow-twitch
fibres. In rodents, the proportion of satellite cells associated with type I fibres
is higher than those in contact with type II fibres
7Figure 1.2: Summary of Skeletal Muscle and Satellite Cell Structure. A; Skeletal muscle is composed of repeating units of sarcomeres, myofibrils, myofibres, and muscle
fibre bundles. Satellite cells reside in a sub-laminar indentation between myofibres surrounded by the basal lamina. Satellite cells are also distinguishable from myonuclei by
their cytoplasmic processes and more abundant heterochromatin (Adapted from Hawke and Garry 2001). B; High magnification electron micrograph showing the close
association between a satellite cell and the basal lamina (bm), which surrounds it completely, and the apposing plasma membranes of the myofibre (mp) and the satellite cell
(sp) (Adapted from Mauro 1961).
8(Schmalbruch and Hellhammer 1977; Gibson and Schultz 1982). The satellite
cell content of predominantly oxidative (type I) muscles tends to be 5-6 times
greater in rats than that of predominantly glycolytic (type II) muscles; it is
thought the increased satellite cell content is due to a combination of increased
capillarity and motor-neuron density in slow oxidative muscles, compared to
fast glycolytic ones. Increased satellite cell density is found with the proximity
of capillaries and at motor-end plates (Wokke et al. 1989). It has also been
suggested that since slow fibres are the first and most frequently recruited for
muscle activity (e.g. the soleus muscle experiences a constant pull in
maintaining standing posture), they perhaps require a larger satellite cell pool
to parallel the daily micro-injuries occurred as a result (Schultz 1989).
Satellite cells have been the point of much discussion since their initial
description by two papers in 1961 (Katz 1961; Mauro 1961). They are so
named due to their anatomical position underneath the basal lamina and they
occupy an identical anatomical position in most vertebrates. This close
association with the basal lamina enables a sense of immediacy between
satellite cells and myofibres and may function as a sensor for muscle fibre
mechanical, structural and functional integrity. For decades, electron
microscopy was the only definitive method for identifying and studying
satellite cells until the discovery of satellite cell-specific molecular markers,
most notably the satellite cell specification marker paired box transcription
factor 7 (pax7) (Seale et al. 2000)  thus making their identification and
characterisation more accessible by light microscopy (see figure 1.3).
Immunohistochemical techniques using specific molecular markers are very
useful for deciphering the activity status of satellite cells but ultrastructural
9Figure 1.3: Light and fluorescence micrographs of pax7 positive satellite cells on untreated rat soleus muscle cross-sections. Note satellite
cells are a sparse population of cells, as denoted by the proportion of satellite cells to myonuclei in the fluorescence photomicrograph
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techniques have enhanced our understanding of satellite cell structure and
morphology. Satellite cells were described by Muir et al. (1965) as flattened,
spindle-shaped structures that align in parallel to the axis of myofibres in intact
adult muscle (see figure 1.2b). Schmalbruch (1978) noted that virtually all
satellite cells exhibit cytoplasmic process that extend from the poles of the
cells, and activation of satellite cells by myotrauma or denervation causes a
significant increase in branching. This branching nature of cytoplasmic
processes is thought to aid the fusion process or migratory activity on
myofibres to sites of trauma (Schultz 1976; Watt et al. 1987). The physical and
morphological characteristics of quiescent satellite cells include a small nuclear
size relative to myonuclei (Watkins and Cullen 1988), high nuclear to
cytoplasmic ratio, with few organelles and large amounts of heterochromatin
compared to myonuclei (reviewed by Schultz and McCormick 1994). These
findings support the idea that satellite cells in adult muscle are predominantly
quiescent and transcriptionally less active. Activated satellite cells tend have a
higher number of organelles compared to quiescent cells, a high number of
caveolae (invaginations of plasma membrane observed in most cell types) and
reduced heterochromatin (reviewed by Champion 1984). Activated satellite
cells are also more easily identified as they appear as swellings on the myofibre
as a result of cytoplasmic extension and increased mitotic activity.
1.2.2 Developmental origins of satellite cells.
In the early stages of embryonic development of mammals and birds, the
mesoderm germ layer (from which skeletal muscle is derived), differentiates
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into transitory structures on either side of the neural tube, collectively known
as the somite (Armand et al. 1983). Satellite cells are thought to be derivatives
of the somite; fate-mapping and chimeric interspecies grafting experiments in
avian embryos demonstrated that transplanted embryonic somatic cells with
distinguishing morphological characteristics to those of the host embryo
migrated from the somite and contributed to the development of the limb
musculature and the postnatal skeletal muscle satellite cell population (Le
Douarin and Barq 1969; Christ et al. 1974). The head, trunk and limb muscles
all develop from the somites but as separate lineages. The somites are further
subdivided into two domains; the epaxial (gives rise to muscles of the back)
and the hypaxial (develops into intercostal, abdominal and limb musculature)
(Ordahl and Le Douarin 1992; Ben-Yair et al. 2003).
Intriguingly, De Angelis et al. (1999) proposed that satellite cells may also be
derived from a non-somitic origin; cells isolated from the embryonic dorsal
aorta had similar morphorlogical characteristics and gene expression profiles to
somite-derived satellite cells, and their transplantation into newborn mice
contributed to postnatal muscle growth. Furthermore, Tzahor et al. (2003)
provided evidence of non-somitic satellite cells, exemplified by some head
muscles, which are derived from the prechordal mesoderm rather than the
somites. It is possible satellite cells derived from either source may not be
mutually exclusive and both lineages could contribute to the postnatal satellite
cell population. Future fate-mapping experiments will have to delineate the
derivation of all satellite cells resident in adult skeletal muscle.
During somitogenesis, it is thought cross-talk between growth factors such as
Wnt proteins, Notch, sonic hedge hog, bone morphogenetic proteins (BMPs)
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and myogenic transcription factors (myogenic factor 5 (myf5), myoD, pax3/7,
etc) between the developing somite and anatomically adjacent structures such
as the ectoderm generates temporally and spatially distinct lineages of
myogenic cells that ultimately lead to the formation of skeletal muscles
(reviewed by Miller et al. 1999). Avian satellite cells are first detected during
the latter stages of embryonic development (around embryonic day 18), upon
formation of the basement membranes and myofibres (Hartley et al. 1992). In
rodents, satellite cells are present in the limbs of mid-gestational mouse
embryos (around embryonic day 15-16) (Cossu et al. 1987). Satellite cell
numbers drop during maturation; they account for approximately 30% of
muscle nuclei in the perinatal hindlimb skeletal muscle but reduce to about
10% by postnatal day 28 and plateau to approximately 2-7% of total muscle
nuclei in adult muscle (Allbrook et al. 1971; Schultz 1974; Halevy et al. 2004).
During the neonatal growth phase, as muscles enlarge, satellite cells are
proliferative and add nuclei to growing myofibres but they are typically
quiescent in mature adult muscle unless activated by various factors for
maintenance and repair.
1.2.3 Satellite cell identification
As mentioned above, satellite cell identification has historically relied on the
use of ultrastructural techniques (electron microscopy) and by definition
constitutes all single nuclei cells located beneath the basal lamina and just
above the plasmalemma of a myofibre regardless of the function or gene
expression profile. In practice however, the use of immunohistochemical
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techniques based on the expression of a range of specific markers that can be
detected by immunostaining represents a more efficient means of satellite cell
identification in their native position. A limiting factor in this field is the fact
that the gene expression profiles of quiescent and activated satellite cells are
largely unknown. Recently, the use of genetically modified reporter mice has
enabled direct detection of satellite cells, based on the specific expression of a
fluorophore (e.g. green fluorescent protein; GFP) or via a reporter dye system
such as E-galactosidase. For example, in nestin-GFP transgenic mice (Mignone
et al. 2004), GFP expression is driven by regulatory elements of the
intermediate filament, nestin, which labels progenitor cells and enables
detection of quiescent satellite cells in isolated myofibres (Day et al. 2007).
Similarly, the Myf5
nLacZ/+
transgenic mouse (Tajbakhsh et al. 1996), in which
one of the Myf5 alleles is modified to drive lacZ expression, results in the
presence of E-galactosidase protein in the nuclei of satellite cells, thus allowing
detection of satellite cells in the presence of X-gal by a distinctive blue stain
(Beauchamp et al. 2000). Another transgenic strain frequently used to label
satellite cells is the MLC3F-nLacZ transgenic mice (Kelly et al. 1995), in
which the regulatory elements of myosin light chain (MLC) direct LacZ
expression in myonuclei but not satellite cells, thus providing a means of
distinguishing between satellite cells and myonuclei (Beauchamp et al. 2000).
Crosses of nestin-GFP and Myf5
nLacZ/+
or MLC3F-nLacZ transgenic mice
enable detection of satellite cells by direct fluorescence and X-gal staining. For
example, the double nestin-GFP/MLC3F-nLacZ transgenic mouse shows clear
distinction between satellite cells (GFP
+
/X-gal
-1
) and myonuclei (GFP

/X-gal
+
)
(Day et al. 2010).
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1.2.4. Satellite cell markers
1.2.4.1 Quiescence
Many regard satellite cell quiescence as a state characterised by decreased cell
size and metabolic activity; however the work of Yusuf and Fruman (2003) on
quiescent lymphocytes discovered quiescence is not merely an inactive basal
state but one that is under active transcriptional control. The study of satellite
cell quiescence is often fraught with difficulty since they are a relatively small
population of cells in vivo and their isolation often results in activation. The
location of satellite cells beneath the basal lamina means that disturbance to the
satellite cell microenvironment increases the probability of activation, which
may alter the gene expression profile. The close association between the
myofiber and the satellite cells suggests active communication between the two
and may be essential for maintaining quiescence. Furthermore, quiescent
satellite cells have also been shown to express syndecan-3, syndecan-4 and c-
met, the hepatocyte growth factor (HGF) receptor, the latter of which is also
expressed by activated satellite cells. All are involved in signal transduction
pathways essential for early activation and proliferation of quiescent satellite
cells and may be responsible for maintaining a state of readiness for
activation (Tatsumi et al. 1998).
Pax7 is the most useful genetic marker for identifying quiescent and activated
satellite cells (see figure 1.3); it has been implicated in satellite cell
specification, as the survival of mice lacking the pax7 gene was compromised
(Seale et al. 2000). The pax7 gene is a member of the paired box containing
gene family, involved in the development of skeletal muscle, organogenesis
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and maintenance of pluripotent stem cell populations (reviewed by Chi and
Epstein 2002). It is commonly expressed in satellite cells but it is down-
regulated upon myogenic differentiation, thus marking pax7 an important
marker for quiescent and activated/proliferating satellite cells. Intriguingly, the
skeletal muscles of pax7
/
mice lack satellite cells and myoblasts are unable to
undergo myogenesis when cultured. Pax7 null mice appear normal at birth but
fail to grow postnatally, lose approximately 50% of their body weight by 7
days compared with wild type litter-mates and usually perish within 2 weeks
after birth (Mansouri et al. 1996). This suggests pax7 is vital for muscle
function and it is indisputably, required for satellite cell development. Recent
evidence suggests pax7 is able to maintain satellite cell quiescence by inducing
inhibitory helix-loop-helix (HLH) proteins  inhibitors of differentiation (Id)
proteins (Id2 and Id3), which block the DNA binding activity of myogenic
regulatory factors (Kumar et al. 2009).
Several other markers of quiescent satellite cells have been described including
the muscle specific cell adhesion molecule M-Cadherin, CD34 (a cell surface
cell-cell adhesion glycoprotein also localised to cells of the haematopoietic and
endothelial cell lineages) and myocyte nuclear factor (MNF) (reviewed in
Hawke and Garry 2001; Wozniak et al. 2005; Zammit et al. 2006). M-
Cadherin is usually expressed in quiescent satellite cells but its expression has
been shown to be up-regulated in upon activation; especially in response to
denervation or traumatic injury (Irintchev et al. 1994; Cornelison and Wold
1997). Other recent markers discovered in quiescent satellite cells include
lysenin (Nagata et al. 2006) and caveolin-1, a membrane protein that forms
oligomers and associates with sphingolipids and cholesterol to give rise to
16
caveolae (Volonte et al. 2004). Neural cell adhesion molecule (NCAM) and
vascular adhesion molecule-1 (VCAM-1) are also potential markers of
quiescent satellite cells.
The molecular signature of quiescent satellite cells in adult skeletal muscle
retains the cells proliferative and differentiative potential throughout their
lifetime and as such, an increase in expression of some genes such as myostatin
is observed. Lines of evidence suggest myostatin, a negative regulator of
muscle mass (McPherron et al. 1997) is expressed in quiescent satellite cells
and myostatin null mice have an increased percentage of actively proliferating
satellite cells compared to wild type littermates (McCroskery et al. 2003).
Myostatin induces a potent cyclin-dependent kinase inhibitor, p21, which
inhibits cell cycle progression and maintains quiescence (Fukada et al. 2007).
There is also increasing evidence for the role of myoD (a prominent marker of
activation) suppression in the maintenance of satellite cell
quiescent/proliferative state. Pax7 overexpression results in a decrease in
myoD protein and promotes activated satellite cells to reacquire a quiescent,
undifferentiated state (Olguin and Olwin 2004). Similarly, the overexpression
of metalloprotease disintergrin ADAM12 protein in proliferating C2C12
myoblasts has been shown to suppress myoD protein and lead to the up-
regulation of quiescence makers p130 and p27, cell cycle arrest and a
quiescence-like phenotype that does not stimulate differentiation (Cao et al.
2003). Gene Set Enrichment Analysis (GSEA) of quiescent satellite cells
observed an up-regulation of gene sets involved in cell-cell adhesion, extra-
cellular matrix maintenance, growth, lipid transport and copper, iron and
calcium homeostasis, most notably an up-regulation of the calcitonin receptor
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and calcitonin, which have been implicated in the attenuation of satellite cell
activation (Fukada et al. 2007).
1.2.4.2 Activation and proliferation
Satellite cell activation is a multi-step process involving the transition from G0-
G1 stage of the cell cycle. It is marked by cell cytoplasmic extension,
expansion of organelles and a lower chromatin density. Satellite activation is
dependent on the availability of extrinsic (e.g., HGF) and intrinsic signals (e.g.,
an up-regulation of myoD and a down-regulation of pax7) to drive the process
forward. Once entered into the first cell cycle, satellite cells may enter a highly
proliferative intermediate progenitor stage as myoblasts capable of myogenic
differentiation and fusion (reviewed by Dhawan and Rando 2005). Activated
satellite cells continue to proliferate as myoblasts and express muscle
regulatory genes such as myogenic factor 5 (myf5) and myoD, both members
of the bHLH family of MRF. Myf5 has been identified in activated and
proliferating satellite cells. It is probably expressed in quiescent satellite cells,
but at a lower level than in proliferating cells (Beauchamp et al. 2000). Myf5
gene expression declines when myoblasts enter differentiation whereas myoD
persists well into the differentiation stage.
MyoD induces the cyclin-dependent kinase inhibitor p21, cyclin D3,
rentinoblastoma protein (pRb) and myogenin, all of which couple the
attenuation of satellite cell proliferation with cell cycle exit and the induction
of myogenic differentiation (Kitzmann et al. 1999). Its DNA binding activity is
inhibited by Id proteins, with which it forms non-functional heterodimers
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incapable of trans-activating the regulatory regions of many muscle specific
genes such as myosin heavy and light chains, desmin, creatine kinase and
others (reviewed by Legerlotz and Smith 2008). Interestingly, myoD-null mice
contain functioning satellite cells although delayed muscle regeneration is
noted; cultured myoblasts from such animals fail to fuse in vitro. In single
myofibre extracts, satellite cells demonstrated a 90% reduction in
differentiation efficiency (Sabourin et al. 1999; Cornelison et al. 2000).
Committed myoblast expressing myoD will continue to proliferate until the
balance of protein expression, including the accumulation of myoD, pushes
cells toward differentiation (reviewed in Yablonka-Reuveni 2011).
The Notch signalling pathway has also been implicated in satellite cell
activation; the Notch receptor (Notch-1) is expressed on activated satellite cells
and its antagonism (demonstrated, for e.g. via overexpression of its inhibitor,
Numb) has been shown to prevent satellite cell activation and proliferation
(Conboy and Rando 2002). The pathway is often found up-regulated in
response to muscle injury, through increased expression of the Notch-1 ligand,
Delta-1, which activates the Notch-1 receptor expressed on satellite cells and
promotes cell proliferation. However, uncontrolled Notch-mediated induction
of satellite cell proliferation has been shown to have consequences for
differentiation. For example, excessive activation of Notch-1 by
overexpression of Delta also delays differentiation by suppressing myoD and
myogenin (Nofziger et al. 1999; Delfini et al. 2000). Taken together, these
findings suggest that Notch-mediated satellite cell proliferation and
differentiation must be intricately balanced between activation and inhibition
of the Notch-1 receptor to appropriately control myogenesis.
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The work of Tatsumi et al.(1998) showed that HGF is capable of satellite cell
activation in vivo and in vitro. It is released during muscle crush injury to
stimulate satellite cell activation. Furthermore, injection of HGF directly into
the tibialis anterior of adult mice resulted in activation of quiescent satellite
cells in the absence of myotrauma. The authors also found that administration
of HGF neutralising antibody during crush injury attenuated satellite cell
activation (Tatsumi et al. 1998).
HGF-mediated activation of satellite cells may be regulated by nitric oxide
(NO), also a potent activator of satellite cells, usually released in injured
muscle (Anderson 2000). Mice deficient in NO production (via nitric oxide
synthase-1 (NOS-1) mutation or pharmacological NOS inhibition) experience
delayed satellite cell activation and muscle regeneration following injury.
Interestingly, the work of Wehling et al. (2001) and Anderson and Vargas
(2003) noted NO promoted muscle regeneration in injured muscle by fulfilling
an anti-inflammatory function. Also, normalisation of aberrant NOS signalling
in mdx mice alleviated the muscle dystrophy phenotype. Intriguingly,
inhibition of NOS reduces the amount of HGF released following myotrauma.
It is therefore likely NO is involved in the release of HGF from the
extracellular matrix and, although the interplay between the HGF and NO/NOS
signals is still unclear, it is probable that both are involved in myotrauma-
induced satellite cell activation (reviewed by Holterman and Rudnicki 2005).
Satellite cell are already activated by relatively mild exercise (reviewed by
Kadi et al. 2005). Exercise-induced activation is triggered by localised ultra-
structural or segmental muscle fibre damage, which in turn initiates the release
of inflammatory substances and growth factors (Roth et al. 2001). The highest
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frequency of fibres with ultra-structural damage should also contain the highest
proportion of active satellite cells. Rupture of the basal lamina in response to
myotrauma causes migration of satellite cells to adjacent myofibers by using
tissue bridges, to participate in the repair process (reviewed by Hawke and
Garry 2001). Exercise-induced myotrauma initiates an immune response to
attract macrophages to the damaged region, which consecutively secrete
various cytokines and growth factors that regulate the satellite cell pool and
modulate the repair process (reviewed by Nathan 1987). Such growth
factors/or cytokines include interleukin-6 (IL-6), fibroblast growth factors
(FGF), insulin-like growth factors (IGF-I, IGF-II, which are specifically up-
regulated in response to hypertrophic signals, e.g., resistance exercise), HGF
and members of the transforming growth factor-E (TGF-E) family. These
factors have pleiotropic actions on satellite cell activity depending on the
combination and concentration of inducing factors. For example, IGFs
specifically increase satellite cell proliferation and differentiation, FGFs have
been observed to attenuate satellite cell differentiation and members of the
TGF-E family, which includes bone morphogenetic protein (BMP) and
myostatin, inhibit satellite cell proliferation and differentiation (e.g., via
suppressing myoD) (reviewed in Hawke and Garry 2001). Macrophages are
also an important component of the repair process following muscle trauma;
for example, there is a lack of muscle regeneration in the absence of
macrophages and an increase in satellite cell proliferation and differentiation is
noted when macrophage numbers are enhanced (Lescaudron et al. 1999).
Several other markers of activation have been proposed; for example, flk, sca-
1, CD45, jagged-1, caveolin-1 etc (Dreyfus et al. 2004; Seale et al. 2004;
21
Volonte et al. 2004; Gnocchi et al. 2009). Although not specific to satellite
cells, they are routinely used in single myofibre analyses for mapping the
molecular signature of satellite cells in various stages of activity.
1.2.4.3 Differentiation and fusion
The onset of myogenic differentiation is marked by the expression of
myogenin and MRF4 (also known as Myf6). It elicits a process whereby
proliferating myoblast withdraw from the cell cycle and either fuse to existing
fibres (e.g. to aid in the repair of damaged segments) or with each other to form
nascent myotubes, which mature to replace damaged fibres. Early
differentiation is also often measured by an increase in creatine kinase activity
(reviewed by Florini and Magri 1989) or the subsequent shift in expression of
contractile protein isoforms from developmental to adult. The up-regulation of
myogenin coincides with the expression of various genes encoding structural
proteins such as myosin heavy chains (Andres and Walsh 1996). Gross defects
in embryonic muscle development of myogenin-null mice have impeded
further study of its role in satellite cell myogenesis. Mouse mutants of
myogenin die at birth and loss of myogenin in postnatal mice (via myogenin
deletion after embryonic development) resulted in animals that were 30%
smaller than control. It appears that myogenin is absolutely required for
embryonic muscle development; myogenin-null mice exhibit severe muscle
deficiencies and unlike single knock-out studies of other MRFs, myogenin has
no redundant or compensatory mechanisms to replace its function (Knapp et al.
2006).
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Markers that have been implicated in the myoblast fusion process include M-
cadherin, M-calpain and desmin amongst others (reviewed by Charge and
Rudnicki 2004). Cadherins are trans-membrane proteins involved in calcium-
dependent cell-cell interactions. As mentioned above, M-cadherin is detected
in quiescent satellite cells but it is markedly induced upon muscle injury,
suggesting it is important for the repair process, which includes fusion of
myoblasts. Interestingly, satellite cells from myoD-/- mice (which fail to fuse
when cultured) demonstrated reduced expression of M-cadherin in response to
injury-induced activation (Sabourin et al. 1999; Cornelison et al. 2000). On the
other hand, M-calpain activity is increased during myoblast fusion, an action
subsequently blocked by calpastatin, an inhibitor of M-calpain. Myoblasts have
also been noted to fuse earlier and faster after injection of M-calpain (Temm-
Grove et al. 1999).
1.2.4.4 Negative regulatory markers
As discussed earlier, myostatin is considered a negative regulator of satellite
cell function. It is a member of the TGF-E family of secreted regulatory
factors; myostatin knock-out mice displayed a 30% increase in body weight,
largely as a result of increased skeletal muscle mass (McPherron et al. 1997).
Additionally, myostatin mutations have been linked to the substantial increase
in muscle mass observed in Belgian Blue and Peidmontese cattle breeds
(Grobet et al. 1997; Kambadur et al. 1997). Recently, the discovery of a
homozygote loss of function myostatin mutation in a German boy presented
with pronounced muscle development at birth has supported the idea that
myostatin specifically controls muscle growth (For a review, see K
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Killefer 2002). The exact mechanisms by which myostatin inhibits muscle
growth are largely unknown, however, myostatin mRNA and protein is
frequently found elevated in various pathological conditions such as human
immuno deficiency syndrome (Gonzalez-Cadavid et al. 1998), hind-limb
unloading (Carlson et al. 1999), thermal injury (Lang et al. 2001), cachexia
(Zimmers et al. 2002), space-flight (Lalani et al. 2000), in age and denervation-
induced muscle atrophy (Baumann et al. 2003).
Studies done by McCroskery et al. (2003) show that myostatin negatively
regulates satellite cell myogenesis. It is produced in increasing amounts as
satellite cells progress through activation, myoblast proliferation and
differentiation. Myostatin signals through the activin receptor IIB-ALK4/5
(activin receptor-like kinase) heterodimer, expressed on satellite cells, to
activate multiple intracellular signalling cascades including SMAD and MAPK
pathways. Activation of these pathways results in the induction of p21/Rb (to
promote G1-S cell cycle arrest via inhibition of cyclin dependent kinases, e.g.,
cdk2) and nuclear translocation of smad4, which blocks myoD transcription.
This results in the inhibition of satellite cell activation and cell cycling in
proliferating myoblasts, which consequently slows down further myogenesis
(reviewed by Joulia-Ekaza and Cabello 2006; Bradley et al. 2008). These
findings are further supported by the work of McCroskery et al. (2005), who
noted higher numbers of activated satellite cells in muscle fibres of myostatin-
null mice relative to wild-type animals.
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1.2.5 Sequential events regulating satellite cell myogenesis
The sequential expression of MRFs is an important regulatory mechanism for
controlling satellite cell myogenesis. The induction of myogenic factors which
drive differentiation and myotube formation will also suppress proliferation
and quiescence markers. For example, pax7 is expressed in quiescent satellite
cells but its expression is reduced in those cells undergoing differentiation.
Likewise, myogenin is reduced in proliferating satellite cells. It appears that a
balance between feed-forward and feed-back mechanisms controls satellite cell
myogenesis, whereby sufficient induction of a certain myogenic factor (e.g.
myoD) stimulates trans-activation of other factors to drive the myogenic
program forward (e.g. myogenin), whilst inhibiting factors are responsible for
maintaining quiescence (e.g. pax7). Studies carried out by Halevy et al. (2004)
in chicken showed increased myogenin expression was concomitant with a
reduction in pax7. Quiescent avian satellite cells expressed pax7 but reduced
MyoD and expressed no myogenin, whilst proliferating satellite cells co-
expressed pax7 and myoD but not myogenin. It is thought those satellite cells
positive for myogenin but negative for pax7 (pax7

/myogenin
+
) may represent
satellite cells that are committed to terminal differentiation. In addition,
suppression of Pax7 whilst maintaining myoD was observed in differentiating
myoblasts. It is thought satellite cells positive for pax7 but negative for myoD
(pax7
+
/myoD

) may represent the reserve pool of satellite cells, those that
return to quiescence after activation (summarised in figure 1.4). Some
myoblasts were shown to maintain pax7 expression, down-regulate myoD
expression and eventually stop proliferating but enter a state quite similar to
25
Fig1.4: Summary of sequential regulation of Satellite Cell Myogenesis.
Quiescent cells express pax7 only, proliferating cells express both pax7 and
MyoD, which then either undergo a stochastic on/off gene switch or
asymmetric division, leading to differentiation or a return to the cell reserve
pool respectively. Myogenin expression induces a decision to undergo
differentiation. Cells expressing all genes are probably at the turning point of
differentiation
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quiescence where they can be rapidly activated again (Halevy et al. 2004;
reviewed by Zammit et al. 2004).
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1.2.6 Satellite cell self-renewal
Satellite cells numbers in adult muscle remain relatively constant through
repeated bouts of injury and regeneration. It is assumed this is as a result of
their ability to self-renew. Activated satellite cells assume divergent fates - not
all cells progress toward myogenic differentiation and some return to
quiescence. It is thought asymmetric division is the chief method by which
satellite cells maintain their baseline cell numbers throughout adult life (Moss
and Leblond 1971). During proliferation, one daughter cell is committed as the
progenitor cell, which returns to a quiescent state (see figure 1.3), whilst the
other commits to differentiation and fusion. It is postulated that after several
cell divisions, pax7
+
/myoD
+
cells may undergo asymmetric division and/or are
subject to a stochastic, non-deterministic process whereby differential
accumulation of one protein or the other, causes some gene(s) to be switched
on/or off. This stochastic on/off process could determine whether a cell
differentiates or returns to the reserve pool (reviewed by Paldi 2003).
This concept of asymmetric division was also proposed by Conboy and Rando,
(2002), who directly implicated Notch-1 and it antagonist Numb in satellite cell
activation and self-renewal. A reduction in Notch-1 signalling due to
increasing Numb expression led to the expression of pax7 and desmin, which
likely indicates a commitment to myogenic lineage. Numb was found to
localise asymmetrically in actively dividing cells, whereby those cell
accumulating Numb show a commitment to myoblast fate. This suggests that
daughter cells produced by satellite cell activation and proliferation assume
divergent cell fates based on the accumulation of Notch and its antagonist in
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actively dividing cells. Taken together, these reports suggest that a combination
of on/off switches of several genes, the differential accumulation of specific
myogenic proteins, coupled with extrinsic cell signals, ultimately push satellite
cells toward a path for self-renewal or myogenic differentiation.
1.2.5 Mechanisms modulating satellite cell activation and regulation
As highlighted above, the gene expression profiles of satellite cells at different
stages of activity paints a complex and intricate picture of satellite cell
regulation. The exchange of signals between different tissues/cells and satellite
cells and vice versa, all form part of the satellite cell micro-environment.
Figure 1.5 below highlights some of the factors that influence satellite cell
activity. These signals are believed to change significantly in various stages of
satellite cell quiescence and activity. Myogenic regeneration responses, which
mediate satellite cell activation, ensue from injury, exercise, muscle loading,
denervation, etc. The nature of the satellite cell microenvironment and its role
in regulating the quiescent and active states of satellite cells or mechanisms of
self-renewal is largely unknown. For example, exercise in humans can induce
activation of satellite cells without proliferation (Appell et al. 1988). As
mentioned above, satellite cells are activated by relatively mild exercise and
the satellite cell pool can increase as early as 4 days following a single bout of
exercise and can be maintained at a higher level following weeks of training
(Kadi et al. 2005). A gradual decrease in the previously enhanced satellite cell
pool is observed upon cessation of training.
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Figure 1.5: Summary of factors influencing satellite cell activity. The
process of muscle regeneration involves growth factors released from a number
of tissues that act either alone or in combination to influence satellite cell
activity, which may include activation, chemotaxis, proliferation,
differentiation and/or fusion. From (Hawke and Garry 2001).
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1.3 SATELLITE CELL RESPONSE TO SKELETAL MUSCLE
HYPERTROPHY
1.3.1 Definition of muscle hypertrophy
Skeletal muscle is highly adaptive and has a remarkable ability to increase its
size to parallel demand; for example during resistance exercise (Kadi, 2004) or
in response to anabolic stimuli such as growth hormones during puberty.
Skeletal muscle hypertrophy is characterised by an increase in muscle fibre
cross sectional area or an increase in the number of muscle fibres. Hypertrophy
could also be classed into two categories; sarcoplamic hypertrophy  an
increase in sarcoplasmic volume without concomitant increase in strength
(typical of body-builder muscles) and myofibrillar hypertrophy  an increase in
myofibre number, which is accompanied by an increase muscle strength and
size (for a review, see Schoenfeld 2010).
Muscle hypertrophy is considered to occur when muscle protein synthesis
exceeds protein breakdown and since skeletal muscle is a postmitotic tissue, it
does not undergo significant cell replacement throughout life. Loss of nuclei
(for e.g. due to apoptosis) reduces the synthetic capacity of myofibres by
increasing the domain size (the cytoplasmic volume served by a single
myonucleus). An efficient method of repair is therefore required to counteract
loss of nuclei and maintain the regenerative capacity of myofibres throughout
the organisms lifetime. This is achieved by the injection of satellite cells,
which add new nuclei to myofibres to preserve domain size and hence
synthetic capacity. Additionally, activated satellite cells express various MRFs
that aid muscle repair and growth.
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1.3.2 Satellite cells and muscle hypertrophy
The concept of a myonuclear domain proposes that a single myonucleus
provides RNA for a limited sarcoplamic volume and that increases in fibre size
must be accompanied by proportional increases in myonuclei. Hypertrophy is
thought to occur by an increase in the number of domains (via an increase in
myonuclear number) as well as an increase in the size of existing domains
(reviewed by Toigo and Boutellier 2006); both mechanisms involve significant
contribution from satellite cells, which donate extra nuclei to myofibres, thus
increasing their capacity to synthesise new contractile proteins (Moss and
Leblond 1971; Barton-Davis et al. 1999).
Various physiological stimuli such as resistance exercise, chronic stretch,
muscle overload (e.g. by agonist ablation or tenotomy) promote hypertrophic
responses in many human and animal models by activating satellite cells
among other systems. It is thought such responses and satellite cell activation
occur because of the induction of various hormones and cytokines such as IGF-
1, HGF and IL-6, which act as upstream of regulators of anabolic processes
(reviewed in section 1.2.4.2 and figure 1.4 above). Among these, IGF-1
appears to be one of the most important factors linking hypertrophy and
satellite cells (Barton-Davis et al. 1999). IGF-1 supplementation via localised
transgene expression is known to prevent age-related muscle wasting (Musaro
et al. 2001). Furthermore, satellite cells isolated from IGF-1 overexpressing
mice show increased regenerative potential compared to non-transgenic
animals; IGF-1 also increased the DNA content per myofibre and the
expression of different myosin isoforms (Fiorotto et al. 2003).
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In summary, it appears the primary role of satellite cells during hypertrophy is
the addition of nuclei to growing myofibres in order to produce bigger muscles
with a greater capacity for peak force generation. Although a number of
questions still remain, it is clear is that satellite cell activity is required for full
compensatory muscle hypertrophy. This was demonstrated in studies done by
Rosenblatt et al. (1992; 1993; 1994), where load-induced hypertrophy of EDL
muscle, by synergistic removal the tibialis anterior in rats, was prevented when
satellite cells were ablated by gamma radiation sterilisation.
1.3.3 Summary of satellite cell activity in non-mechanically induced
hypertrophy models
The role of satellite cells in hypertrophy induced by non-mechanical
intervention such as drugs (e.g. E-agonists), anabolic steroids and nutritional
supplementation is still being elucidated. Numerous studies have shown that
administration of E-agonists induces hypertrophy in many species (reviewed by
Lynch and Ryall 2008) by increasing the rate of contractile muscle protein
synthesis and decreasing the rate muscle protein breakdown. Whether nuclear
addition from satellite cells is implicated in E-agonist-induced muscle growth
has not been clarified and this will be the purpose of the investigations outlined
in chapter 3.
Androgenic anabolic steroids are synthetic derivatives of the male hormone
testosterone, which have been found to increase muscle strength and mass. Use
of anabolic steroids boosts muscle hypertrophy beyond inherent limits by
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increasing the transcription rate of myofibrillar proteins (for a review, see
Aagaard 2004; Bhasin et al. 2006). A rapid increase in activated satellite cells
and myogenesis in response to androgen treatment has been observed in vitro
and in vivo (Joubert and Tobin 1995; Sinha-Hikim et al. 2003; Sinha-Hikim et
al. 2004). The androgen receptor is expressed on satellite cells and it is thought
the accelerated activation of satellite cells is as a result of direct androgen
action, all of which help maintain an optimal nuclear-to-cytoplasmic ratio of
growing myofibres during steroid-induced muscle hypertrophy.
Nutritional supplementation (e.g. timed protein intake in combination with
ergogenic supplements such as creatine) has been shown to enhance muscle
hypertrophy; especially when used in combination with training. Precisely
timed protein supplementation after resistance exercise is thought to increase
the availability of intracellular amino acids, which promote an acute increase in
net protein balance that is utilised by growing myofibres (for a review, see
Gibala 2000). Creatine supplementation augments the muscle hypertrophy
response by eliciting larger increases in fibre cross-sectional area compared to
training alone; chiefly by enhancing satellite cell activity and the production of
MRFs (Dangott et al. 2000; Olsen et al. 2006).
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1.4 SATELLITE CELLS DURING MUSCLE ATROPHY
1.4.1 Overview of muscle atrophy
Muscle atrophy is defined as a reduction in muscle mass occurring through a
reduction is fibre size (hypotrophy) or number (hypoplasia). Changes in the
size are thought to arise from an alteration in nuclear number, nuclear domain
size or a combination of both (reviewed by Allen et al. 1999). As with muscle
hypertrophy, atrophy may arise from a down-regulation of contractile protein
synthetic pathways, an up-regulation of protein degradative pathways or a
combination of both. Muscle atrophy is often a consequence of catabolic
diseases such as cancer, acquired immune deficiency syndrome (AIDS), sepsis,
thermal injury and chronic obstructive pulmonary disease (COPD); in all of
them, it contributes to patient morbidity and mortality, due to the associated
muscle weakness, reduced muscle function, and chronic frailty (reviewed in
Vinciguerra et al. 2010).
Muscle atrophy may also be triggered by disuse (e.g. unloading during limb
immobilisation/unloading, prolonged bed-rest or space-flight), denervation
(e.g. spinal cord injury or sciatic nerve transaction in the rat), fasting and
ageing (for reviews, see Marimuthu et al. 2011; and Narici and de Boer 2011).
Age-related muscle loss (termed sarcopenia) is thought to occur via different
mechanisms relative to other types of atrophy, predominantly involving a
combination of myonuclei loss due to apoptosis, loss of motor units and
reduced regenerative capacity of satellite cells (reviewed by Marzetti et al.
2010). Additionally, muscle atrophy can also be initiated by increased levels of
circulating cytokines and catabolic hormones such as glucocorticoids
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(reviewed by Hasselgren et al. 2005). This is frequently observed in cases of
sepsis, in which the mechanisms of muscle loss and the role of satellite cells
are largely unknown. The latter will be the purpose of the investigations
described in chapters 4 and 5.
1.4.2 Satellite cell response to atrophic stimuli
The behaviour of satellite cells in models of atrophy tends to be quite varied
and dependent on the atrophic stimulus; however a consistent finding appears
to be a loss of myonuclei, which leads to an increase in domain size and thus
reduced synthetic capacity. This is exacerbated by reduced satellite cell
activation and inadequate nuclear replacement (Brack et al. 2005).
Furthermore, hindlimb unloading of juvenile rats resulted in reduced muscle
size after 9 weeks but satellite cell content and proliferative capacity was
reduced within 3 days in soleus and EDL muscles (Darr and Schultz 1989;
Mozdziak et al. 2000).
In a similar model of hindlimb immobilisation utilised by Wanek and Snow
(2000), a ~50% reduction in satellite cell number was noted in the soleus
muscles of casted animals after 10 weeks of immobilisation . Disuse atrophy
from prolonged denervation also produces a similar decline in the satellite cell
population and it is hypothesised this is as a result of satellite cell apoptosis and
lack of neurotrophic input, which negatively impacts satellite cell function due
to reduced induction of growth factors (Viguie et al. 1997). Satellite cells from
denervated muscle show distinctive phenotypic alterations such as proliferative
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resistance, separation from associated fibres and basal lamina disruption (Lu et
al. 1997; Kuschel et al. 1999).
1.5 SUMMARY AND HYPOTHESES
Taken together, the findings in this review highlight the importance of satellite
cells in the maintenance of muscle homeostasis; we hypothesise their up-
regulation in response to hypertrophic stimuli (such as in our clenbuterol pro-
drug model of muscle hypertrophy) and their dysregulation in response to
atrophic stimuli (in the sepsis model of muscle atrophy), which will contribute
the severity of muscle loss or gain. The evidence reviewed above suggests that
effective satellite recruitment predominantly contributes to muscle hypertrophy
by nuclear addition; further understanding of the mechanistic events regulating
satellite cell activity in pharmacological models of hypertrophy and atrophy in
the rat should provide interesting avenues of therapeutic intervention aimed at
combating muscle wasting. Furthermore, there is some evidence of satellite cell
aberration during muscle atrophy which may account for the failure, delay or
resistance of atrophied muscle to full regeneration, due in part to the reduction
in the restorative capacity of satellite cells, especially in ageing muscle.
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CHAPTER 2
General Methods
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2.1 IN VIVO TECHNIQUES
2.1.1 Ethics statement
All procedures involving live animals detailed below were approved by the
University of Nottingham Ethics Review Committee and carried out under UK
Home Office Project and Personal License authority. All animals were
obtained from Charles River Laboratories (Sandwich, UK) and housed in the
Biomedical Services Unit, School of Biomedical Sciences for at least 10 days
after delivery; the holding room temperature was maintained at 21±2°C with a
12hr light/dark cycle (6am-6pm) and standard rat chow (Beekay Foods, Hull,
UK) and tap water was provided ad libitum. The human tissues used in these
studies were obtained for general research purposes from the University of
Bern, Switzerland, with the permission of the Canton of Bern Medical Ethics
Commission.
2.1.2 E2-agonist pro-drug BRL-47672 study
2.1.1.1 Background
The morpholine compound BRL-47672 has a chemical structure similar to the
E2-agonist clenbuterol (see figure 2.1 below); it causes similar anabolic effects
in rats but with reduced haemodynamic effects compared to clenbuterol
(Sillence et al. 1995). It is thought to be metabolised in vivo to the biologically
active clenbuterol and the work of Sillence et al. (1995) noted that BRL-47672
has very little or no direct effect on E2-adrenoreceptors, as daily injection of the
selective E2-antagonist, ICI-118551 showed no effect on the BRL-47672-
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Figure 2.1: Chemical properties of BRL-47672 and Clenbutrol. Adapted
from Sillence et al. (1995)
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induced anabolic responses but these effects were blunted when ICI-118551
was administered in the diet. Similarly, administration of a selective E1-
antagonist also failed to reduce the anabolic effects of BRL-47672, which lead
to the conclusion that BRL-47672 is the pro-drug of clenbuterol and it is
rapidly metabolised in vivo to a potent E2-agonist, thus having less impact on
blood flow and pressure relative to active clenbuterol. This was validated by
our group in the work of Jones et al. (2004) using an in vivo model of
haemodynamics in conscious rats (Gardiner and Bennett 1988). In these
preliminary studies, single bolus doses of clenbuterol or BRL-47672 (250 -
900Pg/kg) were administered to conscious rats surgically implanted with
Doppler flow probes. BRL-47672 caused significant reductions in heart rate,
mean arterial pressure, and hindquarters vascular conductance compared to
clenbuterol over a forty minute measuring period. The pro-drug is therefore
more suitable for chronic administration due to its reduced haemodynamic
response compared to clenbuterol.
2.1.1.2 Animals and tissue collection
Male Wistar rats (150-160g) were randomly assigned to one of two groups and
received daily subcutaneous (s.c.) injections of E2-agonist pro-drug BRL-47672
(900Pg/kg body mass, dissolved in 0.9% sterile saline, n=7) or an equal
volume of 0.9% sterile saline (n=6) for 8 weeks. The dose of 900 mg/kg body
mass of BRL-47672 was used because it demonstrated the greatest effect on
muscle metabolism and function (Baker 2004). Twenty-four hours following
final injections, rats were terminally anaesthetised intraperitoneally (i.p.) with
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120mg/kg of thiobutabarbital sodium (Inactin; Sigma-Aldrich, St. Louis, USA)
and the soleus muscles were excised, snap frozen in liquid nitrogen, and stored
at -80°C for subsequent analysis.
2.1.2 Lipopolysaccharide (LPS) study
2.1.2.1 Background
The administration of LPS is one of the most widely used methods for studying
animal models of Gram-negative sepsis. While some would consider this to be
an inaccurate reflection of the human sepsis syndrome, it nevertheless produces
a hyperdynamic circulatory response similar to human sepsis syndrome
(Gardiner et al, 1995; Parillo, 1993). In addition, LPS is a relatively stable
compound, allows accurate dosing and is associated with a high degree of
reproducibility. This is reviewed further is chapter 4, section 4.2.
2.1.2.2 Animals and surgical preparation
Animals were housed in groups of 3-5 per cage before surgery, but were kept
separate following intravenous catheter implantation. Male Sprague-Dawley
rats (380-480g; Charles River) were anaesthetised with each of fetanyl citrate
(300Pg/kg; i.p., Janssen-Cilag, High Wycombe, UK) and meditomidine
(300Pg/kg; i.p., Domitor, Pfizer, Sandwich, UK), prior to intravenous (i.v.)
catheter implantation in the jugular vein for administration of substances, as
previously described by Murton (2007). Animals assigned to the 24 hr LPS
treatment group were also implanted with arterial catheters for measurement of
mean arterial pressure and heart rate. All catheters were flushed with sterile
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heparinised (15 U/ml) saline (Monoparin; CP Pharmaceuticals Ltd, Wrexham,
UK) and sealed with metal spigots. Whilst under anaesthesia, animals were
fitted with a harness connected to a counter-balanced spring to carry the
catheter, which allowed unrestricted movement within the cage and continuous
administration of substances. Anaesthesia was reversed and analgesia provided
with atipamezole (1mg/kg; s.c., Antisedan, Pfizer, Sandwich, UK) and
buprenorphine (0.03mg/kg; s.c., Vetergesic; Alstoe Animal Health, York, UK),
respectively. Animals were left to recover for 24 hr in individual home cages
(26 x 30 x 38cm) with open access to food and water. Catheters were
connected to an infusion pump via a fluid filled swivel, which maintained a
continuous i.v. infusion of sterile heparinised saline (15 U/ml) at 0.4ml/hr.
Animals were allowed to recover overnight and administration of substances
commenced the following morning.
2.1.2.3 Lipopolysaccharide administration and tissue collection
Prepared rats were divided into six groups; three groups received a continuous
infusion of sterile isotonic saline (0.4 ml/hr) for either 2hr (n=4), 6hr (n=4) or
24hr (n=6) as control. The remaining three groups received a continuous
infusion of LPS (E. coli, serotype 0127:B8; 15Pg/kg/hr - dissolved in sterile
isotonic saline, Sigma, Poole, UK) for either 2hr (n=4), 6hr (n=4) or 24hr
(n=6). After the specified time, animals were terminally anaesthetised with
thiobutabarbital sodium (Inactin; 80mg/kg, i.v., Sigma-Aldrich, St. Louis,
USA). The EDL and gastrocnemius muscles from both limbs were removed as
previously described by Murton (2007), immediately snap frozen and stored in
43
liquid nitrogen for subsequent analyses. Muscle tissues were freeze clamped in
situ with the use of aluminium tongs cooled in liquid nitrogen before removal.
2.1.3 Dexamethasone (Dex) study
2.1.3.1 Background
Administration of low doses of glucocorticoids such as dexamethasone (Dex)
is thought to be beneficial for reducing the symptoms of sepsis and septic
shock by preventing excessive production of pro-inflammatory cytokines and
thus reduce mortality associated with sepsis. Therefore, dexamethasone was
co-administered with LPS to determine if it blunted signalling events
associated with LPS- mediated sepsis. This is reviewed further is chapter 5,
section 5.2.
2.1.3.2 Animals and tissue collection
Male Sprague-Dawley rats (350-450g; Charles River) were implanted with an
intravenous catheter in the jugular vein, under anaesthesia as described above
in section 2.1.2.2. Following surgery, animals were allowed to recover for 24hr
in individual home cages with open access to food and water. A continuous
infusion of sterile heparinised saline (15 U/ml, 0.4ml/hr; i.v.) was administered
via a fluid filled swivel to maintain catheter patency. Following catheterization,
prepared rats were assigned to one of four groups (n=7-8 per group) and
received a continuous intravenous infusions of sterile isotonic saline (0.4ml/hr)
as control, LPS (15Pg/kg/hr), Dex (12.5Pg/kg/hr; Sigma Aldrich, Poole, UK)
or both. In the Dex+LPS group, dexamethasone was administered for 1hr
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before the commencement of and during the 24hr infusion of LPS. After 24 hr,
animals were terminally anaesthetised as described above and the EDL muscle
from both limbs was freeze clamped and removed. Muscles were immediately
snap-frozen and stored in liquid nitrogen for subsequent analyses.
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2.2 MOLECULAR BIOLOGY TECHNIQUES
2.2.1 Analysis of mRNA expression
Quantitative real-time polymerase chain reaction (qRT-PCR)
qRT-PCR is a widely used method for the rapid and accurate determination of
specific mRNA transcripts. Unlike the traditional end-point PCR, which is
often associated with errors and the need for optimisation (reviewed by Stanton
2001), qRT-PCR enables the quantification of specific mRNA transcripts after
each thermal cycle without interfering with the reaction. In summary, RT-PCR
involves the reverse transcription of total mRNA into cDNA and the cDNA
template of interest (the amplicon) is specifically amplified. To achieve this,
two synthetic DNA oligonucleotides (primers) are designed to be
complementary in sequence to opposite ends of template of interest. Successive
heating (to allow strand separation) and cooling (to allow annealing of primers
to DNA template) of the reaction mixture in the presence of DNA polymerase
and deoxyribonucleoside triphosphates (dATP, dCTP, dGTP, dTTP) allows
synthesis of DNA from the two primers in a 5  3 direction, resulting in the
exponential amplification of the amplicon.
Each step of the reaction can be monitored in real-time PCR by the use of a
third shorter fluorescently-labelled DNA oligonucleotide (the probe) designed
to hybridise to the template upstream /downstream of the primers. A variety of
different probes with different chemistries are available. Here, the Taqman
®
probes were used, which consists of a short oligonucleotide, covalently linked
at opposite ends with a 5 reporter dye (6-carboxyl-fluorescein; FAM) and a
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3 minor groove binder (MGB) non-fluorescent quencher (NFQ). When the
probe is intact, the proximity of the quencher reduces the fluorescence emitted
by the reporter dye via Fluorescent Resonance Energy Transfer (FRET). The 5
exonuclease activity of DNA polymerase cleaves the probe to remove the
annealed nucleotides and proceed with polymerisation, thus releasing the
quencher and reporter dyes (figure 2.2). This separation of reporter from its
quencher increases the reporter dye signal, allowing the spectrophotometric
detection of reporter dye emissions when excited by a light source (e.g.
488nm). The fluorescence intensity detected with each PCR cycle increases as
more reporter dye molecules are cleaved and separated from the quencher with
each cycle. Thus, the kinetics of the PCR can be monitored in real time based
on the intensity of fluorescence emissions after each thermal cycle.
The kinetics of the reaction during amplification can be categorised into three
phases; an exponential, linear and plateau phase (see figure 2.3). The
fluorescence intensity is initially below the threshold of detection but gradually
increases with cycle number until it is roughly proportional to amplicon
quantity, such as during the exponential phase, where assuming 100% PCR
efficiency, the amplicon product is doubling after every cycle. It is at this stage
that transcripts are compared since the log of fluorescence detected is
theoretically proportional to the quantity of cDNA sample. An arbitrary
threshold of fluorescence is set in the exponential phase of the reaction by the
Sequence Detection System (SDS; Applied Biosystems, Foster City, USA),
which represents the cycle number at which this threshold of fluorescence is
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Figure 2.2: Schematic representation of the Taqman
®
Polymerase Chain
Reaction (PCR). Diagrammatically describes the steps detailing the principles
behind Taqman probes and Fluorescent Resonance Energy Transfer (FRET) in
one complete cycle of real time PCR reaction.
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Figure 2.3: Schematic representation of the kinetics of Taqman
®
Polymerase Chain Reaction showing the three main phases of the reaction;
an exponential, linear and plateau phase. A threshold of reporter emission is
set in the exponential phase of the reaction by the Sequence Detection System
(SDS) software and the cycle number at which the reporter emission of a
sample reaches this threshold is logged as the cycle threshold (Ct) value.
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achieved, i.e. the cycle threshold (Ct) value. The threshold value of
fluorescence (Ct value) is reached sooner or later depending on the initial
quantity of cDNA at the start of the reaction. Relative quantification of mRNA
is calculated from the acquired Ct values using either a standard curve or
comparative Ct method (User Bulletin No.2 for ABI Prism 7700 SDS (Part No.
430859); Applied Biosystems).
The standard curve method involves the use of serially diluted standards on
each plate examined and mRNA expression is expressed as fold change
relative to an undiluted standard. Absolute mRNA quantification is also
possible using this method if the concentrations of the standards are known.
This is a useful method for mRNA quantification but requires precise pipetting
and accurate determination of standard concentration. On the other hand, the
comparative Ct method uses an endogenous reference to quantify mRNA
expression based on alterations in the steady state mRNA levels of the target
gene relative to the levels of a housekeeping gene. The relative amount of
mRNA between two groups can be calculated thus:
Relative amount of target mRNA = 2
ǻǻ&W
:KHUHǻǻ&t ǻ&t[treatment group]±ǻ&t[control group]
DQGǻ&t = Ct[target gene]  Ct[endogenous reference]
7KHǻ&t is the difference between the cycle threshold of the transcript of
LQWHUHVWDQGWKHHQGRJHQRXVFRQWUROWKHǻ&t of the treated group is normalised
WRWKHPHDQRIǻ&t of the control group. With the comparative Ctmethod, there
is a need for optimisation, as the amplification efficiency of the target gene and
the endogenous reference need to be roughly equal. Efficiency is determined
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from the slope of a standard curve plot of log cDNA concentration versus cycle
number of serially diluted standards, for both the target gene and endogenous
reference primer/probe sets (see figure 2.4). All primer/probe sets amplified
cDNA with similar efficiency (two examples are shown in figure 2.4  the
endogenous reference, HMBS and a target gene, myostatin). An advantage of
the comparative Ctmethod is that once optimised, a standard curve for every
plate analysed is not necessary and sample-to-sample variations in RT-PCR
efficiency or pipetting errors are corrected for by the use of an endogenous
reference. In addition to the efficiency of primer/probe sets, choosing an
appropriate housekeeping gene chosen as an endogenous reference is essential
for reliable results. The housekeeping gene hydroxymethylbilane synthase
(HMBS), also known as porphobilinogen deaminase (PBGD) has been used
extensively by our group and was used here to maintain consistency of results
(Alamdari et al. 2008; Crossland et al. 2008; Murton et al. 2009; Crossland et
al. 2010). HMBS exists in two isoforms; one is expressed in erythorocytes
where it is involved in haem biosynthesis (Chretien et al. 1988). The other is
ubiquitously expressed and has been suggested as a reliable endogenous
reference for use in RT-PCR (Fink et al. 1999). HMBS expression is
unaffected by LPS treatment in skeletal muscle and myocardium (Murton et al.
2009) and we confirmed this in the present studies (figure 2.5) to further
demonstrate HMBS is a suitable reference for mRNA quantification.
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Figure 2.4: Validation of the efficiency of Taqman primer/probe sets. RT-
PCR was performed on a series of duplicate 2-fold dilutions of untreated
gastrocnemius cDNA to obtain a standard curve of log relative cDNA
concentration against Ct number. (A) In the example shown, the correct HMBS
amplicon was amplified at intensity relative to cDNA concentration. (B) RT-
PCR efficiency was calculated according to Applied Biosystems User Bulletin
No.2, from the slope of the curve using the formula: 100 x (10^
(-1/slope)-
1), thus
for HMBS, PCR efficiency was approximately 97%. (C) RT-PCR standard
curve and efficiency for myostatin.
A. HMBS amplicon length and relative intensity
B. HMBS primer/probe set standard curve
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C. Myostatin primer/probe set standard curve
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Figure 2.5: Analysis of Cycle threshold (Ct) values of Hydroxymethylbilane synthase (HMBS) in different muscle tissues following
various interventions (A, B, C; see chapters 4, 5 and 3 respectively). No significant differences were detected control and treated groups. Data
represented as mean ± S.E.M (n=4-8 per group)
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2.2.2 Total RNA extraction
Total RNA was extracted from approximately 20-25mg of frozen wet muscle
by homogenising in 800Pl ice cold TRIzol® (Invitrogen, Paisley, UK)
supplemented with glycogen (10Pg/Pl; Roche, Burgess Hill, UK) as a carrier.
Samples were homogenised over ice for approximately 30 seconds using a
polytron hand-held homogeniser. The homogenates was incubated at room
temperature for 5 minutes prior to the addition of 160Pl chloroform:iso-amyl
alcohol (Sigma) at a ratio of 49:1 respectively. Samples were vortexed briefly
before additional incubation at room temperature for 3 minutes. Homogenates
were then centrifuged for 15 minutes at 12,000g, 4°C and the top clear RNA-
containing aqueous phase was transferred to clean eppendorfs and precipitated
with an equal volume (1:1 ratio) of ice-cold iso-propanol (Sigma). Samples
were left overnight at -20°C to precipitate RNA and subsequently pelleted by
centrifugation at 12,000g for 15 minutes at 4°C.
The pellets were air-dried at room temperature for 5 minutes, washed with
800Pl of 75% ethanol and spun at 10,000g for 10 minutes. The ethanol was
discarded and pellets were once more air dried to remove excess ethanol before
re-suspending in 35Pl RNAse-free water. The quantity of RNA was assessed
spectrophotometrically (ND-100 spectrophotometer, NanoDrop
®
Technologies
Inc, Wilmingtion, USA) by measuring the absorbance at 260nm and 280nm
and quality of RNA was determined by the 260:280 ratios. RNA yields were in
the range of 250 - 350ng/Pl.
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2.2.2.1 Formaldehyde gel electrophoresis
RNA quality was also assessed qualitatively by visually assessing the ratio of
18:28S ribosomal RNA on a 1% formaldehyde gel (1% agarose, 1x MOPS,
0.7% formaldehyde). Briefly, 0.4g of low melting point Nusieve
®
GTG
®
agarose (Bio-Rad Laboratories, UK) was dissolved in 35.3ml double distilled
water by heating and allowed to cool slightly before addition of 4ml 10x
MOPS buffer (400mM MOPS, 100mM sodium acetate, 10mM EDTA;
Eppendorf, Cambridge, UK) and 0.7ml deionised 37% formaldehyde (Sigma).
The gel solution was poured into a prepared plate and comb mould and allowed
to set at 4°C. The gel was run at 130mA for 20 minutes in gel buffer (1x
MOPS, 0.7% formaldehyde) and RNA samples (1Pl) were heated for 15
minutes at 55°C in RNA buffer (0.25Pg/Pl ethidium bromide, 1x MOPS, 50 %
(v/v) deionised formamide, 6% deionised formaldehyde). Samples were mixed
with a loading buffer (43.5% (v/v) glycerol, 2mM EDTA, 0.02% (w/v)
bromophenol blue) and loaded along with a 0.24  9.5 kb RNA ladder
(Invitrogen). RNA was visualised using a UV transilluminator (Syngene,
Cambridge, UK) and images were acquired with Gene Tools software
(Syngene,). See example in figure 2.6.
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Figure 2.6: Qualitative assessment of total RNA extracted. In the example
displayed, 1Pl of extracted RNA was resolved on a 1% formaldehyde gel and
the two bands present in each sample correspond to ribosomal 28S and18S
RNA. The minimal smearing and the approximate 2:1 ratio of 28S:18S RNA
are both indicators of good quality RNA.
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2.2.3 cDNA synthesis
First strand cDNA synthesis was carried out by reverse transcription using 1Pg
of total RNA. RNA samples were incubated with 1Pl of random hexamer
primers (0.5Pg/Pl; Promega, Madison, USA) at 70°C for 5 minutes in a
thermocycler to denature RNA secondary structure and then immediately
placed on ice. To each sample was added 1Pl of Maloney murine leukaemia
virus (MMLV) reverse transcriptase (200 U/Pl; Promega), 5Pl MMLV reverse
transcriptase buffer (Promega), 0.5Pl RNase inhibitor (40 U/Pl; Promega) and
1.25Pl of a nucleotide mix containing dATP, dCTP, dGTP and dUTP (10mM
each; Qiagen, Crawley, UK) up to a final volume of 30Pl with RNAse-free
water. An extra sample, which excluded the reverse transcriptase and had 1Pl
of RNAse-free water instead, was created to use as a reverse transcription
minus (RT-) control in RT-PCR analyses. All samples were incubated at room
temperature for 10 minutes, then 40°C for 1 hr followed by 15 minutes
incubation at 70°C in a thermocycler to inactivate the reverse transcriptase.
2.2.4 Taqman analysis
All Taqman primer/probe sets were obtained from Applied Biosystems (ABI,
Foster City, CA, USA); the primer and probe sequences are unavailable due to
protection of intellectual property rights. However, primers were designed to
span across exon/exon boundaries, thus ensuring genomic DNA was not
amplified. Each primer/probe set was validated in accordance with Applied
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Biosystems User Bulletin No.2 by running a series of RT-PCRs using serially
diluted 2-fold cDNA templates to obtain standard curves of Ct number versus
log relative concentration (see figure 2.4). All probe/primer sets amplified
cDNA with similar efficiencies (reviewed in section 2.2.1), thus allowing use
of the comparative Ct method for relative quantification of gene expression.
Amplicon lengths were verified by resolution on a 4% agarose Tris-borate-
EDTA (TBE) gel (see figure 2.7)
All real-time PCR reactions (including non-template and RT controls) were
carried out in duplicate using the ABI Prism 7700 Sequence Detection System
(Applied Biosystems) in MicroAmp 96-well reaction plates (Geneflow,
Fradley, UK). Each well contained 12.5Pl of Taqman universal master mix
(catalogue no.4369514; Applied Biosystems), 1.25Pl primer/probe mix (final
concentrations were: primers  900nM each and probe  250nM), 2Pl cDNA
template (or no-template control or RT- sample), in a 25Pl final reaction
volume with RNase-free water. Cycling parameters were 50°C for 2 minutes,
95°C for 10 minutes followed by 40 cycles of 95°C for 15 seconds, and 60°C
for 1 minute. The Ct value for each duplicate was averaged and data from the
treated group was normalised to the control group as described in section 2.2.1.
The control group was given a value of 1 and fold changes in mRNA
expression of the treated group are relative to the control group.
2.2.4.1 DNA electrophoresis
The specificity of RT-PCR was verified by resolving PCR products on an
agarose gel alongside a DNA ladder to determine if fragments of the correct
molecular weight were amplified. A 4% agarose gel was used for the resolution
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of small PCR products (see figure 2.7). Briefly, Nusieve
®
GTG
®
agarose (Bio-
Rad) was dissolved in 0.5x Tris-borate-EDTA (TBE; 45mM Tris base, 45mM
boric acid, 1mM EDTA, pH 8) and distilled water by heating. The solution was
allowed to cool slightly, ethidium bromide (0.07Pg/ml) was added before the
gel was cast and allowed to set at room temperature. Loading buffer (43.5%
(v/v) glycerol, 2mM EDTA, 0.02% (w/v) bromophenol blue) was added to
DNA samples at a ratio of 1:1.6 respectively; samples and DNA ladder (100bp
direct load DNA ladder, Sigma) were loaded and the gel was run in 0.5x TBE
running buffer at 200Volts for 20 minutes. RNA was visualised using a UV
illuminator (Syngene) and images were acquired with Gene Tools software
(Syngene).
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Figure 2.7: Verification of correct amplicon lengths for all primer/probe
sets used. RT-PCR using specific primer/probe sets amplified targeted
sequences and produced amplicons of the correct molecular weight when
resolved on a 4% (w/v) agarose gel by electrophoresis.
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2.2.5 Analysis of protein expression (Western blotting)
Western blotting is routinely used for the analysis of protein expression by
using specific antibodies to identify protein targets separated by sodium
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). Proteins
separated according to molecular weight are first transferred electrophoretically
to a membrane support such as nitrocellulose followed by a blocking step to
reduce non-specific antibody interaction and subsequent incubations with
primary and secondary antibodies. Secondary antibodies are usually conjugated
to haptens such as biotin or horse radish peroxidase (HRP) to facilitate
visualisation of protein bands. These blotting steps are preceded by protein
extraction and quantification in order to normalise protein load. Relative
protein expression can be determined by densitometry; comparing the intensity
of protein bands between control and treated groups after normalisation to an
endogenous control, such as E-actin.
2.2.5.1 Muscle protein extraction
Cytosolic and nuclear proteins were extracted from muscle using a
modification of the method by Blough et al.(1999). Approximately 30mg of
frozen muscle was homogenised in 600Pl homogenisation buffer (50mM Tris-
HCl, 1mM EDTA, 1mM EGTA, 1% (v/v) NP-40, 0.1%( v/v) 2-
mercaptoenthanol, pH7.5) supplemented with mammalian protease inhibitor
cocktail (10Pl/ml, Sigma-Alrich, Poole, UK). Muscle lysates were incubated
on ice for 10 minutes before centrifugation (13,000g, 10minutes at 4°C); the
supernatant was used as crude cytosolic protein fraction and stored at -80°C.
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The remaining pellets were resuspended in 500Pl of an ice-cold high salt lysis
buffer (20mM HEPES, 25% (v/v) glycerol, 500mM Nacl, 1.5mM MgCl2,
0.2mM EDTA, pH7.9) supplemented with more protease inhibitor cocktail
(10Pl/ml) and incubated on ice for 30 minutes with intermittent mixing.
Samples were spun (3,000g, 5min at 4°C) and the supernatant was collected as
nuclear protein fraction. The insoluble pellet containing collagen and fibrous
connective tissue was discarded and the soluble nuclear fraction was stored at -
80°C.
2.2.5.2 Muscle protein quantification (Lowry assay)
Extracted proteins were quantified using the Lowry assay (Lowry et al. 1951).
Briefly, 1Pl of each protein sample was submitted for quantification alongside
bovine serum albumin (BSA; 1mg/ml diluted in 0.1M sodium hydroxide
(NaOH)) standards in duplicate. BSA standards were in the range of 0  80Pg
total protein in a final volume of 100Pl in 0.1M NaOH. Protein samples and
blanks (NaOH, homogenisation buffer and water) were also in a final volume
of 100Pl in 0.1M NaOH .All standards/blanks/samples were pipetted onto a 96
well microtitre plate and 50Pl of the Lowry reagent (2% (w/v) sodium
carbonate, 2% (w/v) sodium potassium tartate and 1% (w/v) copper sulphate
solutions at a ratio of 10:1:1 (v/v)) was added to each well and incubated at
room temperature for 10 minutes with gentle rocking. Subsequently, 50Pl of
Folin reagent (Folin and Ciocalteus phenol reagent (Fisher Scientific,
Loughborough, UK) 10% (v/v) in 0.1M NaOH) was added to each well and
incubated for 30 minutes at room temperature with gentle rocking to encourage
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colour development. The plate was read in a plate reader (DYNEX
technologies, Worthing, UK) at 650nm. Protein concentration was determined
based on the absorbance of protein samples (after blank subtraction) relative to
the BSA protein standard curve.
2.2.5.3 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE)
SDS-PAGE separates proteins according to molecular weight and protein
samples are diluted in a reducing buffer containing urea, dithiothreitol (DTT),
2-mercaptoethanol and SDS to denature and solubilise proteins. SDS is an
anionic agent which binds to polypeptide chains in a mass ratio of 1.4:1 to
confer negative charge on the peptides such that their migration speed within
the gel is roughly proportional to their mass, when an electric field is applied to
the gel. Polyacrylamide gels are a chemically inert hydrophilic network of
hydrocarbons cross-linked by bisacrylamide groups. The pore size is
determined by the ratio of polyacrylamide-to-bisacrylamide cross-linker, which
ultimately determines the degree of protein fractionation. The acrylamide
concentration can be varied between 5-20% for various purposes; lower
percentage gels are used for resolving high molecular weight proteins whilst
higher percentage gels resolve smaller proteins. Gradient gels, which are used
within this thesis, resolve both high and low molecular weight proteins and are
useful for achieving a much greater separation. With gradient gels, the pore
size varies uniformly (typically 5% at the top to 20% at the bottom of the gel)
5-20% polyacrylamide resolving gels were poured using a gradient mixer.
Firstly, 5 and 20% resolving gel mixtures were prepared and made up to a
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10ml final volume with deionised water. The 5% solution contained 1.67ml of
30% (w/v) acrylamide (acrylamide to bisacrylamide 37.5:1; Severn Biotech,
Kidderminster, UK), 3.33ml of buffer B (1.1M Tris, 0.1% (w/v) SDS, pH 8.8)
and 100Pl of 0.1% (w/v) SDS. The 20% solution contained 6.67ml acylamide,
3.33ml of buffer A (1.1M Tris, 0.1% (w/v) SDS, 30% (v/v) glycerol pH 8.8),
and 100Pl of 0.1% (w/v) SDS. Just before pouring, 100Pl of 10% (w/v)
ammonium persulpahte (APS) and 10Pl of undiluted
tetramethyleythlenediamine (TEMED; Sigma Aldrich) were added to each
solution and mixed to catalyse polymerisation. The gel was layered at the top
with a thin film of water-saturated butanol, which removed air bubbles and
prevented dehydration, then allowed to set at room temperature.
A 5% stacking gel (0.12M Tris, 0.1% (w/v) SDS, pH 6.8) was similarly
prepared and polymerised using APS and TEMED as above. The stacking gel
(the purpose of which is to concentrate proteins samples into sharp bands
before they enter the main separating gel and trap proteins of molecular
weights above ~250kDa) is poured on top of the resolving gradient gel and
wells are formed into this for protein loading. Protein samples were diluted
with double distilled water to required concentration before the addition of a
Laemmli type SDS buffer (gel application buffer (GAB); 0.15M Tris, 8M urea,
2.5% (w/v) SDS, 20% (v/v) glycerol, 10% (w/v) 2-mercaptoethanol, 3% (w/v)
DTT, 0.1% w/v bromophenol blue, pH6.8) at a ratio of 2.5:1. For example,
20Pl of diluted protein sample to 8Pl of GAB. Samples (containing ~2.5Pg/Pl
of protein) were heated at 95°C for 5mins prior to loading, along with protein
ladders (BIO-RAD All Blue Precision Plus Protein Standards, Hercules, CA,
USA). The gel was run at 40mA (E-C Apparatus Corporation, Milford, MA,
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USA), until the advancing dye front just starts to run out into the surrounding
electrode buffer (0.025M Tris, 0.19M glycine, 0.1% (w/v) SDS).
2.2.5.4 Western blotting
Following electrophoresis, the negatively charged proteins in the gel are
transferred electrophoretically onto nitrocellulose membrane (Amersham,
Hybond-C Extra, GE Healthcare, Little Chalfont, UK). The gel and
nitrocellulose membrane are soaked in Western transfer buffer (0.025M Tris,
0.192M glycine, 20% (v/v) methanol) prior to contact. The membrane was
place next to the gel (taking into account the direction of protein migration)
and sandwiched between absorbent materials and clamped between solid
supports to maintain tight contact between the gel and the membrane. Proteins
were transferred onto nitrocellulose membrane in transfer buffer overnight at
40mA (Fisher Electrophoresis unit) at room temperature. Confirmation of
protein transfer was achieved by staining membrane with Ponceau S solution
(0.1% (w/v) Ponceau S, 10% (v/v) glacial acetic acid) until protein bands were
visible and membranes were subsequently de-stained with TBS-T (tris-
buffered-saline with tween; 10mM Tris, 150mM NaCl, 0.05% (v/v) tween-20,
pH 7.5)
Membranes were blocked with 5% non-fat milk in TBS-T for 1hr at room
temperature and then incubated with primary antibody overnight at 4°C. For
specific antibody information, including dilutions and manufacturer, see
individual chapters. Membranes were washed for 3 x 5 minutes in TBS-T to
remove excess/unbound primary antibody before incubating in HRP-
conjugated secondary antibody for 1hr at room temperature. After washes in
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TBS-T (3 x 5 minutes), membranes were immersed in Enhanced
Chemiluminescence solution (ECL; Western Lightning Plus, Perkin Elmer,
Waltham, MA, USA) for 1-2 minutes according to manufacturers instructions.
Briefly, reagents A and B were mixed at a 1:1 ratio and added to membranes,
which were blotted briefly to remove excess ECL solution before exposure to
hyperfilm (Amersham Hyperfilm ECL, GE Healthcare) for 1 to 30 minutes.
HRP conjugated to the secondary antibody reacts with the chemiluminescence
substrate, which produces light as a by product detected on hyperfilm. The
amount of light produced (signal intensity) is relative to amount of bound
antibodies and therefore the amount of a specific protein on the membrane.
Following exposure, films were developed (developing solution diluted 1:10
with distilled water; Calumet Photographic Ltd, Milton Keynes, UK), fixed
(fixing solution diluted 1:5; Calumet Photographic Ltd), rinsed in water and
air-dried. Films were scanned to produce digital copies and bands were
quantified using densitometry and Gene Tools Software (Syngene, Cambridge,
UK), which produces arbitrary intensity values correlated to the protein band
intensity. These values were adjusted by subtracting the background and
normalising to respective endogenous controls; actin for cytosolic proteins and
lamin A/C for nuclear proteins. Cross-contamination between cytosolic and
nuclear fractions was assessed using these two antibodies; blots of cytosolic
protein fractions showed no bands for lamin after long exposure (>30 minutes).
Similarly, blots containing nuclear protein fractions did not show actin bands
after exposure for over 30 minutes.
67
2.2.6 Histological analyses
2.2.6.1 Immunohistochemistry
To localise and in some cases quantify protein expression in skeletal muscle,
10Pm frozen serial cross sections were cut (Leica Microtome, Leica
Microsystems, Wetzler, Germany) and mounted onto Superfrost
®
Plus slides
(ThermoFisher Scientific, Loughborough, UK). Frozen muscles were first
secured onto a chuck using optimal cutting temperature (OCT) mounting
medium (Tissue-TEK, Sakura, Thatcham, UK); the cryostat chamber
temperature was between -18°C and -24°C and the chuck temperature was in
the range of -16°C to -20°C depending on the optimal cutting parameters of the
tissue being cryro-sectioned. Unless otherwise specified, sections were fixed in
4% Paraformaldehyde/Phosphate-Buffered-Saline (PFA/PBS: 4% (w/v) PFA,
137mM NaCl, 2.7mM KCl, 4.3mM KH2PO4 5mM MgCl2, pH 7.4) for 10
minutes, washed for 3x5 minutes in TBS (0.05M Tris, 0.15M NaCl, pH 7.4)
and the reaction area for each section on the slide was delimited using a liquid
blocker/pap-pen (Sigma-Aldrich).
Sections were then blocked for 1hr at room temperature with 5% normal serum
(Vector Laboratories, Burligame, CA, USA) diluted with TBS. For all
incubation steps, slides were incubated in a moist chamber (tissue paper
saturated with TBS) to prevent dehydration. The blocking serum employed was
from the species in which the secondary antibody was raised (e.g. horse).
Sections were briefly aspirated to remove blocker before incubating with
primary antibody diluted in blocking solution; for specific antibody
information including manufacturer details, dilution, and incubation
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temperature/duration, see chapter 4, section 4.3.4. Negative control sections
were incubated in blocker only. Slides were washed for 3 x 30 minutes in TBS
prior to the addition of a labelled secondary antibody (e.g. biotin) and
incubation at room temperature for 1 hr. Following secondary antibody
incubation, slides were washed for 3 x 5 minutes in TBS. Antibody binding
was visualised with the Vectastain
®
ABC Kit (Vector Labs). The ABC
(Avidin: Biotin enzyme Complex) technique employs avidin, which has very
high affinity for biotin and binds biotin essentially irreversibly at four different
sites. The ABC kit contains reagent A (streptavidin) and reagent B
(biotinylated HRP) and these were mixed in 5ml TBS at a 1:1 ratio and
incubated for a minimum of 1 hr at room temperature, before applying to
sections. This enables the formation of the ABC complex whereby streptavidin
cross-links biotinylated HRP in a three-dimensional array with few
exposed/unbound biotin molecules but with at least one remaining biotin
binding site, to which the biotinylated secondary antibody binds. Secondary
antibodies are conjugated with several molecules of biotin, which increases the
sensitivity and specificity of the reaction. Sections were incubated with ABC
reagent for 30 minutes at room temperature followed by 3 x 5 minute washes in
TBS.
The antigen of interest is visualised by incubating sections with a substrate for
the biotinylated enzyme; in this case, the 3, 3-diaminobenzidine (DAB)
peroxidase substrate kit (Vector Labs) was used according to the
manufacturers instructions. Briefly, 1 drop of buffer stock solution (pH 7.5), 2
drops of DAB stock solution and 1 drop of hydrogen peroxide solution were
added to 2.5ml of distilled water with intermittent mixing in-between. The
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DAB solution was added to sections and colour development was controlled
visually under a light microscope. The optimal duration for colour
development was replicated for the remaining slides. DAB is oxidised by HRP
and leaves a brown precipitate at the site of antigen recognition. To stop the
DAB reaction, slides were rinsed for 3 x 5 minutes in distilled water. As DAB
is a carcinogen, excess solution and that aspirated from slides was neutralised
in equal volumes of 3% (w/v) potassium permanganate and 2% (w/v) sodium
carbonate. Slides were rinsed, air dried and mounted in glycerol gelatine
(Merck, Darmstadt, Germany) for microscopy (DM4000B light microscope,
Leica). Images were acquired using a Micropublisher 3.3 RTV digital camera
(Q-Imaging, British Columbia, Canada) with OpenLab software (Perkin Elmer)
2.2.6.2 Immunofluorescence
Protein expression was also analysed by immunofluorescence to confirm the
co-localisation of protein targets of interest. Tissue samples were cryo-
sectioned as described above in section 2.2.6.1. Formaldehyde vapour fixation
was used to localise secreted protein targets such as TNF-D. This method of
fixation methylates protein lysine groups thereby denaturing and partially
cross-linking proteins. Using vapour fixation minimises the loss of soluble
antibody targets in solution compared to PFA fixation; soluble proteins are
cross-linked in a frozen state, keeping them as close to in vivo structure as
possible. Briefly, tissue paper was saturated with 37% formaldehyde and
placed in a sealed chamber at -20°C, to which slides were immediately added
and fixed in formaldehyde vapour for 30 minutes. After fixing, sections were
washed for 3 x 5 minutes in TBS and the reaction area delimited as above.
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Sections were blocked with 5% normal serum for 1 hr at room temperature and
incubated with primary antibodies (see chapter 4, section 4.3.4.2 for specific
antibody information and conditions). Negative, technical control sections were
incubated with blocker only. Slides were washed for 3 x 5 minutes in TBS
before incubation with fluorescently-labelled secondary antibody or antibodies
(for double detection). The fluorescent secondary antibodies were purchased
from Invitrogen (Paisley, UK) and were used at 1:200, diluted in blocker. The
excitation/emission of the fluorophores conjugated to the secondary antibodies
was carefully considered to prevent antibody species cross-reactivity and
spectral cross over, e.g. rabbit vs mouse  alexa 488 vs 568. Sections were
incubated with the respective secondary antibody (or a combination) in a dark
moist chamber for 1hr at room temperature. Slides were then rinsed for 5 x
5minutes in TBS, air dried and mounted in ProLong Anti-fade Gold with DAPI
(Invitrogen). Visualisation and image acquisition were carried out using a
DMIRB fluorescence microscope with an attached digital camera (Leica) and
OpenLab software (Perkin Elmer).
2.2.6.3 Duolink
®
Bright-field Proximity Ligation Assay (PLA)
The Duolink
®
PLA enables in-situ detection and visualisation of proteins or
protein complexes in tissue samples prepared for microscopy. Specificity for a
single protein target is enhanced by using two different primary antibodies
raised in two different species. Oligonucleotide-conjugated secondary
antibodies (PLUS and MINUS PLA probes), bind to the two different Fc
fragments when in close proximity and combine to form a circular DNA
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Figure 2.8: Schematic representation of Bright-field Proximity Ligation
Assay (PLA) to detect and quantify a single protein target with high
specificity. The use of two primary antibodies directed against different non
competing epitopes on the same antigen increases the specificity of the assay;
this is useful for conditions where the use of either antibody independently
yields unsatisfactory results. The oligonucleotides on the PLA probes when
within less than 40nm of each other are hybridised via linker oligonucleotides
to form a circular DNA template, which is subsequently ligated and amplified
by rolling cycle DNA replication. Complementary HRP-tagged
oligonucleotides hybrise to amplified product and addition of a HRP substrate
(NovaRED) results in its enzymatic conversion to produce a visible
red/brown precipitate at the site of antigen detection.
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template that is subsequently amplified by rolling cycle amplification (see
figure 2.8 for a summary of the method). HRP-tagged oligonucleotides
specifically hybridise with amplified DNA and the signal from each detected
pair of primary antibody is visualised as a quantifiable individual spot by
microscopy
Briefly, cross sections were prepared and fixed in 4% PFA as described in
section 2.2.6.1 above. Cross sections were blocked in 5% normal serum for 1hr
at room temperature. Primary antibodies were added either individually (as an
additional technical negative control) or in combination and negative control
sections were incubated in blocking solution only. See chapter 4 for specific
antibody dilutions and manufacturer information. All were incubated at 4°C
overnight. Sections were washed for 3 x 30 minutes in TBS. The
oligonucleotide-conjugated Minus and Plus PLA probes were used at a dilution
of 1:5 in blocking solution and incubated with respective sections for 2hr at
37°C in a humid chamber. Slides were then incubated in the following
solutions between washes in TBS-T: hybridisation (diluted 1:5 with high purity
distilled water, 15min at 37°C), ligation (ligase was 1U/Pl, 15min at 37°C)
amplification (polymerase was 10 U/Pl, 90min at 37°C) and HRP detection
solutions (diluted 1:5, 30min at room temperature).
Slides were incubated in Duolink
®
substrate solution (containing the HRP
substrate NovaRED
TM
) for 10 minutes at room temperature, washed and
nuclear stained (Mayers Haematoxylin) for 2 minutes. Slides were left under
running tap water for 10 minutes to allow stain development. Prior to mounting
in non-aqueous medium (Canada Balsam with xyelene, Merck, Darmstadt,
Germany) for light microscopy, slides were dehydrated and cleared in
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increasing concentration of ethanol (96%, 99.7% for 2 x 2 minutes each) then
two changes with xylene for 10 minutes. Images acquisition using light
microscopy was performed as described above.
2.2.6.4 Muscle Fibre Diameter Determination
To establish whether BRL-47672 treated muscle exhibited muscle hypertrophy,
muscle fibre diameter in control and treated muscle cross sections were
determined using a quantitative method developed by Briguet et al. (2004).
This method reliably measures the size of muscle fibres based on the minimal
Ferets diameter of muscle fibre cross sections; this is easily done using ImageJ
(Rasband, W.S., ImageJ, National Institutes of Health, Bathesda, Maryland,
USA; ImageJ 1.40g, http://rsb.info.nih.gov/ij) with the ImageJ plug-ins
MosaicJ (Thevenaz and Unser 2007)and TurboReg (Thevenaz, P., Biomedical
Imaging group, Swiss Federal Institute of Technology Lausanne). ImageJ
defines the maximal Ferets diameter as the longest distance between any two
points along the selection boundary. This is also known as the maximum
calliper distance (ImageJ User Guide, IJ 1.40g; http://rsb.info.nih.gov/ij/docs),
whereas the minimal Ferets diameter is the minimal calliper distance (see
figure 2.9). The minimal Ferets diameter is least affected by changes in the
cutting plane in which muscles are sectioned (Briguet et al. 2004) and was
therefore deemed suitable for comparing muscle fibre size in control and
treated rat muscle.
2.2.6.4.1 Image acquisition and analyses
Soleus muscles from saline or BRL-47672-treated rats were processed for
histochemical analysis as described in section 2.2.6.1. Briefly, sections were
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Figure 2.9: Schematic representation of the minimal and maximal Ferets
diameter.
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fixed in 4% PFA, blocked in 5% normal goat sera and stained with rabbit anti-
laminin polyclonal antibody (diluted 1:300; Sigma) for 1 hr at room
temperature. Primary antibody localisation was visualised using the ABC
systems and DAB as outlined above; this localised laminin to the sarcolemma
and created defined borders representing muscle fibres and enabled particle
recognition for fibre diameter measurement using ImageJ software (see figure
2.10). The staining with DAB was controlled visually and allowed to develop
to a strength which was sufficient for the production of definitive borders for
particle recognition.
Images were acquired by light microscopy (Axioplan/Tessover, Carl Zeiss Ltd,
Oberkochen, Germany) using a 1.25x objective lens and OpenLab software
(Perkin Elmer). Three to four sections of each muscle sample was
photographed by acquiring overlapping images which were subsequently
stitched into a single cross-sectional image using MosaicJ. Additionally, an
image of a light microscope stage graticule ruler (Leica) was taken as a
reference for scale calibration using ImageJ. Minimal Ferets diameter analyses
of stained muscle fibres were carried out by firstly selecting the area to be
analysed on the mosaic image, thus excluding folded areas, large artefacts or
areas where staining was too deemed too light for maxima detection.
Firstly, using the ImageJ command Process => Find Maxima => Output type
=> Segmented particles produced an 8-bit binary image output from your
selected image, displaying segmented particles, each of which represents
detected local maxima, the defined borders of muscle fibres. These segmented
particles were analysed by setting measurements to include the Ferets
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diameter (Analyze => Set Measurements => Check Ferets Diameter box) then
by using the ImageJ command Analyze => Analyze Particles => Show
Outlines and checking the Display results box. This counted and measured
particles in the selected area by scanning the image to find the edge of the
particles, then outlining and measuring each particle. This generated another 8-
bit image containing numbered outlines of measured particles (ie, muscle fibres
 see figure 2.10) and a results table displaying the minimal Ferets diameter
among other measurements for each particles. The average minimal Ferets
diameter for each cross section was taken after esclusion of the minimal Ferets
diameter data for small particles such as capillaries and really large particles
representing two or more merged muscle fibres or large arteries and veins.
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Figure 2.10: Schematic summary of Ferets diameter methodology
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2.2.6.5 Stereology
Stereological methods in histology obtain quantitative information about three-
dimensional (3D) features of tissues from two-dimensional physical sections.
10Pm muscle cross sections were prepared from control and treated animals
randomly sampled from the proximal, distal or mid-belly regions of EDL and
gastrocnemius muscles as described above. The total numbers of profiles (i.e.
positive cells) for each section were counted with the aid of an eye-piece
graticule and section scanning (see figure 2.9). The profiles counted were Iba-
1
+
, Pax7
+
, MyoD
+
cells and Ki-67 PLA spots (see chapter 4). A minimum of 3
and a maximum of 5 sections were counted per sample, which were
approximately 100Pm apart (that is roughly every 10th section was taken). The
surface area of each muscle section (Ax-sect) was estimated using a systematic
uniform point grid of known area (a
p
- e.g. 1mm
2
per point) randomly
superimposed over a low magnification image of the section. Points
(represented by the crossing of horizontal and vertical lines over the muscle
section) were counted and an estimate of the surface area of each cross section
is given by the formula: Ax-sect (Pm2) = Ȉ points x (ap/M2) where M is the
magnification used. Using a modification of the method by Mayhew et
al.(1997), an estimate of the number of profiles (Nprof) per volume of muscle
(Vmusc) was calculated using the formula presented in figure 2.9.The mean
diameter of each profile of interest (immuno-positive cells or Ki-67
+
nuclei)
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Figure 2.11: Summary of stereological methodology for the quantification of positive cells in muscle cross sections prepared by immunocytochemistry.
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was estimated from approximately 50 positive profiles using Open Lab
software and integrated into the equation below. The equation assumes the
profiles are roughly spherical (4/) and takes into account the three
dimensional aspects of cells stained via immunohistochemistry (section
thickness/surface area and cell or nuclear diameter) to estimate the number per
volume of muscle. For a review, see Muhlfeld et al. (2009).
.
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CHAPTER 3
Results (I)
Chronic administration of the clenbuterol pro-
drug BRL-47672 increases skeletal muscle satellite
cell activity
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3.1 SUMMARY
High doses of E2-agonists such as clenbuterol have demonstrable anabolic
actions on muscle metabolism and growth, the latter of which is thought to occur
via stimulation of muscle protein synthesis and suppression of protein
degradation. However, the effects on satellite cell activity in vivo are less
documented. The use of clenbuterol to prevent or reverse muscle wasting
accompanied by many disease states (e.g. cancer cachexia, AIDS, etc) has so far
been limited due to deleterious cardiovascular effects. In the present study, the
E2-agonists pro-drug, BRL-47672 was used; it replicates the anabolic actions of
clenbuterol with reduced cardiovascular consequences.
Male Wistar rats were injected with BRL-47672 (900Pg/kg; s.c., n=7) or an
equal volume of saline (n=6) daily for 8 weeks. 24 hrs following final injections,
rats were terminally anaesthetised (Inatin; 120mg/kg; i.p) and the soleus muscles
were removed and analysed for mRNA transcript and protein expression of
muscle and satellite cell specific markers, pax7, ki-67, myoD, myogenin,
myostatin and follistatin.
BRL-47272 caused a slight increase in muscle fibre diameter and is indicative of
muscle fibre hypertrophy. It also caused a significant increases in mRNA
expression of pax7, ki-67, myoD and myostatin relative to saline control
(p<0.05). No significant changes were noted in the mRNA expression of
myogenin and follistatin. The protein expression of pax7 and myoD were
tendentially increased by pro-drug treatment (p~0.12 and p~0.09, respectively).
Protein expression of the myostatin precursor protein was also significantly
increased by BRL-47672 administration (p<0.05).
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Taken together these results suggest the pro-drug increases muscle growth and
thus satellite cell activity (activation/proliferation; denoted by increased pax7,
ki-67 and myoD expression), which is compatible with maintaining myoblasts in
an actively proliferating state of readiness, available for subsequent
incorporation by growing myofibres. However, the transient effects of chronic
E-agonist administration may have resulted in skeletal muscle acclimatisation,
which could include the stimulation of compensatory pathways, such as
myostatin up-regulation. This could have limited myoblast differentiation
(denoted by reduced/unchanged myogenin) and ensured further muscle growth
was limited but not entirely ablated. Intermittent E-agonist administration
coupled with myostatin suppression (for e.g., via an inhibitory transgene
expression such as follistatin) may represent an effective method of preventing
E-receptor desensitization in order to maintain exponential muscle growth and
prevent or reverse severe muscle atrophy.
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3.2 INTRODUCTION
Endogenous beta agonists such as noradrenaline, adrenaline and isoprenaline are
produced by the sympathetic nervous system and adrenal medulla to stimulate E-
adrenoreceptors in peripheral tissues. These activate downstream signalling
pathways controlling heart rate and contractility, vasoconstriction (gut and skin),
or vasodilatation in skeletal muscle (reviewed in Lynch and Ryall 2008).
Synthetic E-agonists, which are structurally similar and can elicit similar
responses in peripheral tissues, were primarily used to treat asthma and other
chronic obstructive diseases until it became apparent doses higher than those
used therapeutically could increase muscle growth.
Consequently, the anabolic actions of E-agonists on skeletal muscle have been
extensively studied as a means to prevent or reverse muscle wasting in numerous
disease states such as cachexia, sepsis, sarcopenia and muscular dystrophies. The
main mechanisms by which E-agonists elicit anabolic responses in skeletal
muscle are traditionally believed to occur by stimulating protein synthesis,
suppressing protein degradation or a combination of both (Emery et al. 1984;
Benson et al. 1991). Canonical E-agonists signalling is well described; its
downstream effects include the activation of protein kinase A (PKA) via
hetrotrimeric G-protein (GDs subunit) and cyclic AMP, and the activation of
phosphoinositol 3-kinase (PI3K)-protein kinase B (AKT) via the GEF subunit,
all of which are regulators of both protein synthesis and degradation (for a
review, see Ryall and Lynch 2008)
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In addition to anabolic alterations in skeletal muscle, several studies have
implicated E-agonists in the transition of muscle fibre type phenotype from a
slow-oxidative to faster oxidative-glycolytic fibres (Zeman et al. 1988; Criswell
et al. 1996; Rajab et al. 2000; Jones et al. 2004). Postnatal fibre type transitions
are initiated to meet physiological demand (reviewed in Sieck and Regnier
2001); for instance inactivity results in a general shift in myosin heavy chain
(MHC) isoform expression and metabolic properties from type I to II and
endurance training promotes a shift in the opposite direction. Similar fibre type
transitions have been reported in response to hormonal imbalances, electrical
stimulation and in human skeletal muscle during ageing, whereby a decrease in
the number and size of fast fibre types has been associated with impaired muscle
function in the elderly (Termin and Pette 1992; Larsson et al. 1994; Dutta et al.
1997; Balagopal et al. 2001).
Whilst the mechanisms underlying changes in fibre type toward a slower
phenotype have been extensively characterised (Hughes 2004; Oh et al. 2005;
Handschin et al. 2007; Kim et al. 2008), the pathways regulating the
establishment and maintenance of fast fibre type phenotypes have remained
largely unknown (Grifone et al. 2004). One hypothesis is that they are thought to
occur by the transient modulation of myoD-myogenin expression (reviewed in
Talmadge 2000). Adult slow muscles contain a high myogenin:myoD ratio
whereas the reverse is seen in fast muscles (low myogenin, high myoD) and E-
agonist-induced fast fibre type transitions are concomitant with altered
expression of myogenin and myoD (high myoD, low myogenin). However, this
is appears to be dependent on the activity status of the muscle; Mozdziak et al.
(1998) showed that clenbuterol did not induce fibre type transitions in
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overloaded soleus muscle. Likewise, clenbuterol fed to rats in a hindlimb
immobilisation study led to an increase in myogenin but no change in myoD
(Delday and Maltin 1997). These fibre type transitions are not without
consequences for muscle function; although largely dose-dependent, a dramatic
shift from a slow to fast MHC phenotype can alter muscle contractile properties
(Ryall et al. 2004) and increase muscle fatigability (Dodd et al. 1996).
A major drawback of E-agonists which has limited their use in a clinical setting
is their potentially deleterious effects on the cardiovascular system. Clenbuterol
administration causes substantial haemodynamic changes in rats; it increases
heart rate and vascular conductance in the hindquarters, whilst reducing mean
arterial blood pressure (Rothwell et al. 1987; Jones et al. 2004). These changes
increase the risk of ischemia, congestive heart failure, arrhythmias and even
sudden death. Therefore, in the present study, the pro-drug of clenbuterol, BRL-
47672 (Sillence et al. 1995) was administered. It is thought to be metabolised to
a potent E2-agonist in vivo. The work of Jones et al. (2004) demonstrated BRL-
47672 minimised the cardiovascular and haemodynamic effects compared to
clenbuterol without compromising anabolic and fibre type changes.
The effects of chronic E2-adrenergic stimulation on satellite cell activation are
less documented. There have been numerous demonstrations of the growth
promoting effects of E-agonists on skeletal muscle; however, the link between
satellite cell activation and myogenesis and E-agonist-induced muscle growth
remains elusive. Studies on E2-agonist treated satellite cell cultures either found
a lack of effect (Young et al. 1990; McMillan et al. 1992) or an increase in
proliferation but no apparent change in differentiation or fusion (Grant et al.
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1990). Consistent with these studies was a time and dose-dependent increase in
protein and DNA content, which was attributed to satellite cell activation. In
vivo, clenbuterol stimulated earlier activation and proliferation of satellite cells
in transplant studies (Roberts and McGeachie 1992). Maltin and Delday (1992)
found evidence of satellite cell activation and some division in denervated and
innervated muscles of clenbuterol treated rats. Whether E2-agonists act directly
to stimulate satellite cell activation or indirectly as a result of increased blood
flow and delivery of blood-borne mitogens remain undetermined.
Two prominent markers of satellite cell activation (myoD) and differentiation
(myogenin) are implicated in E2-agonist-induced modulation of MHC phenotype
but as far as we are aware, no studies have correlated these fibre type transitions
or the growth promoting effects of E2-agonists with a comprehensive picture of
satellite cell activity. Lines of evidence suggest that the mRNA and protein
expression of these two MRFs accumulate preferentially in activated satellite
cells, proliferating myoblasts and newly formed myotubes, especially following
trauma (Cooper et al. 1999). It is also possible changes in the level of myoD and
myogenin expression could occur in the nuclei of mature muscle fibres or
activated satellite cells but it is still unclear which has the predominant source of
myoD and myogenin in normal adult muscle (Dedkov et al. 2003). In the present
study, we examine the effects of long term %RL-47672 pro-drug treatment on
the expression of well characterised satellite cell markers. Discovery of the role
of satellite cells in changes in muscle mass and postnatal fibre type transitions
could illuminate how skeletal muscle adaptations occur in disease states that lead
to muscle dysfunction.
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In addition, myostatin, a negative regulator of muscle mass, is examined to
determine its role in the anabolic actions of E2-agonists. Lack of myostatin leads
to increased skeletal muscle mass (McPherron et al. 1997), while conversely,
systemic administration of myostatin leads to muscle wasting in rodents
(Zimmers et al. 2002). Therefore it is tempting to speculate that the anabolic
actions of E-agonist probably occur by down-regulating myostatin. Myostatin
shares structural and regulatory similarities with members of the TGF-E
superfamily; these include an N-terminus which functions as a secretory signal
and a proteolytic processing site (RSRR) in the C-terminus. It is synthesised as
high molecular weight precursor protein that migrates on SDS-PAGE at ~52-
55kDa; this is higher than that predicted from myostatins 375 amino acid
sequence, and has been attributed to differential glycosylation of the uncleaved
protein. This is subsequently cleaved by furin, a calcium-dependent serine
protease to release the biologically active ~12.5kDa C-terminal mature protein
(Lee and McPherron 2001). A ~40kDa N-terminal Latency Associated Peptide
(LAP), which lacks the signal peptide and a ~26kDa protein suspected to
represent a dimeric form of the mature 12.5kDa protein have also been reported.
Further analyses of the molecular forms of myostatin are described in appendix
I. The bioavailability of the 12.5kDa C-terminal peptide is tightly regulated
through post-translational modifications and sequestration of its precursors
(reviewed in Bradley et al. 2008; Huang et al. 2011). Myostatin is also reviewed
in chapter 1, section 1.2.4.4.
In summary, the aims of the present study are to examine the effects of long
term BRL-47672 pro-drug administration on the expression of well
characteristed satellite cell markers pax7, myoD and myogenin. We hypothesise
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that pro-drug treatment should increase muscle growth and activate these factors
since satellite cell avtivation could be a primary mechanism by which muscle
hypertrophy occur. Secondly, we hypothesise that stimulation of these factors is
synonymous with a suppression of negative markers of satellite cell activity,
such as myostatin. Therefore, we aim to examine the expression of myostatin
and its antagonist follistatin to determine whether stimulation of satellite cell
activity in hypertrophying muscle is achieved via myostatin suppression or
follistation stimulation.
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3.3 METHODS
3.3.1 Animals and tissue collection
Male Wistar rats (150-160g; Charles River, Margate, UK) were randomly
assigned to one of two groups and received daily injections of E2-agonist pro-
drug BRL-47672 (900Pg/kg; s.c., n=7) or an equal volume of Saline (n=6) for 8
weeks. Twenty-four hours following final injections, rats were terminally
anaesthetised with Inactin (120mg/kg; i.p., Sigma-Aldrich, UK) and the soleus
muscles were excised, snap frozen in liquid nitrogen, and stored at -80°C for
subsequent analysis.
3.3.2 Analysis of muscle fibre hypertrophy
Evidence of muscle fibre hypertrophy was assessed using the minimal Ferets
diameter method as described in chapter 2, section 2.2.6.4. This quantitative
analysis outlines individual muscle fibres via histological staining using laminin
antibody.
3.3.3 mRNAMeasurements (Real Time PCR)
Total RNA was extracted from approximately 20mg of frozen wet muscle using
TRIzol
®
(Invitrogen, Paisley, UK) according to the manufacturers protocol. The
quality and quantity of RNA was assessed spectrophotometrically by measuring
the absorbance at 260nm and 280nm. First strand cDNA synthesis was carried
out using 1Pg of total RNA as described in chapter 2 section 2.2.3. Taqman
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Table 3.1: Catalogue and Unigene Numbers for Taqman Primer/Probes sets
Gene Catalogue Number Unigene Number
HMBS Rn00565886_m1 Rn.11080
Pax7 Rn00834076_m1 Rn.226327
MKi-67 Rn01451446_m1 Rn.73551
MyoD1 Rn00598571_m1 Rn.9493
Myogenin Rn00567418_m1 Rn.9465
Myostatin Rn00569683_m1 Rn.44460
Follistatin Rn00561225_m1 Rn.162557
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primer/probe sets (Table 3.1) were obtained from Applied Biosystems (ABI,
Foster City, CA, USA) and real-time PCR was performed using Taqman gene
expression master mix (Applied Biosystems) in a MicroAmp 96-well reaction
plate (Geneflow, Fradley, UK). Reactions were carried out in an ABI Prism
7000 sequence detection system in duplicate; each well contained 2Pl cDNA
template, 12.5Pl PCR master mix and 1.25Pl primer/probe mix in a 25Pl
reaction volume.
Relative quantification of gene expression between control and treated groups
was calculated using the 2
ǻǻ&W
method. Briefly, duplicate cycle threshold (Ct)
values for each control or treated sample were averaged and the 'Ct calculated
by subtraction of the corresponding mean Ct of an endogenous control (HMBS).
ǻǻ&t was calculated by subtracting the 'Ct of prodrug treated samples from the
mean 'Ct of corresponding time-matched saline controls and the relative amount
of target mRNA was determined by 2
ǻǻ&W
. The saline control groups were given
a value of 1 and fold changes in mRNA expression of LPS treated groups were
calculated relative to their corresponding control group. Thus values >1 or <1
indicate an increase or decrease in mRNA expression from control, respectively.
3.3.4 Protein measurements (Western blotting)
Protein extractions and western blotting was carried out as described in chapter
2, section 2.2.5, to determine the protein expression of the targets listed in table
3.2. Briefly, cytosolic and nuclear proteins were extracted using a modification
of the method by Blough et al. (1999), for the extraction of proteins from
striated muscle. Approximately 30mg of frozen muscle was homogenised in
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Table 3.2: Primary and secondary antibodies used in the Western blotting
protocol.
Primary Antibodies Supplier Dilution
Mouse Anti-Pax7 mAb
DSHB
Iowa City, IA, USA 1:500
Rabbit Anti-MyoD (C-20) pAb
Santa Cruz Biotechnology
Santa Cruz, CA, USA 1:500
Mouse Anti-Myogenin mAb
DSHB
Iowa City, IA, USA 1:500
Rabbit Anti-Myostatin, Near C-
terminus pAb
Millipore
Billerica, MA, USA
1:250
Mouse Anti-E-Actin, mAb Sigma AldrichPoole, UK 1:25000
Secondary Antibodies
Swine Anti-Rabit
Immunoglobulins/HRP
Dako
Glostrup, Denmark
1:2000
Rabbit Anti-Mouse
Immunoglobulins/HRP
Dako
Glostrup, Denmark
1:2000
,
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0.6ml homogenisation buffer (50mM Tris-HCl, 1mM EDTA, 1mM EGTA, 1%
(v/v) NP-40, 0.1% (v/v) 2-mercaptoenthanol, pH7.5).Mammalian protease
inhibitor cocktail was added homogenisation buffer (0.01% (v/v); Sigma-Alrich,
Poole, UK) before use. Muscle lysates were centrifuged (13,000g, 10 min at
4°C) and the supernatant was used as crude cytosolic protein fraction. The
remaining pellets were resuspended in 500Pl of an ice-cold buffer (20mM
HEPES, 25% (v/v) glycerol, 500mM NaCl, 1.5mM MgCl2, 0.2mM EDTA
pH7.9) supplemented with protease inhibitor cocktail (0.01% (v/v) ) and
incubated on ice for 30 minutes with intermittent mixing. Samples were spun
down (3,000g, 5min at 4°C) and the supernatant collected as nuclear protein
fraction. Extracted proteins were quantified using the Lowry assay (Lowry et al.
1951) and diluted to required concentration before the addition of a Laemmli
type SDS buffer (gel application buffer (GAB); 0.15M Tris, 8M urea, 2.5%
(w/v) SDS, 20% (v/v) glycerol, 10% (w/v) 2-mercaptoethanol, 3% (w/v) DTT,
0.1% w/v bromophenol blue, pH6.8) at a ratio of 2.5:1. For example, 20Pl of
diluted protein sample to 8Pl of GAB. Samples were heated at 95°C for 5mins
prior to loading.
Unless otherwise stated, 50Pg of total protein from samples were loaded onto 5-
20% SDS-PAGE gel and separated by molecular weight then transferred
overnight onto nitrocellulose membranes (GE Healthcare, Little Chalfont, UK).
Equal loading of samples was confirmed by Ponceau S staining of membranes.
Membranes were blocked for 1hr with 5% (w/v) non-fat milk in Tris-buffered-
saline-tween (TBS-T; 10mM Tris, 150mM NaCl, 0.05% (v/v) tween-20, pH 7)
at room temperature followed by an overnight incubation at 4°C in primary
antibody and for 1hr in the appropriate HRP-conjugated secondary antibody at
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room temperature (Table 3.2). Protein bands were visualised by enhanced
chemiluminescence plus (Perkin Elmer, MA, USA) and quantified by
densitometry using GeneTools software (Syngene, Cambridge, UK) after
background subtraction and normalising to actin or lamin control.
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3.3.5 Statistical Analyses
The raw data from each experiment was tested for normality using GraphPad
Prism v6. Data were tested for the tendency to assume a Gaussian distubution
using the Kolmogorov-Smirnov and the D'Agostino-Pearson omnibus tests and
were found to be consistent with a Gaussian distribution. All data are
represented as the mean ± standard error of the mean (S.E.M) and comparisons
between the control and treated groups were performed using unpaired t-tests
and statistical significance was accepted at p<0.05.
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3.4 RESULTS
3.4.1 Analysis of muscle fibre diameter
Although several lines of evidence suggest muscle does undergo muscle fiber
hypertrophy in response to clenbuterol and similar agonsits (reviewed in
section 3.2), we firstly wanted to determine whether the tissues analysed
exhibited signs of muscle hypertrophy. This was done using the Ferets
diameter method; a quantitative method developed by Briguet et al. (2004) for
measuring the size of muscle fibres using the minimal Ferets diameter of a
muscle fibre cross section (described in detail in chapter 2, section 2.2.6.4).
Based on this analysis, there was a slight but statistically significant increase in
the muscle fibre diameter of treated samples, which suggests BRL-47672
elicited muscle growth (see figure 3.1)
3.4.2 mRNA and protein expression of muscle specific markers
Currently, it is unclear how satellite cells are implicated in E-agonist mediated
changes in muscle growth and fibre type composition. The effects of 8 weeks
pro-drug treatment on the mRNA and protein expression of early, late and
negative satellite cell markers were measured by real-time PCR (figures 3.2
and 3.3).
Pro-drug treatment elicited significant increases in the mRNA expression of
early markers pax7 and ki-67 relative to saline control (p<0.05). MyoD mRNA
expression was also significantly increased relative to control (p<0.05) and the
98
protein expression of both pax7 and myoD showed a similar tendency (p~0.12
and p~0.09, respectively).
There was no significant change in the mRNA and protein expression of the
late marker of myogenin. Interestingly, there was a significant ~5.5 fold
increase in myostatin mRNA expression relative to saline control. There was
no change in follistatin mRNA expression, which lends credibility to the
increased expression of myostatin observed since the two are thought to act
antagonistically against each other (Lee and McPherron 2001; Gilson et al.
2009).
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Figure 3.1: Muscle fibre diameter of rat soleus muscle following 8 weeks of
Saline or E2-agonist BRL-47672 administration. Values are means ± S.E.M,
n=3-4.Signficantly different from corresponding saline control via Students
unpaired t-test: **p<0.005
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Figure 3.2: mRNA expression of transcripts involved in satellite cell function and muscle growth in rat soleus muscle following 8 weeks
of Saline or E2-agonist BRL-47672 administration. Relative mRNA expression of saline controls was set at 1. Values are means ± S.E.M,
n=6-7.Signficantly different from corresponding saline control via Students unpaired t-test: *p<0.05.
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Figure 3.3: Protein expression of satellite cell specific markers in rat soleus
muscle following 8 weeks of saline or E2-agonist BRL-47672
administration. Values are means ±S.E.M. The densities of immunoreactive
bands were measured by western blotting and representative bands for each
treatment group are shown above their corresponding bar in duplicate. n=6-7
per group. Significantly different from Saline group: *p<0.05 using a
Studentsunpaired t-test.
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c) Myogenin protein expression
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3.4.2 Myostatin Protein Expression
The protein expression of myostatin followed a similar trend with its total
mRNA expression. There was a statistically significant increase (p<0.05) in
pro-myostatin protein expression but no change was detected in the protein
expression of the latency form of the peptide relative to saline controls (figure
3.4). The former was detected as a ~55kDa migrating immuno-reactive band in
cytosolic fractions by western blotting, representing the unprocessed form of
the protein. This increase in total myostatin mRNA and pro-myostatin protein
expression suggests myostatin synthesis was enhanced in response to pro-drug
administration but its further processing was limited as the latency form was
unchanged relative to control.
When probed for myostatin protein, nuclear fractions of control and treated
samples showed no obvious myostatin bands although the same blots were
positive for the endogenous control lamin A/C bands (figure 3.5). Figure 3 in
appendix I show that myostatin protein could be detected in nuclear fractions if
the concentration of protein loaded is very high. In 200Pg of total protein load,
the active dimeric myostatin was detected in the nuclear extracts from four
different muscle types. We deduced that since myostatin is a rare protein, it is
probably below the limit of detection in the nuclear protein fractions.
Thus we sought to determine the minimum concentration of active myostatin
protein that can be detected by western blotting (figure 3.6). Decreasing
concentrations of the recombinant myostatin peptide were loaded and blotted
for myostatin. Muscle homogenate from EDL and gastrocnemius muscles were
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Figure 3.4: Myostatin protein expression in Rat Soleus muscle following 8
weeks of Saline or E2-agonist BRL-47672 administration. Values are means
±S.E.M. The densities of immunoreactive bands were measured by western
blotting and representative bands for each treatment group are shown above
their corresponding bar in duplicate. n=7-8 per group. Significantly different
from Saline group: *p<0.05 using a Students unpaired t-test.
Myostatin protein expression
Pr
o-M
yo
sta
tin
LA
P M
yo
sta
tin
0.0
0.5
1.0
1.5
2.0
Saline
BRL-47672
*
R
e
la
tiv
e
P
ro
te
in
E
x
p
re
s
s
io
n
(o
p
tic
a
ld
e
n
s
it
y
)
105
Figure 3.5: Myostatin protein was below threshold of detection in nuclear
protein samples of Control and treated Rat Soleus muscles by western
blotting. (A) Representative immunoblot showing bands for endogenous
Lamin A/C. (B) The same blot was negative for myostatin protein bands when
blotted below 70kDa marker. 50Pg of protein sample was loaded per lane.
Blots were developed with ECL for 2 minutes and A was exposed to
photographic film for 5 and B for 10 minutes, which is usually sufficient to
pick up any rare species of myostatin.
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Figure 3.6: The minimum concentration of recombinant myostatin protein
detectable by western blotting. (A) Ponceau stain to confirm protein transfer.
(B) Immunoblot of myostatin protein bands in untreated adult skeletal muscle
extract and recombinant myostatin peptide mix. Blot was exposed to hyperfilm
for 5 minutes to enable detection of rare species of myostatin. (C) Short 30
seconds exposure of B. Loading order: 1-EDL cytosolic fraction, 2-
Gastrocnemius cytosolic fraction, 3- 100ng/Pl, 4- 75ng/Pl, 5 -50ng/Pl, 4 -
25ng/Pl, 5 -10ng/Pl, 6 -5ng/Pl, 7 -1ng/Pl.
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also loaded as positive controls. The minimum concentration of peptide
detected was 10ng/Pl; bands containing a lower concentration were not
detected after long exposure (>30 minutes)
The work by Gonzalez-Cadavid (1998) showed that 7ng/Pl of a myostatin
peptide, which was composed of c-terminal fragments (the epitope used to
raise the antibody) was sufficient to block antibody activity. Therefore it is
tempting to speculate this is similar to the minimum amount of the mature
myostatin peptide that may be required for detection via western blotting in our
samples. Our results show the minimum concentration detectable is 10ng/Pl,
thus we can surmise the nuclear fractions contained very little myostatin
(<7ng) and so below threshold of detection. When put within the context of
muscle mass, the 50Pg of total nuclear protein loaded represented 0.38mg of
the 30mg (roughly 1.3%) wet muscle initially homogenenised. This was
calculated from the volume of homogenate loaded per lane (6.4Pl on average)
and the volume of total homogenate extracted (500Pl); thus (6.4/500Pl) x 30mg
= 0.38mg. The total volume of diluted protein sample loaded per lane was
20Pl, therefore the final concentration of protein per sample was 50Pg/20Pl =
2.5Pg/Pl on average. Given the minimum concentration of myostatin
detectable was 10ng/Pl and the final concentration of nuclear protein loaded
being ~2.5Pg/Pl, this represents a factor of 250.
Therefore, we could speculate that the final concentration of the loaded nuclear
protein fraction would need to be 250 times higher in order to detect myostatin,
which would have to be at a concentration of 10ng/Pl or greater. The
equivalent protein concentration per sample would have to be ~625Pg/Pl (2.5 x
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250), 12500Pg total nuclear protein, or roughly 95mg (0.38 x 250) of muscle
will be required. These assumptions do not take into account antibody
sensitivity and western blotting variability or the pool of endogenous myostatin
(i.e. cytosolic or secreted myostatin), which is likely variable.It is
representative of enriched nuclear myostatin..
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3.5 DISCUSSION
Daily i.p. injections of BRL-47672 for 8 weeks significantly increased
(p<0.05) the mRNA (and tendentially, protein) expression of the satellite cell
specific marker pax7. Pax7 is a well established marker for tracing cells of the
myogenic lineage; it is expressed exclusively in satellite cells (Seale et al.
2000) and studies on ageing in mice have shown that loss of Pax7 expression
leads to a loss of the stem cell phenotype, allowing satellite cells to
differentiate into fibroblasts thus contributing to increased fibrosis during
ageing (Brack et al. 2007). Hence, pax7 is a good measure of the muscle
satellite cell population. The increase in pax7 expression in response to chronic
E-agonist treatment is an indication for an increase in satellite cell number.
This is the first such report to link E-agonist mediated muscle hypertrophy with
increased pax7 expression in adult muscle.
These observations are directly correlated with the increased mRNA
expression of ki-67, a well known marker of proliferation. Although not
exclusively expressed in satellite cells, it is increasingly used as a marker for
assessing the proliferative potential of satellite cells (Mackey et al. 2009). Ki-
67 was chosen because it has a distinct proliferative role; for example, it is not
involved in DNA repair unlike other markers of proliferation such as PCNA
(proliferating cell nuclear antigen). Ki-67 is also present in cell nuclei through
G1-S and G2 phases of the cell cyce, thus offering a larger window/opportunity
for detection. It is likely this increase in ki-67 mRNA expression is due to
satellite cell proliferation. E sympathomimetics such as clenbuterol increase
muscle blood flow by relaxing the smooth muscle of blood vessels, thus
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increasing the availability of blood-borne mitogens and cytokines that activate
satellite cells (Roberts and McGeachie 1992). Our study highlights the
possibility that the increased protein and DNA content observed in animals
administered E-agonist is due to increased satellite cell activation and
proliferation. Whether initial recruitment of satellite cells is required for
muscle hypertrophy or satellite cells are recruited as myofibres enlarge remains
to be determined. Rats fed clenbuterol showed increased muscle mass prior to
any significant increase in DNA content (Reeds et al. 1988). However, Jones et
al. (2004) saw an increase in myoD protein expression 1 day after i.p. injection
of BRL-47672. It appears the dose and method of administration may play an
important part in the degree of satellite cell activity elicited.
Additional evidence for increased satellite cell activation and proliferation is
demonstrated by a significant (p<0.05) in myoD mRNA and a similar tendency
in protein expression. Satellite cell myogenic potential relies on the sequential
expression or repression of pax7 and MRF genes (myoD, myf5, myogenin,
MRF4). Increased expression of pax7 and myoD is associated with actively
proliferating satellite cells with a potential for differentiation (Halevy et al.
2004; Zammit et al. 2004). It is likely the pro-drug increases the differentiation
potential of activated satellite cells to improve availability for recruitment into
growing myofibres. An increase in pax7 and myoD could also be indicative of
an increase in the satellite cell population due to E-agonist-induced
proliferation of satellite cells (denoted by increased ki-67 expression).
Interestingly, the mRNA and protein expression of myogenin in treated
samples showed no change relative to control. It is possible that although BRL-
47672 stimulated satellite cell activation and proliferation, it may have no
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effect on terminal differentiation of myoblasts. This stage of myogenesis is
thought to be regulated through independent mechanisms in adult muscle.
Myogenin is not involved in satellite cell development or maintenance but its
induction is necessary and sufficient for the formation of myotubes or fusion to
fibres (Knapp et al. 2006). MyoD and Myogenin are thought to be regulated
through independent mechanisms in adult muscle (Delday and Maltin 1997).
The study by Delday and Maltin (1997) reported that myoD was decreased
whilst myogenin was increased in immobilised clenbuterol fed rats, so the up-
regulation of either may be dependent on atrophy elicited or lack thereof. It is
interesting to note that myogenin is a known activator of ubiquitin ligases
during muscle atrophy (Moresi et al. 2010), thus unaltered levels of myogenin
expression observed are perhaps a function of the reduced protein degradation
pathways, frequently observed in E-agonist treated animals.
MyoD and myogenin are expressed at high levels during development but
expression is reduced in adult muscle. They are believed to be involved in
establishing and maintaining adult muscle phenotype, as myoD is expressed at
higher levels than myogenin in fast muscle (Hughes et al. 1993b; Voytik et al.
1993). Myogenin is associated with the expression of the slow type I myosin
heavy chain isoform and the fast type IIA heavy chain isoform. The fast type
IIA heavy chain isoform has the slowest contraction speed compared to type
IIB and IIX heavy chain isoforms, with which myoD expression is associated
(Hughes et al. 1997). These results support a previously published report by
our group, that high myoD and low myogenin expression in chronically treated
rats are associated with changes in MHC composition from a slow type 1
phenotype to a fast type II phenotype (Jones et al. 2004).
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However, some investigators have suggested myoD and myogenin may not
simply have a casual relationship to fibre type in mature muscle, but rather that
the relative ratios of all MRFs regulate myosin heavy chain isoform
distribution than are changes in a single MRF (Jacobs-El et al. 1995; Hu et al.
1997). It is unlikely that the up-regulation myoD protein expression after a
single injection of BRL-47672 reported by Jones et al.(2004) is merely a pre-
requisite for fibre-type switching, but rather a result of increased satellite cell
activation and myogenesis, for their subsequent recruitment onto muscle fibres
to decrease the nuclear domain size. Furthermore, if myoD is the primary
positive regulator of the fast MHC isoform expression, myoD knockout should
result in reduced numbers of fast fibres. However, the EDL muscle of myoD
knockout mice contained normal levels of fast (type IIb) fibres. Conversely, the
soleus contained reduced proportions of slow type I fibres, elevated numbers of
fast type IIx fibres and no type IIb fibres (Hughes et al. 1993a). Indeed, mice
over-expressing myogenin show no alterations in MHC-based fibre types
compared to wild type in the EDL, TA and soleus muscles (Hughes et al.
1999). It is possible BRL-47672 elicits growth promoting effects via satellite
cell activation and maintaining increased myoD protein levels in a state of
readiness essential for the subsequent recruitment of myoblasts into fibres to
decrease the nuclear domain and thus increase myofibre synthetic capacity to
allow fibre hypertrophy.
The increase in myostatin total mRNA and pro-myostatin protein in treated
animals is indicative of increased myostatin synthesis that is not compatible
with increased precursor processing. Given its key role in muscle homeostasis,
it is not surprising that the availability of bioactive myostatin is tightly
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regulated (e.g. through cleaving of precursor and sequestration in LAP) and
that the mature c-terminal peptide is not always detectable in adult muscle (see
figure 3.3 above). Additionally, there were no alterations in the LAP myostatin.
This labile form of the protein usually plays an inhibitory role in the negative
auto-regulatory feedback mechanism of pro-myostatin. However, the work of
McMahon et al. (2003) postulates that LAP myostatin probably represents a
stable pool of myostatin; it was unaffected by mass physiological changes in
rat hindlimb suspension studies. Since the low molecular weight forms of
mature myostatin were not detected after long exposure, we hypothesise that
myostatin protein was synthesised in response to its increased mRNA transcript
but further processing was low. These results are consistent with myostatin
being a negative regulator of muscle mass despite muscle hypertrophy.
Increased myostatin is not always associated with muscle atrophy (Carlson et
al. 1999). Whilst several reports show increased myostatin in skeletal muscle
during atrophy (Gonzalez-Cadavid et al. 1998; Sakuma et al. 2000), studies
showing a lack of association between myostatin expression and atrophy have
also been found. For example, Wehling et al. (2000) showed that myostatin
levels in rat hindlimb muscles were elevated during atrophy from hindlimb
unloading, but myostatin still remained elevated when muscles were
subsequently loaded with daily exercise.
Interestingly, increased myostatin expression has been linked to activation of
satellite cells in controlling excessive myogenesis and muscle growth.
Myostatin has a negative effect on satellite cell differentiation in culture
(Langley et al. 2002). In vivo, the increased myogenesis observed in the
absence of myostatin (McMahon et al. 2003) is an additional demonstration of
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myostatins ability to suppress terminal myogenic differentiation. This suggests
that under normal physiological conditions, myostatin up-regulation is a
negative feedback mechanism to inhibit satellite cell differentiation and further
limit muscle fibre hypertrophy and hyperplasia. This is further evidenced in
another myostatin knockout mouse model, in which skeletal muscle
hypertrophy and hyperplasia is prevented if satellite cell myogenesis is blocked
by gamma irradiation (Rosenblatt and Parry 1992). This suggests that with the
absence of myostatin, muscle still doesnt grow if satellite cells are prevented
from functioning.
Furthermore, the anabolic effects of E-agonists are transient; it is believed
growth characteristics disappear with prolonged treatment (McElligott et al.
1989; Maltin and Delday 1992; Kissel et al. 2001) due to adreno-receptor
desensitization (by internalisation) (Kim et al. 1992) or lack of downstream
effectors (reviewed in Lohse 1993). Indeed, Rothwell et al. (1987), found a
50% reduction in E-receptor density when rats were chronically treated with
clenbuterol for 18 days. The same phenomenon is seen with satellite cell
myogenesis in vitro; when C2C12 cells are treated with the E-agonist
ractopamine, a clear increase in proliferation is observed, with no discernable
change in rate of differentiation (Shappell et al. 2000)). There is also an
increase in cell number, protein and DNA content of myoblasts but not
myotubes after 48hr and no increase in cell number, protein or DNA content at
later passage (Grant et al. 1990), suggesting older satellite cells are less
functional or responsive to the growth promoting effects of E-agonists. A
reduction in drug effect is also seen in vivo; a study by Reeds et al. (1986)
showed that the growth promoting effects of clenbuterol were evident after 4
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days of administration but these effects became less with time and were
blunted by day 21.
The BRL-47672 pro-drug also displays evidence of a transient effect. In the
study by Jones et al. (2004) the highest magnitude of change for myoD protein
was 1 day after treatment but then did not change significantly between 4-8
weeks. This reduction in drug effect could represent an eventual limitation of
skeletal muscle growth imposed by reduced synthetic capacity due to reduced
satellite cell recruitment. This could explain the increased synthesis of
myostatin when the pro-drug is administered chronically. The half life of
agonist probably plays a significant role in the temporal effects of E-agonist
administration; although the half-life of BRL-47672 is unknown, we can infer
this to be similar to analogous compounds such as salbutamol and clenbuterol,
which have half lives of approximately 3-4 hours and 12 hours respectively.
It is uncertain if myostatin up-regulation due to chronic E-agonist treatment has
a role in maintaining the fibre type transition. Welle et al. (2009) found
myostatin knockout did not down-regulate genes encoding slow myosin
isoforms, whereas myostatin knockout resulted in a switch from slow to fast
myosin fibre types, in studies done by Steelman et al. (2006) and Girgenrath et
al. (2005). Previous research has also shown that myostatin is preferentially
expressed in fast-twitch muscles in mice (Carlson et al. 1999), therefore it is
tempting to speculate increased myostatin expression is a result of an increased
percentage of fast type II fibres in treated animals, previously reported by our
group in Jone et al. (2004).
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We can surmise from our study that the transient effect of E-agonist treatment
elicits satellite cell activity, which is controlled by myostatin up-regulation.
This influences satellite cell differentiation (low myogenin expression) but not
activation/proliferation (increased pax7/ki-67/myoD) such that further muscle
growth is checked but not entirely ablated. Chronic administration of E2-
agonists eventually leads to acclimatisation of skeletal muscle and stimulation
of compensatory pathways, in which myostatin may be involved. Intermittent
administration of the pro-drug may represent a more effective means of
preventing E2-receptor desensitisation, similarly to intraperitoneal injection of
E-agonists, which is more effective for muscle hypertrophy than its
administration via drinking water (Moore et al. 1994). A combination of
intermittent E2-agonist stimulation and myostatin suppression (for example,
myostatin suppression by transgenic overexpression of its inhibitory pro-
domain (Kim et al. 2011)) may present a more effective means of preventing or
reversing muscle atrophy.
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CHAPTER 4
Results (II)
Continuous lipopolysaccharide infusion
transiently suppresses components of the satellite
cell myogenic program.
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4.1 SUMMARY
Sepsis is a complex and potentially fatal condition arising from an exacerbated
inflammatory response to an infection. The rapid and debilitating loss of
skeletal muscle mass is a major cause of mortality in critically ill patients. Loss
of skeletal muscle mass is thought to be the result of increased suppression of
myofibrillar protein synthesis and stimulation of muscle protein degradation.
The effects of sepsis on the pathways regulating muscle mass, especially the
influence on satellite cells, are poorly understood. The present study utilises a
rodent model of sepsis to examine the effects of lipopolysaccharide (LPS)-
induced endotoxaemia, to examine the mRNA and protein expression of select
components of the inflammatory response and the satellite cell myogenesis.
Male Sprague-Dawley rats were continuously infused with saline (0.4ml/hr,
i.v.) or LPS (15 Pg/kg/hr, i.v.) for either 2hr (n=4), 6hr (n=4) or 24hr (n=6).
After the specified times, animals were terminal anaesthetised (Inactin; 80
mg/kg, i.v.) and the extensor digitorum longus (EDL) and gastrocnemius
muscles were removed, snap-frozen and stored in liquid nitrogen for
subsequent analyses.
LPS infusion caused significant, early (<2hr) elevations in the expression of
inflammatory cytokines TNF-D, IL-6 and NF-NB relative to control, which
were subsequently, slightly attenuated after 24hr. The increase in local muscle
cytokine expression was attributed to increased muscle macrophage infiltration
and activation. Additionally, TNF-D protein was localised to the macrophages
in treated muscles. The differential increase in cytokines paralleled the
suppression of the satellite cell specific markers pax7 and myoD, which were
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concomitant with a reduction in pax7
+
and myoD
+
satellite cells in the
gastrocnemius muscle. Pax7 mRNA, protein and pax7
+
satellite cells showed a
tendency to a return to basal levels of expression/numbers, whilst myoD
mRNA, protein and myoD
+
satellite cells remained reduced relative to control,
after 24 hr of LPS. LPS also caused an early (<2hr) increase in myostatin
mRNA and protein, which was subsequently reduced relative to control after
24hr in both muscles.
These results indicate that LPS increases the levels of inflammatory cytokines
in skeletal muscle, in a temporally-dependent manner that is concomitant with
a time-dependent, cytokine concentration-dependent effect on satellite cell
activity. Early elevations in cytokine expression produced a greater magnitude
of pax7 and myoD suppression. Such alteration of satellite cell activity may
contribute to the progression of muscle atrophy, due to the suppression of
muscle compensatory mechanisms, which include satellite cell activation,
differentiation and fusion for nuclear supplementation. This LPS-induced
reduction in satellite cell readiness could have consequences for muscle
regeneration following atrophy. LPS-induced impairment of satellite cell
function could lead to less effective muscle homeostasis, which could have
consequences for muscle regeneration following atrophy.
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4.2 INTRODUCTION
Sepsis is a severely debilitating condition, the clinical manifestations of which
include marked muscle loss, hypotension and multiple organ failure resulting
in high levels of morbidity and mortality (reviewed in Bone et al. 1992). It
arises from an excessive systemic inflammatory response to an infection,
initiated through an inflammatory cascade via the innate immune response.
Infection can be caused by a range of circulating microbial antigens such as
fungi, parasites viruses and Gram-negative bacteria (e.g. Escherichia coli),
which accounts for 35% of septic cases (Alberti et al. 2002).
Lipopolysaccharide (LPS) is a bacterial outer membrane component largely
responsible for the endotoxic properties of Gram-negative bacteria. It is an
essential component of bacterial viability and has a highly conserved structure
that is recognised by the innate immune system (reviewed in Cohen 2002).
LPS activates the innate immune response by eliciting the production of
monocyte/macrophage derived inflammatory mediators such as Tumour
Necrosis Factor Alpha (TNF-D), Interleukin-6 (IL-6) and Nuclear Factor -
kappa B (NF-NB), which in turn mediate the release of more TNF-D and IL-6
(reviewed in Lu et al. 2008). A signal cascade follows from the recognition of
LPS by the soluble shuttle protein LPS-binding protein (LPB), which facilitates
the association of LPS to a cell surface protein complex including the
membrane-bound monocyte differentiation antigen CD14, the trans-membrane
Toll-like receptor-4 (TLR4) and its adaptor protein MD2 (myeloid
differentiation protein-2). The formation of this complex elicits a subsequent
downstream intracellular signalling cascade through adaptor proteins such as
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myeloid differentiation protein (MyD88) and various kinases (e.g.IL-1 receptor
associated kinase (IRAK), TNF receptor associated factor (TRAF6), etc); this
ultimately leads to the activation and nuclear translocation of NF-NB and the
production of pro-inflammatory cytokines such as TNF-D and IL-6 (reviewed
in Guha and Mackman 2001).
Activation of the innate immune system in response to infection is normally a
protective phenomenon; however, during sepsis the host response is
exacerbated. Macrophages and neutrophils release cytokines such as TNF-D
and IL-6, which in turn activate surrounding monocytes and endothelial cells to
secrete more cytokines and chemokines. The result is a positive feedback loop
where, if unchecked, causes continuous release of pro-inflammatory mediators
that trigger repeated cycles of inflammation, potentially resulting in systemic
inflammation and multiple organ damage. Increased levels of circulating
cytokines at the onset of sepsis have been implicated in the impairment of the
normal function of most organs (reviewed in Jacobi 2002) including skeletal
muscle, where a profound loss of muscle mass in septic patients increases the
recovery times and reduces the quality of life due to chronic frailty and muscle
weakness.
The exact mechanisms underlying sepsis induced muscle loss are still poorly
understood but inflammatory cytokines such as TNF-D, IL-6 and NF-NB are
frequently implicated. It is important to note that cytokines often act in synergy
(Paludan 2000) and the effects often attributed to the action of one may
actually be due to the coordinated action of several cytokines. Therefore a
comprehensive review of the role of cytokines in sepsis induced muscle loss is
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beyond the scope of this chapter. The production and early release of TNF-D
by immune cells appears to be a major step that mediates cachetic muscle
wasting (reviewed in Tracey and Cerami 1993). The catabolic actions of TNF-
D were first demonstrated in tumour bearing nude mice, where marked muscle
loss was noted (Tracey et al. 1990). Secondly, administration of TNF-D to
rodents altered several protein synthetic, protein degradative and apoptopic
pathways and resulted in hindlimb muscle atrophy after eight days (Llovera et
al. 1993). Exposure to LPS or increased production of TNF-D activates NF-NB,
which is controlled by the phosphorylation and subsequent degradation of INB,
which sequesters NF-NB in the cytosol, preventing nuclear translocation and
transcription (reviewed in Baldwin 1996). NF-NB belongs to a family of
pleiotropic transcription factors, of which there are five members in mammals:
p50/p105, p52/p100, RelA (p65), c-Rel and RelB. They form homo- or hetero-
dimers in different combinations to mediate gene transcription of various
inflammatory cytokines (including TNF-D and IL-6) immune-regulatory
molecules, acute-phase stress response proteins and several enzymes, including
those involved in protein degradation by the ubiquitin proteasome system, such
as the E3 ubiquitin ligase Muscle Ring Finger 1 (MuRF1) (reviewed in Li et al.
2008). The role of IL-6 in muscle atrophy may be multifunctional; although
plasma levels are elevated during infection, elevations in response to exercise
are also common and are thought to play an anti-inflammatory role by
inhibiting the production of TNF-D (reviewed in Pedersen et al. 2003). IL-6-
deficient mice display impaired inflammatory response and are more resistant
to muscle damage (Scuderi et al. 2006). Conversely, IL-6 transgenic mice
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experience significant muscle loss, which is attenuated by administration of
anti-mouse IL-6 receptor antibody (Tsujinaka et al. 1996).
In short, several studies suggest the concerted action of these cytokines may
mediate many of the conditions that initiate the rapid loss of muscle mass
during sepsis; by coordinating a reduction in muscle protein synthesis and an
up-regulation of protein degradation (Vary and Kimball 1992; Lang et al.
2007). Furthermore, derangements in translational efficiency (via repression of
translation initiation and suppression of the guanidine exchange factor eIF2B)
(Vary et al. 1994; Murton et al. 2009), enhanced protein degradation (via up
regulation of the ubiquitin proteasome , calpian and lysosome-dependent
proteolytic pathways) (Voisin et al. 1996; Lecker et al. 1999) carbohydrate
oxidation (Alamdari et al. 2008) and in the development of insulin resistance
(Lang et al. 1990) have been noted. For a review, see Hasselgren et al (2005).
Under normal physiological conditions, muscle protein synthesis and
degradation is precisely adjusted to maintain appropriate muscle mass. An
imbalance in signalling among the regulatory pathways (e.g. IGF-1,
AKT/PI3K, GSK3/mTOR, MAFbx/MurF1 etc) in numerous disease states,
characterised by systemic inflammation such as cancer, AIDS, and sepsis are
widely considered to initiate muscle atrophy. For a review, see Glass (2005).
The multifactorial nature of sepsis has made it difficult to fully understand the
molecular mechanisms underlying its pathogenesis, development of effective
therapeutic strategies. Treatment in a clinical setting is often reactive rather
than proactive and prevention of muscle wasting is often a secondary
consideration in critical care. Animal models have proven an effective means
of studying the pathophysiology of sepsis, especially within the context of
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muscle atrophy. Current research employs a variant of three methods for the
induction of Gram-negative sepsis; administration of live bacterial, surgical
induction of peritonitis via caecal ligation and puncture (CLP) or the
administration of bacterial toxin such as LPS. Each method has its benefits and
limitations; for example the CLP procedure delivers a variable microbial dose
and the distance of caecum ligated and the size of puncture is major
determinant of the degree of sepsis elicited. Although the infusion of live
bacteria represents an effective way to investigate extreme cases of sepsis often
seen in a clinical setting such as meningococcemia pneumococcal bacteraemia,
the severity and reproducibility of the septic response is dependent on the dose,
species and viability of bacteria as well as the route of administration. Also,
certain strains of bacteria used in such models, whilst able to elicit an infection
in rodents, have no effects on humans or are not commonly reported in
critically ill patients. For a review, see Poli-de-Figueiredo et al, (2008).
The rat model of LPS induced endotoxaemia described here-in was developed
and optimised within our research group; it produces a hyperdynamic
circulatory response that mimics the cardiovascular changes seen in the early
stages of human clinical sepsis (Parrillo 1993; Gardiner et al. 1995). This
experimental model, which involves a continuous infusion of a non-lethal dose
of LPS in conscious chronically instrumented rats, produces a high degree of
reproducibility and allows accurate dosing. Since increased serum LPS in
critically ill patients is associated with severity and mortality rate of sepsis
(Casey et al. 1993), it is beneficial to be able to calibrate the dose of toxin
administered in order to appropriately measure responses. Previous work on
this model by our research group has focussed on the metabolic consequences
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of sepsis including the changes in carbohydrate metabolism (Alamdari et al.
2008; Crossland et al. 2008), alterations in protein synthesis (Murton et al.
2009) and the molecular events characterising the up-regulation of components
of the ubiquitin proteasome system (Strachan 2012); ultimately, to elucidate
the pathways dysregulated in sepsis mediated muscle atrophy. In this chapter
we describe the expression profiles of satellite cell myogenic regulatory factors
(MRFs) during the early stages of endotoxaemia, which when impaired, may
limit muscle regeneration after atrophy
Little is reported of satellite cell specific responses to LPS in vivo but a few
studies have explored the behaviour of satellite cells in inflammatory milieu in
vitro (Gallucci et al. 1998; Li and Schwartz 2001; Doyle et al. 2011). Cultured
myoblasts respond to inflammatory stimuli and have been shown to express
TLR4. This suggests satellite cells participate in infection control and may not
be inconsequential to the inflammatory response (reviewed by Lightfoot et al.
2009). Furthermore, C2C12 myotubes treated with LPS experienced a dose-
dependent loss of myosin heavy chain (MHC) myofribrillar protein and a
reduction in myotube diameter after 48h (Doyle et al. 2011). Myotube atrophy
was due to a coordinated stimulation of the ubiquitin-proteasome and
autophagy-lysosomal pathways. Likewise, highly purified human myoblasts,
when stimulated with pro-inflammatory agents such as TNF-D or LPS,
selectively express and secrete IL-6, which activate myofibrillar cachectic
proteolysis (Ebisui et al. 1995; Gallucci et al. 1998) or myoblast proliferation
(Austin and Burgess 1991; Cantini et al. 1995), although the choice of action
may be time/dose dependent. There is also evidence of muscle fibres and
myocytes responding to LPS stimulation via TLR4 in vivo; studies by Frost et
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al. (2004; 2006) noted LPS administration failed to elicit nitric oxide synthase
(NOS) expression in myocytes of C3H/HeJ mice harbouring a mutation in the
LPS receptor. Additionally, LPS-induced NOS was found to co-
immunoprecipitate with the muscle specific caveolin-3 protein.
A review by Degens (2009) highlights the importance of the in vivo satellite
cell microenvironment during systemic inflammation; circulating systemic
factors affect the regenerative capacity of satellite cells, which may contribute
to the slow progressive loss of muscle mass over time. This is supported by the
impaired regeneration of young rat muscle when transplanted into an old rat
(Carlson and Faulkner 1989), where chronic low grade systemic inflammation
is thought to be the main cause of impairment (Bruunsgaard et al. 2001;
Degens 2007) and the rejuvenation of old satellite cells exposed to serum from
young animals (Conboy et al. 2005). It is speculated the increased levels of
circulating inflammatory cytokines during sepsis impairs satellite cell function
by altering the expression of MRFs. This could likely explain why satellite
cells exposed to TNF-D in vitro or inflammatory milieu in vivo are able to
proliferate but not differentiate (Foulstone et al. 2004; Langen et al. 2006).
Likewise, mice over-expressing or injected with TNF-D exhibited reduced
MyoD protein levels (Langen et al. 2004) that were concomitant with impaired
muscle regeneration. In the present study, we describe the expression profile of
the inflammatory cytokines TNF-D, IL-6 and NF-NB and their influence of on
components of satellite cell myogenesis during the early stages of
endotoxaemia.
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In summary, the aims of the present study are to examine the regulation of
satellite cell activity in apharmocological model of atrophy (via continuous
LPS administration) in the rat. More specifically, to measure the expression of
inflammatory markers in order to determine what impact they have on satellite
activity. We hypothesise that increased expression of inflammatory cytokines
in response to continuous LPS infusion should have a negative effect on
components of the satellite cell myogenic program, thus contributing to
progressive inflammation-mediated muscle wasting.
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4.3 METHODS
4.3.1 Animals and tissue collection
Animal work was carried out as described in chapter 2, section 2.1.2.2. Briefly,
male Sprague-Dawley rats (380-480g; Charles River, Sandwich, UK) were
anaesthetised with fetanyl citrate (300Pg/kg; i.p., Janssen-Cilag, High
Wycombe, UK) and meditomidine (300Pg/kg; i.p., Domitor, Pfizer, Sandwich,
UK) prior to catheter implantation in the jugular vein for administration of
substances. Under anaesthesia, animals were fitted with a harness to carry the
catheter and allowed unrestricted movement. Anaesthesia was reversed with
atipamezole (1mg/kg; s.c., Antisedan, Pfizer, Sandwich, UK), analgesia was
provided (buprenorphine; 0.03 mg/kg, s.c., Vetergesic; Alstoe Animal Health,
York, UK) and animals were left to recover for 24 hours with open access to
food and water. The venous line was connected to an infusion pump via a fluid
filled swivel, which maintained a continuous i.v. infusion of sterile heparinised
saline (15U/ml) at 0.4ml/hr to maintain catheter patency.
Prepared rats were divided into six groups; three groups received a continuous
infusion sterile isotonic saline (0.4ml/hr) for either 2h (n=4), 6h (n=4) or 24h
(n=6) and the remaining three groups received a continuous infusion of LPS
(E. coli, serotype 0127:B8; 15 Pg/kg/hr i.v., Sigma, Poole, UK: dissolved in
sterile isotonic saline;) for either 2h (n=4), 6h (n=4) or 24h (n=6). After the
specified times, animals were terminally anaesthetised with sodium
pentobarbital (Inactin; 80 mg/kg, i.v., Sigma-Aldrich, St. Louis, USA). The
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extensor digitorum longus (EDL) and gastrocnemius muscles from both limbs
were removed and immediately snap frozen and stored in liquid nitrogen.
4.3.2 mRNA measurements (real-time PCR)
Total RNA was extracted from approximately 25mg of frozen wet muscle
using TRIzol
®
(Invitrogen, Paisley, UK) according to the manufacturers
instructions. The quality and quantity of RNA was assessed
spectrophotometrically (by measuring the absorbance at 260nm and 280nm)
and qualitatively by visually assessing the ratio of 18:28S ribosomal RNA on a
1% formaldehyde gel. First strand cDNA synthesis was carried out using 1Pg
of total RNA, as described in chapter 2, section 2.2.3. Taqman
®
primer/probe
sets (Table 4.1) were obtained from Applied Biosystems (ABI, Foster City,
CA, USA). Real-time PCR was performed using Taqman gene expression
master mix (Applied Biosystems) in a MicroAmp 96-well reaction plate
(Geneflow, Fradley, UK). Reactions were carried out in an ABI Prism 7000
sequence detection system in duplicate; each well contained 2Pl cDNA
template, 12.5Pl PCR master mix and 1.25Pl primer/probe mix in a 25Pl
reaction volume (See Chapter 2, section 2.2.4)
Relative quantification of gene expression between time matched control and
LPS-treated groups was calculated using the 2
ǻǻ&W
method. Briefly, duplicate
cycle threshold (Ct) values for each control or treated sample were averaged
and the 'Ct was calculated by subtraction of the corresponding mean Ct of an
HQGRJHQRXVFRQWURO+0%6ǻǻ&t was calculated by subtracting the 'Ct of
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Table 4.1: Catalogue and Unigene Numbers for Taqman primer/probes
sets
Gene Catalogue Number Unigene Number
HMBS Rn00565886_m1 Rn.11080
TNF-a Rn00562055_m1 Rn.2275
IL-6 Rn00561420_m1 Rn.9873
NFkB1 Rn01399583_m1 Rn.2411
Pax7 Rn00834076_m1 Rn.226327
MKi-67 Rn01451446_m1 Rn.73551
MyoD1 Rn00598571_m1 Rn.9493
Myogenin Rn00567418_m1 Rn.9465
Myostatin Rn00569683_m1 Rn.44460
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LPS treated samples from the mean 'Ct of corresponding time-matched saline
controls and the relative amount of target mRNA was determined by 2
ǻǻ&W
.
The saline control groups were given a value of 1 and fold changes in mRNA
expression of LPS treated groups were calculated relative to their
corresponding control group. Thus values >1 or <1 indicate an increase or
decrease in mRNA expression from control, respectively.
4.3.3 Protein measurements (Western Blotting)
Protein extractions and western blotting was carried out using approximately
30mg of muscle, as described in chapter 2, section 2.2.5 and chapter 3 section
3.3.3, to determine protein expression of the targets listed in table 4.2.
4.3.4 Histology
4.3.4.1 Immunohistochemistry
To localise and quantify (see section.4.3.6 below) macrophage infiltration of
skeletal muscle in response to LPS infusion, 10Pm frozen serial cross sections
were cut (Leica Microtome, Leica Microsystems, Wetzler, Germany) and
mounted onto Superfrost
®
Plus slides (ThermoFisher Scientific,
Loughborough, UK) as described in chapter 2, section 2.2.6. Cross sections of
normal adult brain tissue were used as a positive control for the antibody
because brain tissue is specific for microglia. Sections were fixed in 4%
Paraformaldehyde/Phosphate-Buffered-Saline (PFA/PBS: 4% (w/v) PFA,
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Table 4.2: Primary and secondary antibodies used in the Western blotting
protocol.
Primary Antibody Supplier Dilution
Goat Anti-TNFDpAb R&D Systems
Mineapolis, USA
1:500
Goat Anti-IL-6 pAb R&D Systems
Mineapolis, USA
1:500
Rabbit Anti-NFkB p105/p50 [E381]
mAb
Abcam
Cambridge UK
1:2500
Rabbit Anti-Iba1 pAb Wako
Osaka, Japan
1:500
Mouse Anti-Pax7 mAb DSHB
Iowa City, IA, USA
1:500
Rabbit Anti-MyoD (C-20) pAb Santa Cruz Biotechnology
Santa Cruz, CA, USA
1:500
Mouse Anti-Myogenin mAb DSHB
Iowa City, IA, USA
1:500
Rabbit Anti-Myostatin, Near C-
terminus pAb
Millipore
Billerica, MA, USA
1:250
Secondary Antibody Supplier Dilution
Rabbit Anti-Goat
Immunoglobulins/HRP pAb
Dako
Glostrup, Denmark
1:2000
Swine Anti-Rabit
Immunoglobuline/HRP pAb
Dako
Glostrup, Denmark
1:2000
Rabbit Anti-Mouse
Immunoglobulins/HRP pAb
Dako
Glostrup, Denmark
1:2000
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137mM NaCl, 2.7mM KCl, 4.3mM KH2PO4 pH 7.4) for 10 minutes, washed
for 3x5 minutes in Tris-Buffered-Saline (TBS: 0.05M Tris, 0.15M NaCl, pH
7.4) and blocked for 1hr with at room temperature with 5% normal horse serum
(Vector Laboratories, Burligame, CA, USA). Sections were incubated with
rabbit anti-Iba-1 polyclonal antibody (Wako, Osaka, Japan), diluted 1:1000 in
blocking solution at 4°C for 72 hr. Control sections were incubated in blocker
only. Primary antibody was visualised with vectastain anti-mouse kit (Vector
Labs) as described in chapter 2, section 2.2.6.1. Slides were rinsed, air dried
and mounted in glycerol gelatine (Merck, Darmstadt, Germany) for
microscopy (DM4000B light microscope, Leica). Iba-1
+
macrophages were
counted and expressed per volume of muscle, as outlined in chapter 2, section
2.2.6.4.
4.3.4.2 Immunofluorescence
Iba-1 and TNF-D were co-localised by immunofluorescence to determine the
major source of cytokine production. Muscle samples from representative
animals showing high TNF-D and Iba-1 expression were cryo-sectioned and
fixed in formaldehyde vapour for 30 minutes at -20°C as described in chapter
2, section 2.2.6.2. This method of fixation methylates protein lysine groups
thereby denaturing and partially cross-linking proteins. Using vapour fixation
minimises the loss of soluble antibody targets in solution compared to PFA
fixation; soluble proteins are tagged in a frozen state, keeping them as close to
natural as possible. Sections from normal adult brain tissue were used as a
positive control for both antibodies Sections were blocked with 5% normal
horse serum for 1hr at room temperature. Antibody dilutions were: goat anti-
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TNF-D (1:100) and rabbit anti-Iba-1 (1:1000). Technical control sections were
incubated with blocker only and all sections were incubated for 72hr at 4°C.
Secondary antibodies were donkey anti-rabbit Alexa488 and donkey anti-goat
Alexa594, diluted 1:200 each (Invitrogen, Paisley, UK). Sections were
incubated with the respective secondary antibody or a combination of both in
for 1hr at room temperature, rinsed and mounted with ProLong anti-fade gold
with DAPI (Invitrogen).
4.3.4.3 Duolink
®
Bright-field Proximity Ligation Assay (PLA)
The Duolink
®
PLA enables in-situ detection and visualisation of individual
proteins or protein complexes in tissue samples prepared for microscopy.
Specificity for a single protein target is enhanced by using two different
primary and oligonucleotide-conjugated secondary antibodies (PLUS and
MINUS PLA probes), which when in close proximity (within 40nm) combine
to form a circular DNA template that is subsequently amplified by rolling cycle
amplification. HRP-tagged oligonucleotides specifically hybridise with
amplified DNA and the signal from each detected pair of primary antibody is
visualised as a quantifiable individual spot by microscopy (see chapter 2,
section 2.2.6.3 for a detailed description).
Preliminary optimisation experiments using two commercially available
antibodies for ki-67 (rabbit polyclonal and mouse monoclonal anti-ki-67,
Vector Labs) determined that when used individually by
immunohistochemistry, the polyclonal antibody gave a good signal but with
high background whilst the monoclonal antibody produced a low background
with poor signal. Duolink
®
PLA was therefore an ideal candidate to amplify the
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signal detected without compromising signal-to-noise ratio. Briefly, muscle
cross sections from randomly assigned 2hr and 24hr treated animals were
prepared and fixed in 4% PFA as described above. Cross sections from human
embryonic tissue were used as a positive control and all were blocked in 5%
normal horse serum for 1hr at room temperature.
Antibodies were added at a dilution of 1:100 in blocking solution either
individually (as an additional technical negative control) or in combination and
control sections were incubated in blocking solution only. All were incubated
at 4°C overnight. The oligonucleotide conjugated anti-mouse (MINUS) and
rabbit (PLUS) PLA probes were incubated with respective sections for 2 hours
at 37°C. Sections were then incubated in the following solutions in-between
washes in TBS-T: hybridisation (15min at 37°C), ligation (15min at 37°C)
amplification (polymerase 90min at 37°C) and HRP detection solutions (30min
at room temperature). Slides were incubated in Duolink
®
substrate solution
(containing the HRP substrate NovaRED
TM
) for 10 minutes at room
temperature, washed and nuclear stained for 2 minutes. Prior to mounting in
non-aqueous medium (Canada Balsam with xyelene, Merck, Darmstadt,
Germany) for light microscopy, slides were dehydrated and cleared in
increasing concentration of ethanol then xylene.
4.3.4.4 Stereology
Stereological methods in histology obtain quantitative information about three-
dimensional (3D) features of tissues from two-dimensional physical sections.
Using a modification of the method by Mayhew et al.(1997),10Pm muscle
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cross sections were prepared from control and treated animals randomly
sampled from the proximal, distal or mid-belly regions of EDL and
gastrocnemius muscles as described in section 2.2.6.4. The total numbers of
profiles (i.e. Iba-1
+
, pax7
+
, myoD
+
cells or ki-67
+
PLA spots) for each section
were counted with the aid of an eye-piece graticule using a section scanning
technique (see figure 2.9). The surface area of muscle cross-sections (Ax-sect)
was estimated using a systematic uniform point grid of known area. Points
(represented by the crossing of horizontal and vertical lines over the muscle
section) were counted and an estimate of the surface area of each cross section
is given by the formula below, which estimates the number of profiles (Nprof)
per volume of muscle (Vmusc).
Nprofiles = total number of positive cells per sample
Ax-sect = total surface area of muscle cross sections in sample group (Pm2)
D = profile diameter (Pm)
t = muscle section thickness (Pm)
Ȉp = sum of all points per sample
a
p
= area per point  surface area of 1 grid on uniform point grid
M = magnification
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4.3.5 Statistical analyses
Some of the data obtained were inconsistent with a Gaussian distribution and
tests for normality (such as the Kolmogorov-Smirnov and the D'Agostino-
Pearson omnibus tests used by Prism) and plots of frequency distribution could
not definitvely prove the data were sampled from a Gaussian distribution
(D'Agostino and Stephens 1986). With smaller data sets (where n=4),
normality tests and frequency distributions did not have enough power to
detect modest deviations from the Gaussian ideal; therefore comparisons
between control and treated groups, between different sampling points (e.g.,
2hr vs 6hr) were performed using the Kruskal-Wallis one-way analysis of
variance (ANOVA), a non-parametric test. The Dunns multiple comparision
post-hoc test was used to highlight significant difference between treated
groups and sampling points (e.g., 2hr LPS vs 24hr LPS groups). Significance
was accepted at p<0.05.
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4.4 RESULTS
4.4.1 Inflammatory Cytokines
Sepsis induced alterations in skeletal muscle metabolism and growth are
thought to be fibre-type and tissue specific (Vary and Kimball 1992; Murton et
al. 2009). The study by Tiao et al (1997) also suggested that the EDL (a
primarily fast muscle) is more susceptible to atrophy than the slow-twitch
soleus muscle. Therefore, we measured the mRNA transcripts and protein
expression of the inflammatory cytokines TNF-D, IL-6 and NF-NB in the EDL
and gastrocnemius (a muscle of mixed fibre type composition) to determine
whether a muscle of intermediate characteristics, such as the gastrocnemius,
relative to the soleus and EDL, would display intermediate responses to
endotoxin relative to the other two muscles.
There were substantial transient increases in the mRNA expression of TNF-D
and IL-6 across all time points, in both the EDL and gastrocnemius muscles.
The highest mRNA expression was after 2hr LPS infusion and the lowest was
after 24hr compared to their corresponding time-matched saline controls. These
expression profiles were synonymous with the respective protein expression,
which were also highest after 2hr of LPS (figures 4.1 - 4.3). TNF-D protein
expression after 24hr of LPS was lower relative to saline control, whilst its
mRNA was increased in both EDL and gastrocnemius muscles at this sampling
point (~3 fold and ~5 fold respectively). We do not believe this represents
divergent fates of TNF-DmRNA and protein expression but likely denotes
increased proteolytic processing of the ~26kDa membrane-bound TNF-
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D(Kriegler et al. 1988by a family of TNF-Alpha-Converting-Enzyme
(TACE) such as A-Disintergrin-and-Metalloproteinase-domain-containing
protein 17 (ADAM17), which cleaves the membrane bound precursor of TNF-
Dto its mature soluble form (reviewed in Black 2002). The protein expression
of IL-6 in gastrocnemius muscle was not measured due to time constraints but
based on its similar mRNA expression profile to the EDL muscle; we surmised
its protein expression following LPS is also similar to that of the EDL.
Interestingly, the magnitude of mRNA expression of both cytokines was
considerably higher in the gastrocnemius compared to the EDL, especially
after 2hr of LPS (TNF-D: 22 vs. 10 fold and IL-6: 660 vs. 135 fold). Tiao et al.
(1997) reported that the fast twitch EDL was more susceptible to atrophy than
the slow twitch soleus muscle due to differential activation of the energy-
ubiquitin-dependent proteolytic pathway. It is likely the increased sensitivity of
the gastrocnemius muscle to LPS reported here highlights a fibre type specific
response to LPS that may be independent of the degree of potential atrophy
elicited.
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Figure 4.1: Expression of TNF-D a) mRNA and b) protein in EDL and gastrocnemius
muscle following 2, 6 or 24hr continuous LPS or saline infusion. a) Relative mRNA
expression of saline controls was set at 1; bars denote fold change in mRNA expression from
corresponding time matched control with values >1 = increased mRNA expression and <1 =
decreased mRNA expression. Values are means ±S.E.M. b) The densities of ~26kDa TNF-D
immunoreactive bands (Kriegler et al. 1988) were measured by western blotting and
representative bands for each group are shown above their corresponding bar. n=4 (2, 6hr) n=6
(24hr). By Kruskal-Walis 1-way ANOVA: significantly different from corresponding time
matched control group:
*
p<0.05,
**
p<0.005. Significantly different from 2hr LPS treated
group:
+
p<0.05,
++
p<0.005. Significantly different from 6hr LPS treated group:
#
p<0.05
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Figure 4.2: Expression of IL-6 a) mRNA and b) protein in EDL muscle following 2, 6 or
24hr continuous LPS or saline infusion. a) Relative mRNA expression of saline controls was
set at 1; bars denote fold change in mRNA expression from corresponding time matched
control with values >1 = increased mRNA expression and <1 = decreased mRNA expression.
Values are means ±S.E.M. b) The densities of ~24kDa IL-6 immunoreactive bands were
measured by western blotting and representative bands for each group are shown above their
corresponding bar. n=4 (2, 6hr) n=6 (24hr). By Kruskal-Wallis 1-way ANOVA: significantly
different from corresponding time matched control group:
***
p<0.0005. Significantly different
from 2hr LPS treated group:
+
p<0.05.
a) IL-6mRNA expression  EDL
b) IL-6protein expression  EDL
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Figure 4.3: Fold changes in IL-6 mRNA expression in gastrocnemius muscle following 2,
6 or 24hr continuous LPS or saline infusion. Relative mRNA expression of saline controls
was set at 1; bars denote fold change in mRNA expression from corresponding time matched
control with values >1 = increased mRNA expression and <1 = decreased mRNA expression.
Values are means ±S.E.M. n=4 (2, 6hr) n=6 (24hr). By Kruskal-Wallis 1-way ANOVA:
significantly different from corresponding time matched control group:
*
p<0.05,
**
p<0.005.
Significantly different from 2hr LPS treated group:
+
p<0.05,
++
p<0.005. Significantly different
from 6hr LPS treated group:
#
p<0.05.
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The transient up-regulation of pro-inflammatory cytokines such as TNF-D and
IL-6 is mediated in part by NF-NB signalling (Muller et al. 1993), therefore we
measured NF-NB mRNA and protein expression in the EDL to compare its
expression profile to that of TNF-D and IL-6. NF-NB mRNA was significantly
~3 fold higher in the EDL after 2 and 6hr but was only ~1.6 fold higher than
control after 24hr (figure 4.4a). As described in section 4.1, NF-NB belongs to
a family of pleiotropic transcription factors, which form homo- or hetero-
dimers in different combinations to mediate gene transcription. There are five
members in mammals: RelA(p65), RelB and c-Rel are categorised as one
group. They are synthesised as mature proteins containing an N-terminal Rel
Homology Domain (RHD), which is essential for dimerization and DNA
binding, and a C-terminal containing the transcriptional activation domain. The
latter group consists of NF-NB1 p50/p105 and NF-NB2 p52/p100 proteins;
these are synthesised as large precursors (p105 and p100 respectively) and
proteolytic processing at the C-terminal gives rise to the RHD-containing p50
or p52, both of which lack the C-terminal trans-activation domain and thus
hetero-dimerization is required for gene transcription. NF-NB dimers are
retained in the cytoplasm by specific inhibitors (INBs) and the precursor
proteins p105 and p100. These mask their nuclear localisation signal (NLS)
and prevent nuclear translocation, thus maintaining NF-NB in an inactive state
in the cytoplasmic compartment (reviewed in Li et al. 2008).
The inhibitory p105 and the processed, active p50 subunits of NF-NB were
measured by western blotting. Both subunits were significantly higher in LPS
treated muscle after 2hr and showed a tendency to be higher after 6hr (p~0.07
144
and p~0.2 respectively). No significant change was detected after 24h of LPS
for either subunit (figure 4.4b).
The protein expression of NF-NB in gastrocnemius muscle was not measured;
we speculate, from the mRNA data (figure 4.5) that the expression profiles of
both cytokines were likely similar in both muscles.
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Figure 4.4: Expression of NF-NB a) mRNA and b) protein in EDL muscle following 2, 6
or 24hr continuous LPS or saline infusion. a) Relative mRNA expression of saline controls
was set at 1; bars denote fold change in mRNA expression from corresponding time matched
control with values >1 = increased mRNA expression and <1 = decreased mRNA expression.
Values are means ±S.E.M. b) The densities of ~105kDa and ~50kDa immunoreactive bands,
corresponding to the p105 and p50 subunits of NFkB, were measured by western blotting and
representative bands for each group are shown above their corresponding bar. n=4 (2, 6hr) n=6
(24hr). By Kruskal-Wallis 1-way ANOVA: significantly different from corresponding time
matched control group:
*
p<0.05,
**
p<0.005. Significantly different from 2hr LPS treated
group:
+
p<0.05,
++
p<0.005. Significantly different from 6hr LPS treated group:
#
p<0.05.
a) NFkB mRNA expression  EDL
b) NFkB protein expression - EDL
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Figure 4.5: Fold changes in NF-NB mRNA expression in gastrocnemius muscle following
2, 6 or 24hr continuous LPS or saline infusion. Relative mRNA expression of saline controls
was set at 1; bars denote fold change in mRNA expression from corresponding time matched
control with values >1 = increased mRNA expression and <1 = decreased mRNA expression.
Values are means ±S.E.M. n=4 (2, 6hr) n=6 (24hr). By Krukal-wallis 1-way ANOVA:
significantly different from corresponding time matched control group:
*
p<0.05,
***
p<0.0005.
Significantly different from 2hr LPS treated group:
+
p<0.05,
+++
p<0.0005.
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4.4.2 Macrophage Infiltration
Macrophages play an important role in cytokine production. In fact TNF-D is
one of the most abundantly synthesised products of activated macrophages and
accounts for about 5% of their total secretory content (Beutler et al. 1985a).
The degree of macrophage infiltration in skeletal muscle in response to LPS
was measured using ionised calcium binding adaptor molecule 1 (Iba1), a well
characterised macrophage/microglia marker specific for quiescent and
activated macrophages (Imai et al. 1996). Iba1 is a 17kDa EF-hand calcium
binding protein implicated in macrophage membrane ruffling, motility and
phagocytosis of infectious particles (Ohsawa et al. 2000).
Iba1
+
cells were detected on cross sections of untreated adult rat brain tissue
(microglia) and gastrocnemius muscle (macrophages) by
immunohistochemistry (figure 4.6). A first impression indicated that the
frequency of Iba1
+
cells was distinctly higher in LPS treated muscle; thus the
total number of distinct positive cells per area of muscle were counted on
sections from saline and LPS treated gastrocnemius and EDL muscle as
described in section 4.3.4.4. The total number of macrophages in muscle
increased after LPS administration across all time points in both muscles
(figure 4.7). Interestingly, the numbers of macrophages were higher in the
gastrocnemius than the EDL, which corresponds to the higher cytokine mRNA
expression observed for gastrocnemius muscle (see figures 4.1a, 4.2a and
4.3a).
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Figure 4.6: Representative photomicrographs of Iba1
+
microglia/macrophages on 10Pm
cross sections of rat brain (A-B) and gastrocnemius muscle (C-F). A and C are no primary
antibody controls; C and D are cross sections from normal adult rat muscle, whilst E and F are
from Saline and Lipopolysaccharide infused animals. Arrowed; Iba
+
cells, Scale bars; A, C, D
= 50Pm B, E, F = 25Pm
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Figure 4.7: The total number of Iba1
+
macrophages in rat gastrocnemius and EDL
muscle following 2, 6 or 24hr LPS or saline continuous intravenous infusion. 10Pm
cryosections were stained against Iba1 via immunocytochemistry and positive cells counted by
light microscopy. Values ±S.E.M. n=3 (2, 6hr) n=5 (24hr). By Kruskal-Wallis 1-way ANOVA:
significantly different from corresponding time matched control:
*
p<0.05,
**
p<0.005.
Significantly different from 2hr LPS treated muscle:
+
p<0.05. Significantly different from 6hr
LPS treated muscle:
#
p<0.05.
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To verify the increased presence of macrophages in LPS treated muscle, we
also measured Iba1 protein expression by western blotting. Iba1 was higher in
LPS treated gastrocnemius muscle after 2hr and 24hr (figure 4.8). The EDL
muscle also showed a tendency toward higher levels of Iba1 protein after 2 and
24hr of LPS. Although the quantitative immunohistochemistry results are more
striking compared to Western blotting results, both methods provide sufficient
evidence for increased muscle macrophage infiltration.
The appearance of macrophages was also studied by immunohistochemistry
and immunofluorescence to examine morphological changes (if any) after LPS
administration (figure 4.9 and 4.10). Qualitatively, macrophages were larger
and expressed more Iba1 after 24hr continuous LPS infusion; these had a
distinct cytoplasm and were indicative of activated macrophages, which tend to
be larger due to cytoplasmic expansion (Wirenfeldt et al. 2009). From counting
macrophages, we also had the impression saline treated sections showed more
quiescent macrophages, which were smaller in diameter, contained more
prominent thin branching processes and expressed less Iba1 (Finnie et al.
2010).
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Figure 4.8: Expression of Iba1 protein in grastrocnemius and EDL muscle following 2, 6
or 24hr continuous LPS or saline infusion. Values are means ±S.E.M. The densities of
~17kDa immunoreactive bands were measured by western blotting and representative bands
for each group are shown above their corresponding bar. n=4 (2, 6hr) n=6 (24hr). Significantly
different from corresponding time matched control group:
*
p<0.05,
**
p<0.005. Significantly
different from 2hr LPS treated group:
+
p<0.05 by 1-way ANOVA
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Figure 4.9: Representative photomicrographs of Iba1
+
cells on 10Pm cross sections of rat
brain (A), Saline (B,D) and LPS-treated (C,E) gastrocnemius muscle. A, shows Iba1
+
microglia in untreated adult brain; B-C are 2hr treated muscle, whilst D-E are from 24hr Saline
and LPS infused animals. Scale bars; 10Pm
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Figure 4.10: Representative photomicrographs of Iba1
+
microglia and macrophages in
untreated adult rat brain (A-C), Saline (D-F) and LPS-treated (G-I) gastrocnemius
muscle. 10Pm cryosections were stained against Iba1 for 72h and visualised via
immunofluorescence. Scale bars; 100Pm
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4.4.3 TNF-D/macrophage co-localisation
TNF-D is a myokine expressed by myocytes in skeletal muscle (Li 2003); we
assessed the distribution of TNF-D expression in gastrocnemius muscle,
because it showed a higher magnitude of TNF-D mRNA expression compared
to the EDL, to determine the predominant source of secretion. As expected, the
saline treated samples showed some TNF-D+ signals but were of lower
intensity compared to LPS counterparts (figure 4.11). TNF-Dwas distributed in
sporadic patches on the LPS treated samples, the majority of expression was
localised to macrophages (arrowed) and myocytes with some freely dispersed
TNF-D+ granules around endomysial and perimysial connective tissue.
Interestingly, some TNF-D expression was seen in 24hr saline treated samples
although mostly localised to degenerating muscle fibres (arrowhead).
Sections were incubated with TNF-Dand Iba1 simultaneously to confirm the
presence of TNF-Dexpressing microglia/macrophages (figure 4.12). Of 22
random Iba1
+
macrophages counted on cross sections of 24hr LPS treated
gastrocnemius muscle, only about 13 cells (~60%) were also positive for TNF-
alpha. However, there were plenty of free floating TNF-D+ granules in close
proximity to Iba1
+
cells; confirming that most of macrophages secrete TNF-D.
In contrast, corresponding control sections showed only ~15% Iba1
+
macrophages also positive for TNF-D (two cells were positive for both out of
thirteen counted).
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Figure 4.11: Representative high magnification photomicrographs of TNF-D expression
in Saline and LPS treated rat gastrocnemius muscle. 10Pm frozen cross sections were
stained against TNF-D and visualised via immunofluorescence. A-C: 2h saline, D-F: 2h LPS,
G-J: 24h saline, K-N: 24h LPS. Positive signals are localised to degenerating fibres
(arrowheads) and macrophages (arrows). J, N are composite images at a higher magnification.
Scale bars: A-C, G-I, K-M = 100Pm. D-F, J, N = 50Pm.
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Figure 4.12: TNF-D expression is localised to Iba1+ i) microglia and ii) macrophages in untreated adult rat brain and LPS treated gastrocnemius. i) A-B: brain and
gastrocnemius no primary antibody control respectively.10Pm frozen cross sections were stained against Iba1, TNF-D or both and visualised via immunofluorescence. Some
microglia/macrophages are positive for both antibodies (arrowed). Scale bars; 100Pm
1) Untreated Adult Rat Brain (microglia)
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ii) LPS-treated Rat Gastrocnemius (macrophages)
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4.4.4 Myogenic Regulatory Factors (MRFs)
The mRNA and protein expression patterns of early markers (pax7, myoD, ki-
67), late markers (myogenin) and a negative regulator (myostatin) of satellite
cell were measured following LPS administration.
LPS infusion differentially suppressed pax7 in the EDL and gastrocnemius
muscles (figure 4.13); pax7 mRNA was suppressed after 6hr of administration
and stayed reduced after 24hr in the EDL. Pax7 protein demonstrated a
tendency toward decreased expression after 6 and 24hr in the EDL. The
gastrocnemius muscle displayed an earlier suppression of pax7 mRNA and
protein; there was a tendency toward decreased pax7 as early as 2hr after
continuous infusion (p~0.13 and p~0.15; mRNA and protein, respectively).
Pax7 mRNA and protein expression was still low after 6hr in the
gastrocnemius, but there was a tendency toward a return to basal levels after 24
hr.
MyoD also displayed a similar time dependent response to LPS administration;
myoD mRNA and protein was differentially suppressed in both muscles, with
the gastrocnemius showing an earlier, more dramatic decrease compared to the
EDL (figure 4.14). However, unlike pax7, myoD was still lower relative to
control after 24hr, in both muscles. Taken together, these results suggest the
gastrocnemius is more sensitive to LPS-mediated myogenic suppression
relative to the EDL.
These results were verified by quantitative immunohistochemistry using 3-D
stereology as described in chapter 2, section 2.2.6.4 and above in section
4.3.4.4. The total number of pax7
+
and myoD
+
satellite cells were estimated per
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volume of muscle (figure 4.15).The gastrocnemius was used because it is
larger than the EDL muscle and ensured there was sufficient tissue available
for cyrosectioning. LPS caused short term changes in the number of pax7
+
quiescent/proliferating satellite cells. The number of pax7
+
satellite cells
decreased significantly after 2hr and 6hr, but there was a tendency toward a
return to baseline levels by 24hr. In contrast, myoD
+
satellite cells decreased
significantly across all time points and similarly to RT-PCR and western
blotting data, myoD was still suppressed after 24hr of LPS administration.
Similarly to the Iba-1 data from Western blotting and quantitative IHC reported
in section 4.4.2 above, the pax7 and myoD IHC data presented here are also
more striking. Heterogeneity of macrophages and satellite cells suggest
Western blotting results, which show total relative levels of protein expression,
are not representative of quantitative IHC, which show numbers of
macrophages and satellite cells expressing Iba-1, pax7 or myoD.
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Figure 4.13: Expression of Pax7 a) mRNA and b) protein in EDL and gastrocnemius
muscle following 2, 6 or 24hr continuous LPS or saline infusion. a) Relative mRNA
expression of saline controls was set at 1; bars denote fold change in mRNA expression from
corresponding time matched control with values >1 = increased mRNA expression and <1 =
decreased mRNA expression. Values are means ±S.E.M. b) The densities of ~55kDa pax7
immunoreactive bands were measured by western blotting and representative bands for each
group are shown above their corresponding bar. n=4 (2, 6hr) n=6 (24hr). By Kruskal-Wallis 1-
way ANOVA: significantly different from corresponding time matched control group:
*
p<0.05.
Significantly different from 2hr LPS treated group:
+
p<0.05. Significantly different from 6hr
LPS treated group:
#
p<0.05
a) Pax7 mRNA expression
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Figure 4.14: Expression of MyoD a) mRNA and b) protein in EDL and gastrocnemius
muscle following 2, 6 or 24hr continuous LPS or saline infusion. a) Relative mRNA
expression of saline controls was set at 1; bars denote fold change in mRNA expression from
corresponding time matched control with values >1 = increased mRNA expression and <1 =
decreased mRNA expression. Values are means ±S.E.M. b) The densities of ~34kDa MyoD
immunoreactive bands were measured by western blotting and representative bands for each
group are shown above their corresponding bar. n=4 (2, 6hr) n=6 (24hr). By Kruskal-Wallis 1-
way ANOVA: significantly different from corresponding time matched control group:
*
p<0.05,
**p<0.005, ***p<0.0005.Significantly different from 2hr LPS treated group:
+
p<0.05,
++
p<0.005. Significantly different from 6hr LPS treated group:
#
p<0.05
a) MyoD mRNA expression
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Figure 4.15: The total number of Pax7
+
quiescent/proliferating and MyoD
+
activated
satellite cells in rat gastrocnemius muscle following 2, 6 or 24hr LPS or saline continuous
intravenous infusion. 10Pm cryosections were stained against pax7 and myoD via
immunohistochemistry. Positive cells were counted by light microscopy and expressed per
volume of muscle. Values are means ±S.E.M n=4 (2, 6hr) n=6 (24hr). By 1-way ANOVA:
significantly different from corresponding time matched control:
*
p<0.05,
**
p<0.005,
***
p<0.0005. Significantly different from 2hr LPS treated muscle:
+
p<0.05. Significantly
different from 6hr LPS treated muscle:
#
p<0.05.
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The Ki-67 nuclear antigen is a well known marker of proliferation and
although not exclusively expressed in satellite cells, it is increasingly used as a
marker for assessing the proliferative potential and activation status of satellite
cells (Mackey et al. 2009; Snijders et al. 2012).
There was a gradual increase in ki-67 mRNA expression in the EDL muscle,
peaking after 24hr of LPS (~2.5fold compared to corresponding time-matched
control). In contrast, the gastrocnemius showed a gradual decline in ki-67
mRNA: it peaked after 2hr (again ~2.5 fold compared to control) followed by a
tendency toward a return to baseline levels after 24hr of LPS infusion (figure
4.16a). This mirrored/reversed expression pattern in both muscles likely
represents a delayed response to LPS by the EDL. It appears the gastrocnemius
muscle is more sensitive to LPS and responds earlier and quicker to the toxin
than the EDL. This is reflected in the pax7 and myoD expression data where
the gastrocnemius showed an earlier and more dramatic response to LPS and in
the case of pax7 and ki-67, a tendency toward basal levels of expression after
24hr. In addition, TNF-D and IL-6 mRNA was greater in the gastrocnemius.
Ki-67 is a large protein (>340kDa) and often difficult to resolve via Western
blotting. We detected the nuclear antigen with a monoclonal and polyclonal
antibody using a commercially available proximity ligation assay as described
in section 4.3.4.3; it detects the proximity of the two antibodies bound to a
single protein target. Ki-67
+
nuclei were counted on 2hr and 24hr saline and
LPS treated EDL muscle cross sections to compare the mRNA and protein
expression trends at those time points. Ki-67 protein expression was
significantly lower after 2hr but returned to baseline levels after 24hr (figure
4.16b-c)
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Figure 4.16a: Ki-67 mRNA expression in EDL and gastrocnemius muscle following 2, 6
or 24hr continuous LPS or saline infusion. Relative mRNA expression of saline controls was
set at 1; bars denote fold change in mRNA expression from corresponding time matched
control with values >1 = increased mRNA expression and <1 = decreased mRNA expression.
Values are means ±S.E.M. n=4 (2, 6hr) n=6 (24hr). By Kruskal-Wallis 1-way ANOVA:
significantly different from corresponding time matched control group:
*
p<0.05. Significantly
different from 2hr LPS treated group:
+
p<0.05. Significantly different from 6hr LPS treated
group:
#
p<0.05
2
6 24 2 6
24
165
Figure 4.16b. Low and high magnification photomicrographs of Ki67
+
cells in embryonic
tissue (A-B) and 24hr Lipopolysaccharide treated EDL muscle (C-D). 10Pm cryosections
were incubated with a polyclonal and monoclonal antibody against Ki67 simultaneously. The
proximity of the two antibodies bound to the same target was determined by Proximity
Ligation Assay (PLA). A,C are controls with one of the antibodies omitted. Arrowed; Ki67
+
cell in LPS muscle. Scale bars: A,C = 50Pm. B,D = 20Pm
Figure 4.16c: The number of Ki67
+
nuclei on 2 and 24hr saline and LPS treated rat EDL
muscle. Nuclei containing Rolling-cycle Products (RCPs) from Bright-field Proximity
Ligation Assay (PLA) for Ki67 were counted by light microscopy and expressed per volume of
muscle. Data presented as mean ± S.E.M. n=4(2hr) n=4(24hr). By Kruskal-Wallis 1-way
ANOVA: significantly different from corresponding time-matched control:
*
p<0.05.
Significantly different from 2hr LPS treated muscle:
+
p<0.05.
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Myogenin is also a well characterised marker for satellite cells and is involved
in terminal differentiation of satellite cells (Yablonka-Reuveni and Rivera
1994). Surprisingly, LPS administration significantly increased myogenin
mRNA in a time dependent manner (figure 4.17). Myogenin protein also
showed a tendency toward increased expression after 24hr. Myogenin protein
expression was not measured in the gastrocnemius muscle because myogenin
mRNA data from the gastrocnemius (figure 4.18) displayed a similar
expression profile to the EDL.
Unlike myoD, which was suppressed at all time points measured, myogenin
expression was increased when circulating cytokine levels were at their lowest.
It appears sepsis-mediated suppression of myogenesis relies more heavily on
the suppression of myoD and that myogenin levels are not influenced as
greatly.
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Figure 4.17: Expression of Myogenin a) mRNA and b) protein expression in EDL
following 2, 6 or 24hr continuous LPS or saline infusion. a) Relative mRNA expression of
saline controls was set at 1; bars denote fold change in mRNA expression from corresponding
time matched control with values >1 = increased mRNA expression and <1 = decreased
mRNA expression. Values are means ±S.E.M. b) The densities of ~25kDa myogenin
immunoreactive bands were measured by western blotting and representative bands for each
group are shown above their corresponding bar. n=4 (2, 6hr) n=6 (24hr). Significantly different
from corresponding time matched control group:
*
p<0.05,
**
p<.005. Significantly different
from 2hr LPS treated group:
+
p<0.05,
++
p<0.005 by 1-way ANOVA.
a) Myogenin mRNA expression  EDL
2 6 24
b) Myogenin protein expression
2 6 24
0.0
0.1
0.2
0.3
0.4
Control
LPS
P
ro
te
in
E
x
p
re
s
s
io
n
,
a
rb
it
ra
ry
u
n
it
s
168
Figure 4.18: Fold changes in Myogenin mRNA expression in Gastrocnemius muscle
following 2, 6 or 24hr continuous LPS or saline infusion. Relative mRNA expression of
saline controls was set at 1; bars denote fold change in mRNA expression from corresponding
time matched control with values >1 = increased mRNA expression and <1 = decreased
mRNA expression. Values are means ±S.E.M. n=4 (2, 6hr) n=6 (24hr). By Kruskal-Wallis 1-
way ANOVA: significantly different from corresponding time matched control group:
**
p<0.005. Significantly different from 2hr LPS treated group:
+
p<0.05,
++
p<0.005.
Significantly different from 6hr LPS treated group:
##
p<0.005
Myogenin mRNA expression  Gastrocnemius
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4.4.5. Myostatin
Alterations in skeletal muscle mass are often associated with myostatin
dysregulation (reviewed by Elkina et al. 2011) and a number of studies have
reported an up-regulation of myostatin in conditions characterised by muscle
atrophy, such as cancer (Liu et al. 2008) and HIV infection (Gonzalez-Cadavid
et al. 1998). Since sepsis is associated with substantial muscle loss, myostatin
mRNA and protein levels were determined to decipher its role (if any) in
sepsis-mediated muscle wasting. Myostatin mRNA and protein expression was
measured in gastrocnemius and EDL muscle to determine fibre type
differences, since fast twitch muscle is reported to display higher susceptibility
to atrophy during sepsis (Tiao et al. 1997) and endotoxaemia (Murton et al.
2009) relative to slow twitch muscles.
Cytosolic and nuclear protein were extracted and quantified by Western
blotting, using densitometry, as described in chapter 2, section 2.2.5. We
detected four different myostatin migrating bands in muscle cytosolic and
nuclear protein fractions (see chapter 3, section 3.3.4). These are reported in
the literature as the unprocessed/pro-myostatin (~55kDa), Latency-Associated-
Peptide (LAP; ~40kDa), ~26kDa immuno-reactive myostatin (often referred to
as a myostatin dimer) and processed/mature (12.5kDa) forms of myostatin
(Thomas et al. 2000; Anderson et al. 2008).
Both the EDL and gastrocnemius muscles displayed an increase in myostatin
mRNA followed by a gradual decrease; relative fold changes in mRNA
compared to corresponding time matched saline controls were highest after 2hr
of LPS infusion and lowest after 24hr (figure 4.19a). Additionally, the
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gastrocnemius muscle appeared to be more sensitive to the toxin; the fold
changes of myostatin mRNA transcript were greater.
All four species of myostatin were detected in the cytosolic fractions of EDL
extracts but only the ~40kDa LAP form was detected in the nuclear fractions.
Nevertheless all protein forms followed a similar expression profile to
myostatin mRNA; protein levels were either unchanged or highest after 2hr of
LPS and lowest after 24hr compared to controls (figure 4.19b). The exception
was in the nuclear fraction where the ~40kDa LAP myostatin was increased
compared to control after 6hr of infusion but was decreased after 24hr. This
increase in nuclear LAP myostatin after 6hr was concomitant with a decrease
in cytosolic LAP myostatin within the same time point and likely represents
nuclear translocation of myostatin. Indeed, the same phenomenon is observed
in the gastrocnemius muscle where a decrease in cytosolic LAP myostatin after
2hr is concomitant with an increase nuclear LAP myostatin within the same
time point (figure 4.19c). It suggests this species of myostatin is shuttled to the
nuclear compartment in response to LPS.
In contrast to the EDL, we only detected the ~40kDa LAP species of myostatin
in the gastrocnemius muscle (figure 4.19c). This is not unexpected as some
authors have speculated that myostatin may be regulated differently in different
muscle tissue within the same organism (Wehling et al. 2000). Whilst the EDL
exhibited a gradual decrease in myostatin protein across all time points,
remaining tendentially low compared to control after 24 hr, the gastrocnemius
showed a tendency toward a return to baseline levels of myostatin protein by
24hr. Protein levels in the cystosolic fraction were significantly low after 2hr
and gradually increased whilst the opposite was seen in the nuclear fraction;
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myostatin was significantly high after 2hr and gradually decreased. As
mentioned above, this likely indicates nuclear translocation of myostatin,
especially at the 2hr time point.
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Figure 4.19a: Expression of Myostatin mRNA in EDL and gastrocnemius muscle
following 2, 6 or 24hr continuous LPS or saline infusion. Relative mRNA expression of
saline controls was set at 1; bars denote fold change in mRNA expression from corresponding
time matched control with values >1 = increased mRNA expression and <1 = decreased
mRNA expression. Values are means ±S.E.M. n=4 (2, 6hr) n=6 (24hr). By Kruskal-Wallis 1-
way ANOVA: significantly different from corresponding time matched control group:
*
p<0.05.
Significantly different from 2hr LPS treated group:
+
p<0.05. Significantly different from 6hr
LPS treated group:
#
p<0.05
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Figure 4.19b: Expression of cytosolic and nuclear Myostatin protein in EDL muscle following
2, 6 or 24hr continuous LPS or saline infusion. Values are means ±S.E.M. The densities of
myostatin immunoreactive bands were measured by western blotting and representative bands for
each group are shown above their corresponding bar. n=4 (2, 6hr) n=6 (24hr). By Kruskal-Wallis 1-
way ANOVA: significantly different from corresponding time matched control group:
*
p<0.05,
**
p<0.005. Significantly different from 2hr LPS treated group:
+
p<0.05,
++
p<0.005. Significantly
different from 6hr LPS treated group:
#
p<0.05,
##
p<0.005
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Figure 4.19c: Expression of cytosolic and nuclear Myostatin protein in gastrocnemius
muscle following 2, 6 or 24hr continuous LPS or saline infusion. Values are means ±S.E.M.
The densities of ~40kDa LAP myostatin immunoreactive bands were measured by western
blotting and representative bands for each group are shown above their corresponding bar. n=4
(2, 6hr) n=6 (24hr). By Kruskal-Wallis 1-way ANOVA: significantly different from
corresponding time matched control group:
*
p<0.05,
**
p<0.005. Significantly different from
2hr LPS treated group:
+
p<0.05,
++
p<0.005. Significantly different from 6hr LPS treated
group:
#
p<0.05 by 1-way ANOVA
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4.5 DISCUSSION
Continuous LPS infusion resulted in the transient elevation of all three
inflammatory cytokines in the EDL and gastrocnemius muscles. Whilst LPS
caused a modest, time-dependent increase in NF-NB expression, there were
substantial elevations in TNF-D and IL-6, especially the latter. NF-NB is an
important mediator of LPS effects and inflammatory induction (reviewed in
Muller et al. 1993; Guha and Mackman 2001); therefore it appears pertinent
that modest increases in its expression are sufficient to induce considerable
increases in its downstream effectors, most notably TNF-D and IL-6. These
results are similar to the findings by Waller et al. (1995), where in an identical
model, an early (1-2hr) elevation in plasma TNF-Dwas noted. Likewise,
Alamdari et al. (2008) and Murton et al. (2009) observed a similar expression
profile for TNF-D and IL-6.
LPS rapidly induces these cytokines and plasma levels peak after 2 hrs but
such elevations are transient due to tight regulatory mechanisms and a limited
half life. For example, TNF-D is highly unstable with an approximate half-life
of 6-7 minutes; it is rapidly degraded after binding and a highly specific radio-
iodinated assay for TNF-D developed by Beutler et al. (1985b) showed that it
is quickly absorbed by the liver, kidney and gastro-intestinal tract to achieve
rapid plasma clearance. As a result, additional release of LPS-induced
inflammatory cytokines is most dramatic in the initial phase just after the
appearance of endotoxin. Consequently, consecutive or continuous
administration of LPS to rats show a reduction in effect after initial
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administration (Waage 1987) and alterations in signalling are blunted by 24
hours (el-Dwairi et al. 1998).
These increases in inflammatory cytokines were partly due to increased muscle
macrophage infiltration. Using a well characterised macrophage/microglia
specific marker (Iba-1), we demonstrated increased numbers of macrophages in
the EDL and gastrocnemius muscles. This was concomitant with increased Iba-
1 protein expression and macrophage activation. In addition, approximately
60% of Iba-1 positive macrophages co-localised with TNF-D; thus confirming
that macrophages were a major source of cytokine production in muscle during
endotoxaemia. Skeletal muscle recruitment of macrophages is normally a
protective phenomenon; they are essential for triggering muscle regeneration
following injury via phagocytosis of cellular debris and stimulation of
myoblast proliferation (reviewed in Chazaud et al. 2009). However, excessive
LPS induced macrophage infiltration during endotoxaemia contributes and
perpetuates the inflammatory response by increasing macrophage activation,
thus increasing the production of inflammatory cytokines, which in turn
mediate many of the derangements in muscle homeostasis. Indeed, many of the
alterations to muscle homeostasis observed with LPS administration can be
replicated with administration of inflammatory cytokines such as TNF-D and
interleukins; these changes are likely to be due to a cascade of events such as
the induction of nitric oxide synthase triggered by cytokines (Gardiner et al.
1998). It is worth noting that macrophages are not the only source of cytokine
production in rat skeletal muscle (Borge et al 2009); TNF-D was also produced
locally by myocytes during endotoxaemia and likely contributes to the
inflammatory milieu.
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Transient elevations of inflammatory cytokines in the EDL and gastrocnemius
muscles had a direct, time and dose-dependent impact on satellite cell specific
markers. At the time points at which cytokine expression was highest (i.e. 2hr),
myogenic regulatory factors pax7, myoD and myogenin, were more
dramatically altered. High levels of cytokines transiently suppressed the
expression of pax7 and the number of pax7
+
resident satellite cells. Whether the
reduction in pax7
+
satellite cells is due to apoptosis or transient repression of
pax7 transcription is undetermined but elevated cytokines, especially TNF-D
has been implicated in pax7 dysregulation.
A study by Palacois et al. (2010) showed that TNF-D activated p38DMAPK
and promoted polycomb repressive complex silencing of the pax7 promoter.
Silencing pax7 allows satellite cell differentiation to proceed as pax7 is known
to induce inhibitors of differentiation (Id proteins), which transcriptionally
repress the induction of myogenic basic Helix Loop Helix (bHLH) proteins,
thus maintaining a state of quiescence (Kumar et al. 2009). TNF-D is also
implicated in preferential apoptosis of satellite cells, denoted by a steady
increase in caspase-8 activity when C2 cells are cultured in vitro to mimic
muscle wasting (Stewart et al. 2004) and the increased susceptibility of satellite
cells from old animals to apoptosis compared to young due to raised plasma
TNF-D (Jejurikar et al. 2006).
Whilst pax7 expression and pax7
+
satellite cell numbers showed a tendency
toward a return to basal levels by 24hr of LPS infusion, myoD expression and
myoD
+
satellite cells remained suppressed relative to control at this time point.
It is tempting to speculate that the modest increase in cytokines, observed after
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24hr relative to earlier time points sampled, was still sufficient to continuously
down-regulate myoD and suppress satellite cell activation. MyoD suppression
is frequently implicated as a major patho-mechanism in the development of
critical illness myopathy (reviewed by Friedrich 2006). Down-regulation of
myoD in inflammatory conditions is thought to occur through TNF-D and NF-
NB dependent mechanisms; TNF-D induced activation of NF-kB suppressed
C2C12 myoblasts and constitutive in vivo expression of TNF-D in mouse
muscle down-regulated myoD mRNA (Guttridge et al. 2000). NF-NB is able to
check satellite cell myogenesis by stimulating cyclin D1 at the level of the
promoter, thus maintaining hyperphosphorylated pRb and cell cycle
progression (Guttridge et al. 1999; Mitin et al. 2001). TNF-D and NF-NB-
mediated suppression of satellite cells also results in the loss of myoD protein
through increased destabilisation and proteolysis via the ubiquitin proteasome
pathway (Langen et al. 2004). As well as contributing to muscle wasting, this
could have serious consequences for subsequent muscle regeneration, as myoD
regulates the expression of myofibrillar proteins and loss of myoD can lead to
further down-regulation of myosin (Acharyya et al. 2004).
The levels of myogenin were unaltered relative to control at the 2hr time point
when cytokine levels were at their highest and were increased after 6hr and
24hr of LPS when circulating cytokines were attenuated. TNF-D also is a
known inhibitor of myogenin (Layne and Farmer 1999) but physiological
levels added to medium have been shown to stimulate myogenic differentiation
via activation of the p38 MAPK pathway, stimulation of Myocyte Enhancer
Factor 2C (MEF2C), myogenin, p21 and MHC in C2C12 myoblasts (Chen et
al. 2007). TNF-D mediated effects on myogenesis assume divergent fates and
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its ability to either inhibit or stimulate myogenin is partly concentration and
time-dependent. As a result, it is the considered paradigm that TNF-D mediated
suppression of myogenesis relies more heavily on the suppression of myoD
and myogenin levels only play a minor role (Wieteska-Skrzeczynska et al.
2011). Decreased NF-NB activity is also associated with increased myoblast
differentiation (Guttridge et al. 1999) and taken together, this likely explains
the time-lagged induction of myogenin  expression was highest with reduced
cytokines.
As mentioned in section 4.2, the exact role of IL-6 in myogenic regulation
during endotoxaemia is not apparent. Whilst clear roles for TNF-D and NF-NB
in the regulation of satellite cell activity in cachectic muscle wasting have been
described, that of IL-6 maybe more complicated; a possible function of IL-6
during endotoxaemia is the suppression of TNF-D (Clowes et al. 1983) - a
protective anti-inflammatory phenomenon that may be necessary for the
stimulation of muscle regeneration following atophy. This is supported, albeit
loosely, by its association with in vivo protection in cardiac muscle (Smart et
al. 2006). IL-6 is also thought to play an anti-inflammatory role during exercise
(Pedersen et al. 2003) and staphylococcal enterotoxaemia (Matthys et al. 1995)
essentially by inhibiting TNF-D production and negatively regulating acute
phase proteins (Tilg et al. 1997). However, the most widely accepted paradigm
is that IL-6 modulates the inflammatory response and facilitates cachectic
muscle wasting; for example, by shortening the half life of long lived proteins
through activation of proteolytic pathways (Ebisui et al. 1995). However, as
much evidence exists for (Ebisui et al. 1995; Tsujinaka et al. 1996; Haddad et
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al. 2005) as well as against (Garcia-Martinez et al. 1994; Williams et al. 1998;
Serrano et al. 2008) the involvement of IL-6 in muscle wasting.
An elevation in circulating IL-6 is observed in many disease states as well as in
the elderly and healthy individuals, especially after intense or pro-longed
exercise. Its role within the context of skeletal muscle may be multifunctional;
it has disparately been reported to regulate carbohydrate and lipid metabolism,
cause muscle atrophy or increase satellite cell proliferation. We found evidence
of the latter by using Ki-67, a marker of proliferation to assess the proliferative
status of muscle during endotoxaemia. The gastrocnemius muscle displayed
high Ki-67 mRNA expression at peak cytokine levels, after 2hrs of LPS;
likewise, the EDL displayed a time-lagged increase in Ki-67 mRNA after 24hr
of infusion but whether this was directly IL-6 mediated is undetermined. It
does however support the notion previously reported by our group that a
reduction in the protein-to-DNA ratio (Gamrin et al. 1996), an index of net
muscle protein mass (i.e. reduced alkaline soluble protein content and
increased DNA content) accompanies endotoxaemia in the EDL muscle after
24hr LPS infusion (Crossland et al. 2008; Murton et al. 2009).
IL-6 is known to promote satellite cell proliferation via activating c-Myc in a
STAT3-dependent manner. Thus regulating cell cycle kinetics (through up-
regulation of numerous cyclins and down-regulation of p21), which are
involved in the G1 cell growth phase (Toth et al. 2011). Indeed, an increase in
IL-6 protein in satellite cells following muscle damage was concomitant with
increased cyclin D1 expression and satellite cell number (McKay et al. 2009).
Furthermore, IL-6 knockout mice display impaired satellite cell proliferation
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and myonuclear accretion in a STAT3-cyclin D1-depedent manner (Serrano et
al. 2008). TNF-Dalso differentially influences satellite cell proliferation
(Szalay et al. 1997; Layne and Farmer 1999). Satellite cells exposed to
inflammatory milieu may be able to proliferate (evident in the gastrocnemius
muscle at the 2hr time point for Ki-67 mRNA expression), but not necessarily
proceed toward differentiation (evident by myoD suppression in the same
muscle at the same time point of sampling). It is possible that fluctuations
between high cytokine-low MRF expression and low/basal cytokine-high MRF
expression, ultimately tips the balance between satellite cell quiescence,
growth or apoptosis.
The expression profile of myostatin, a negative regulator of satellite cell
activity, displayed the most congruent evidence of direct cytokine action on
muscle homeostasis. Both its mRNA and protein expression were directly
correlated with TNF-D, IL-6 and NF-NB expression; myostatin was up-
regulated when theses cytokines were at their peak, i.e. 2hr after LPS infusion
and the gradual reduction in cytokine elevation was congruent with reduced
myostatin. NF-NB directly influences myostatin regulation by binding to
putative NF-NB responsive elements in the 5 regulatory region of the
myostatin promoter (Ma et al. 2001). Myostatin is often up-regulated following
stress in an extracellular signal-regulated kinase (ERK)-dependent manner
(Bish et al. 2010), therefore it is not surprising that the initial endotoxin insult
and dramatic elevation of inflammatory cytokines resulted in an increase in
myostatin mRNA and protein after 2 hours of infusion.
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The early increase in myostatin may be responsible for the suppression of the
satellite cell markers pax7 and myoD, which were also suppressed by early
peak elevations of cytokines after 2hr of LPS. It is likely myostatin had a direct
negative effect on satellite cell activity during the early stages of
endotoxaemia, and the reductions in pax7 and myoD was one such
consequence of cytokine-mediated myostatin up-regulation. Indeed, one of the
known downstream targets of myostatin (through smad signalling) is myoD;
down-regulation of myoD had been demonstrated during cachexia via TNF-D
mediated NF-NB dependent and independent pathways (Dogra et al. 2006;
McFarlane et al. 2006).
Myostatin also inhibits pax7 expression in an ERK1/2-MAPK-dependent
manner and the genetic inactivation or functional antagonism of myostatin
resulted in an increase in pax7 expression. Thus increased expression of
myostatin negatively influences satellite cell activation, proliferation and self
renewal (McFarlane et al. 2008). The direct action of myostatin on pax7 and
myoD promoter activity (McFarlane et al. 2006; McFarlane et al. 2008) is
supported by its increased nuclear translocation following LPS infusion. Its
increased nuclear localization suggests myostatin may play more of a
transcriptional role during the early stages of endotoxaemia, to modulate the
transcription of genes essential for satellite cell activation, self renewal and
differentiation.
The return to basal and reduced expression of myostatin after 6 and 24 hr of
LPS respectively, saw a return to basal levels of pax7 expression whilst myoD
remained low. In addition to the myostatin mediated suppression of myoD,
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other factors such as TNF-D and NF-NB also directly contribute to its mRNA
destabilisation and protein degradation (Guttridge et al. 2000; Langen et al.
2004); as a result, the attenuation of myostatin signalling is insufficient to
return myoD to basal levels of expression. As mentioned above, such an
inhibition could have serious consequences for subsequent muscle growth and
repair following inflammation-associated muscle wasting; the work of Langen
et al.(2004) showed that TNF-D mediated suppression of myoD (through NF-
NB signalling) inhibited myogenic differentiation, interfered with muscle
regeneration and contributed to muscle wasting. The same authors also found
that in a murine model of chronic pulmonary inflammation, muscle wasting
(indicated by decreased body weight) and elevated inflammatory cytokines
were concomitant with attenuated satellite cell activity and impaired muscle
regeneration (Langen et al. 2006).
Finally, a consistent observation throughout this study was the differential
response of the fast twitch EDL and mixed fibre type gastrocnemius muscle to
LPS infusion. As mentioned above, the gastrocnemius was more sensitive to
LPS and this likely reflects its higher degree of vascularisation compared to the
EDL. Capillary architecture is muscle specific; slow fibres being more
oxidative, tend to have higher capillary density than fast fibres which are more
glycolytic. The density and distribution of the microvascular supply in different
muscles parallels their metabolic demand (Egginton 2011) and the
heterogeneity in microvascular supply of different muscles reflect differences
in fibre type composition and mechanical load, ultimately to normalise the ratio
of oxygen delivery to consumption. Hence, the ratio of capillaries-to-fibre in
muscles involved in locomotion increases with the proportion of oxidative
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fibres (reviewed by Hudlicka 1985). The gastrocnemius muscle, being of
mixed fibre type composition requires greater oxygen delivery compared to the
EDL and thus displays increased blood flow (Gray and Renkin 1978), which
facilitates increased delivery and removal of endotoxin. As a result, the
gastrocnemius muscle responded to the toxin infusion earlier, at a greater
magnitude and in some instances (e.g. pax7 expression) showed a tendency
toward earlier recovery than the EDL.
In summary, we have described the effects of continuous LPS infusion on the
expression profile of three key cytokine markers of systemic inflammation and
the resulting impairment of satellite cell activity. Modest increases in cytokine
expression help rather than impair the regenerative process and the apparent
contradiction to their action on satellite cell inhibition may be explained by the
fact that their effects are concentration and time dependent. It is believed
satellite cells play a vital role in maintaining muscle homeostasis, modulating
the balance between muscle growth and loss. LPS, through its induction of
excessive cytokine production, tips that balance such that pathogenic
alterations that instigate muscle loss compromise the satellite cell
microenvironment and thus satellite cell function; leading to less effective
muscle homeostasis, which in turn could have consequences for muscle
regeneration or growth following sepsi- induced muscle atrophy.
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CHAPTER 5
Results (III)
Co-infusion of low dose dexamethasone is
additive to lipopolysaccharide induced myogenic
suppression
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5.1 SUMMARY
Results from the study presented in chapter 4 suggested a role for LPS-induced
elevations in inflammatory cytokines, in the suppression of skeletal muscle
myogenesis, via the down-regulation of key satellite cell transcripts such as
pax7 and myoD. Strategies aimed at suppressing elevated inflammatory
cytokines, such as low dose glucocorticoid therapy, could be beneficial in
increasing survival from severe sepsis. Therefore, we examined whether
administration of low dose dexamethasone (equivalent to 300Pg/kg/day - less
than half the dose reported to induce muscle atrophy), would prevent elevations
in inflammatory cytokines and thereby reduce LPS-induced myogenic
suppression.
Male Sprague-Dawley rats were continuously infused with saline (0.4ml/hr,
i.v.), LPS (15 Pg/kg/hr), Dex (12.5Pg/kg/hr.) or Dex+LPS, intravenously, for
24hr (n=7-8 per group). Animals were terminally anaesthetised and EDL
muscles were removed, snap-frozen and stored in liquid nitrogen for analysis
of mRNA and protein expression of markers for systemic inflammation and
satellite cell myogenesis.
Dex infusion during endotoxaemia caused a reduction in LPS-induced up-
regulation of muscle TNF-D, IL-6 and NF-NB mRNA expression. Dex blunted
the LPS-induced increase of the macrophage marker, Iba-1. However, Dex
infusion suppressed pax7 and myoD mRNA and protein expression. Dex+LPS
co-infusion resulted in an additive effect on satellite cell myogenic
suppression, greater than that elicited by either substance alone. Dex caused a
reduction in myogenin and blunted the LPS-induced increase in myogenin.
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Combined Dex+LPS infusion resulted in additional suppression of myostatin
mRNA and protein after 24hr compared to the LPS or Dex only groups.
We concluded that low dose dexamethasone had an anti-inflammatory effect
by suppressing transcript levels of inflammatory cytokines and inhibiting
muscle macrophage infiltration. However, the suppression of inflammation had
consequences for satellite cell myogenesis, which can benefit from modest
muscle inflammation (for e.g. during muscle regeneration from injury).
Therefore, negative regulation of satellite cells by glucocorticoids could
impede their efficacy in the treatment of inflammatory muscle disorders.
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5.2 INTRODUCTION
The previous chapter described the effects of lipopolysaccharide (LPS) on
satellite cell myogenic activity during the early stage of endotoxaemia. LPS
transiently suppressed satellite cell specific markers by modulating
inflammatory cytokine expression through the increased recruitment of
macrophages (see chapter 4). Glucocorticoids are frequently proposed in the
treatment of sepsis and inflammatory muscle myopathies, due to their ability to
prevent excessive cytokine production and reduce some of the symptoms
associated with systemic inflammatory response syndrome (reviewed by Rhen
and Cidlowski 2005). Glucocorticoid-mediated down-regulation of systemic
inflammation can restore homeostasis, decrease morbidity and improve
survival of septic patients when low to moderate doses are used (reviewed in
Meduri et al. 2009).
Glucocorticoids are able activate gene transcription of target genes by binding
to glucocorticoid receptors in the cytosolic compartment, thereby forming a
complex. This translocates to the nucleus and binds to Glucocorticoid
Response Elements (GRE) in the promoter of target genes for transcriptional
activation (e.g. anti-inflammatory IL-10, IL-10R, TGF-E, etc) and in some
instances, transcriptional repression (e.g. pro-inflammatory IL-1, TNF
receptors, NF-kB, etc) of specific transcription factors involved in stress
related homeostasis (Galon et al. 2002). Activation of cytoplasmic
glucocorticoid receptors by endogenous (e.g. cortisol from increased
adrencorticotrophic hormone (ACTH) activity and Hypothalamic-Pitituary-
Adrenal (HPA) axis stimulation) or exogenous synthetic glucocorticoids (e.g.
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dexamethasone) administration limits the inflammatory response by aiding
antigen clearing, stimulating cell trafficking and scavenger systems, whilst
halting cellular immune responses by inhibiting antigen presentation and T-cell
activation.
Glucocorticoids have been shown to have a variety of effects on skeletal
muscle growth and metabolism, most notably in inflammatory myopathies such
as Duchenne muscular dystrophy (DMD), where long-lasting benefits such as
increased muscle strength and function are noted. Since DMD involves
repeated cycles of muscle injury and regeneration, these beneficial effects have
been attributed to reduced muscle inflammation and the suppression of
cytotoxic cells (reviewed by Bogdanovich et al. 2004). In addition,
glucocorticoids have been reported to stimulate myoblast proliferation and
differentiation in culture (Ball and Sanwal 1980; Guerriero and Florini 1980)
and daily administration of the glucocorticoid prednisone increased the
proliferative activity of satellite cells and demonstrated a protective effect on
exercise induced muscle fibre damage in a rodent exercise model (Jacobs et al.
1996).
However studies depicting negative effects on skeletal muscle, predominantly
muscle catabolism can also be found; for example increased proteolytic activity
is observed in many animal and human models where glucocorticoids are
administered (reviewed by Tisdale 2007). Furthermore, glucocorticoid levels
are elevated in muscle wasting conditions and are associated with the up-
regulation of atrogenes in vivo and in vitro (Cassano et al. 2009). The catabolic
actions of glucocorticoids on skeletal muscle are thought to occur via
stimulation of protein degradative, and suppression of protein synthetic
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pathways (reviewed by Schakman et al. 2008). As a result, the use of
glucocorticoids in the treatment of sepsis has remained contentious and it is
currently hypothesised that the diametric effects observed are dependent on the
dose, as well as the type of glucocorticoid administered. High doses of
dexamethasone (equivalent to 700Pg/kg/day or more) are known to cause
muscle atrophy in rats (Tiao et al. 1996; Zhao et al. 2008). This is
characterised by large increases in the rate of muscle protein breakdown
(Auclair et al. 1997; Chrysis and Underwood 1999) and negative regulation of
protein synthetic machinery (Shah et al. 2000).
However, given the evidence supporting a role for elevated pro-inflammatory
cytokines in the aetiology of muscle wasting (reviewed by Spate and Schulze
2004), strategies aimed at suppressing increases in pro-inflammatory cytokines
without compromising muscle recovery could be beneficial in the treatment of
sepsis. Previous work done by our group demonstrated that a low dose of
dexamethasone (equivalent to 300Pg/kg/day) is sufficient for suppressing pro-
inflammatory cytokine mRNA levels without producing the catabolic effects
associated with higher doses of glucocorticoids (Crossland et al. 2010).
Therefore the aims of this study were two-fold; to examine the effects of low
dose dexamethasone on satellite cell activity, when administered continuously
for 24 hours and its influence on cytokine mediated myogenic suppression
when administered one hour before and during LPS infusion.
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5.3 METHODS
5.3.1 Animals and tissue collection
All animal work was carried out as described in section chapter 2, section
2.1.3. Briefly, Male Sprague-Dawley rats (380-480g; Charles River) were
anaesthetised with fetanyl citrate (300Pg/kg; i.p., Janssen-Cilag) and
meditomidine (300Pg/kg; i.p., Domitor, Pfizer) and implanted with intravenous
catheters for administration of substances. Under anaesthesia, animals were
fitted with a harness to allow unrestricted movement. Anaesthesia was reversed
with atipamezole (1mg/kg; s.c., Antisedan, Pfizer), analgesia was provided
(buprenorphine; 0.03 mg/kg, s.c., Vetergesic; Alstoe Animal Health) and
animals were left to recover for 24 hours (with access to food and water) before
the commencement of experiments. The venous line was connected to an
infusion pump via a fluid filled swivel, which maintained a continuous
intravenous infusion of sterile heparinised saline (15U/ml) at 0.4ml/hr to
maintain catheter patency.
Following catheterization, prepared rats were assigned to one of four groups
(n=7-8 per group) and received a continuous intravenous infusions of sterile
isotonic saline (0.4ml/hr) as control, LPS (15Pg/kg/hr; E. coli, serotype
0127:B8, Sigma Aldrich), Dex (12.5Pg/kg/hr; Sigma Aldrich) or Dex+LPS
simultaneously. Dex was administered for 1hr before and throughout the 24hr
infusion. After 24hr, animals were terminally anaesthetised (sodium
pentobarbital (inactin); 80 mg/kg, i.v.) and the EDL muscle was freeze
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clamped and removed. Muscles were immediately snap-frozen and stored in
liquid nitrogen for subsequent analyses.
5.3.2 mRNA measurements (real-time PCR)
Real time PCR was carried out as described in section chapter 2, section 2.2.1
and chapter 4, section 4.3.2 for the transcripts listed in table 5.1. All Taqman
primer/probe sets were obtained from Applied Biosystems. Reactions were
carried out in an ABI Prism 7000 sequence detection system in duplicate; each
well contained 2Pl cDNA template, 12.5Pl PCR master mix and 1.25Pl
primer/probe mix in a 25Pl reaction volume, the latter of which had final
concentrations of 900nM for each primer and 250nM for the Taqman probe.
Relative quantification of gene expression between control and treated groups
was calculated using the 2
ǻǻ&W
method. The saline control group was given a
value of 1 and fold changes in mRNA expression of treated groups were
calculated relative to the control group. Thus values >1 or <1 indicate an
increase or decrease in mRNA expression from control respectively.
5.3.3 Protein Measurements (Western Blotting)
Protein extraction and western blotting was carried out as previously described
in chapter 2, section 2.2.5 and chapters 3-4, to determine protein expression of
the targets listed in table 5.2
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Table 5.1: Catalogue and Unigene Numbers for Taqman Primer/Probes
sets
Gene Catalogue Number Unigene Number
HMBS Rn00565886_m1 Rn.11080
TNF-a Rn00562055_m1 Rn.2275
IL-6 Rn00561420_m1 Rn.9873
NFkB1 Rn01399583_m1 Rn.2411
Pax7 Rn00834076_m1 Rn.226327
MyoD1 Rn00598571_m1 Rn.9493
Myogenin Rn00567418_m1 Rn.9465
Myostatin Rn00569683_m1 Rn.44460
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Table 5.2: Primary and secondary antibodies used in the Western blotting
protocol.
Primary Antibody Supplier Dilution
Goat Anti-TNFDpAb R&D Systems
Mineapolis, USA
1:500
Goat Anti-IL-6 pAb R&D Systems
Mineapolis, USA
1:500
Rabbit Anti-NFkB p105/p50 [E381]
mAb
Abcam
Cambridge UK
1:2500
Rabbit Anti-Iba1 pAb Wako
Osaka, Japan
1:500
Mouse Anti-Pax7 mAb DSHB
Iowa City, IA, USA
1:500
Rabbit Anti-MyoD (C-20) pAb Santa Cruz Biotechnology
Santa Cruz, CA, USA
1:500
Mouse Anti-Myogenin mAb DSHB
Iowa City, IA, USA
1:500
Rabbit Anti-Myostatin, Near C-
terminus pAb
Millipore
Billerica, MA, USA
1:250
Secondary Antibody Supplier Dilution
Rabbit Anti-Goat
Immunoglobulins/HRP pAb
Dako
Glostrup, Denmark
1:2000
Swine Anti-Rabit
Immunoglobuline/HRP pAb
Dako
Glostrup, Denmark
1:2000
Rabbit Anti-Mouse
Immunoglobulins/HRP pAb
Dako
Glostrup, Denmark
1:2000
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5.3.4 Statistical Analyses
As reported in the previous study, not all data obtained were consistent with a
Gaussian distribution; slight deviations from the Gaussian ideal (i.e., skewness
of data) were noted in frequency distribution plots of some data sets. Therefore,
a non parametric statistical test was used - the Kruskal-Wallis one-way analysis
of variance (ANOVA), followed by the Dunns multiple comparison test to
compare differences between saline control and treatment (e.g., Saline vs Dex)
and between different treated groups (LPS vs Dex). All data are presented as
the mean ± standard error of the mean (S.E.M) and significance was accepted
at the 5% level (p<0.05).
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5.4 RESULTS
5.4.1 Cytokines
As reported in chapter 4, 24hr of LPS infusion elevated TNF-D mRNA
expression but there was a decrease in protein relative to saline control, which
likely represents increased proteolytic processing of the ~26kDa membrane
bound protein by TACE enzymes. Dex infusion significantly decreased TNF-D
mRNA expression and a co-infusion of Dex 1hr before and during LPS
infusion prevented LPS induced elevation in TNF-DmRNA (figure 5.1).
Although Dex suppressed LPS mediated increase in TNF-D mRNA, it did not
significantly alter its protein expression compared to saline control.
Dexamethasone infusion significantly reduced IL-6 mRNA compared to saline
control and blunted LPS-induced increase in IL-6 mRNA expression, when
both substances were co-administered. However, infusion of either substance
did not significantly alter IL-6 protein expression (figure 5.2).
LPS infusion resulted in a tendency toward an increase in NF-NB mRNA
expression, which was significantly reduced by Dex infusion relative to saline
control. Co-infusion of both substances attenuated the LPS-mediated increase
in NF-NB mRNA (figure 5.3). No significant changes were detected in NF-NB
p105 protein expression but the p50 subunit protein expression showed a
tendency toward an increase after LPS infusion (p~0.18 vs. saline). Dex
infusion alone elicited no significant change on p50 protein relative to control.
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Dexamethasone suppression of NF-NB is thought to occur at the mRNA
transcriptional level, via two main mechanisms; activated glucocorticoid
receptors bind to GREs and up-regulate INB gene expression, thereby
increasing the levels of the NF-NB inhibitor and allowing increased
cytoplasmic retention (Scheinman et al. 1995). Another principal mechanism
of suppression occurs via ligand-bound glucocorticoid receptors, which interact
directly with cytosolic NF-NB subunits (e.g. p65), and down-regulate their
trans-activation potential without affecting DNA binding capability (Ray and
Prefontaine 1994).
Co-infusion of LPS and Dex caused an increase in p50 protein expression. This
suggests dexamethasone suppressed NF-NB mRNA transcription but had
limited influence on its protein pool. LPS increased NF-NB mRNA and protein
synthesis (also see chapter 4, section 4.4.1) but it appears that dexamethasone,
whilst able to regulate further protein synthesis by suppressing mRNA
transcription, did not negatively regulate the NF-NB protein pool.
As discussed in the last chapter, some of the changes in cytokine expression
can be attributed to muscle macrophage infiltration. We measured the protein
expression of the macrophage marker Iba-1 in saline and treated samples, to
determine the magnitude of infiltration based on the expression of Iba-1 protein
by Western blotting. There was a slight increase (p~0.0.8) in Iba-1 protein
expression in LPS treated samples (figure 5.4). Dex infusion caused a
significant reduction in Iba-1 protein relative to saline control and blunted Iba-
1 expression in LPS+Dex treated samples. It appears that the immune
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suppressing actions of dexamethasone may also have an effect on
macrophages.
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Figure 5.1: Expression of Tumour TNF-D a) mRNA and b) protein expression in EDL
muscle following 24hr continuous intravenous infusions of either saline, LPS, Dex or both
(Dex/LPS). a) Relative mRNA expression of saline controls was set at 1; bars denote fold
change in mRNA expression from saline control with values >1 = increased mRNA expression
and <1 = decreased mRNA expression. Values are means ±S.E.M. b) The densities of ~26kDa
TNF-D immunoreactive bands were measured by western blotting and representative bands for
each treatment group are shown above their corresponding bar. n=7-8 per group. By Kruskal-
Wallis 1-way ANOVA: significantly different from saline group:
*
p<0.05,
***
p<0.0005.
Significantly different from LPS-treated group:
+
p<0.05,
+++
p<0.0005. Significantly different
from Dex-treated group:
##
p<0.005.
a) TNF-DmRNA expression
b) TNF-Dprotein expression
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Figure 5.2: Expression of IL-6 a) mRNA and b) protein EDL muscle following 24hr
continuous intravenous infusion of either saline, LPS, Dex or both (Dex/LPS). a) Relative
mRNA expression of saline controls was set at 1; bars denote fold change in mRNA expression
from saline control with values >1 = increased mRNA expression and <1 = decreased mRNA
expression. Values are means ±S.E.M. b) The densities of ~24kDa IL-6 immunoreactive bands
were measured by western blotting and representative bands for each treatment group are
shown above their corresponding bar. n=7-8 per group. By Kruskal-Wallis 1-way ANOVA:
significantly different from saline group:
*
p<0.05,
**
p<0.005. Significantly different from LPS-
treated group:
+
p<0.05,
+++
p<0.0005. Significantly different from Dex-treated group:
#
p<0.05.
a) IL-6 mRNA expression
b) IL-6 protein expression
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Figure 5.3: Expression of NF NB a) mRNA and b) protein in EDL muscle following 24hr
continuous intravenous infusion of either saline, LPS, Dex or both (Dex/LPS). a) Relative
mRNA expression of saline controls was set at 1; bars denote fold change in mRNA expression
from saline control with values >1 = increased mRNA expression and <1 = decreased mRNA
expression. Values are means ±S.E.M. b) The densities of ~105kDa and ~50kDa NF-NB
immunoreactive bands were measured by western blotting and representative bands for each
treatment group are shown above their corresponding bar. n=7-8 per group. By Kruskal-Wallis
1-way ANOVA: significantly different from saline group:
*
p<0.05. Significantly different from
LPS-treated group:
+
p<0.05,
+++
p<0.0005. Significantly different from Dex-treated group:
#
p<0.05.
a) NFkB mRNA expression
b) NFkB protein expression
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Figure 5.4: Expression of Iba-1 protein in EDL muscle following 24hr continuous
intravenous infusion of either saline, LPS, Dex or both simultaneously (Dex/LPS). Values
are means ±S.E.M. The densities of ~17kDa Iba1 immunoreactive bands were measured by
western blotting and representative bands for each treatment group are shown above their
corresponding bar. n=7-8 per group. By Kruskal-Wallis 1-way ANOVA: significantly different
from saline group:
*
p<0.05. Significantly different from LPS-treated group:
+
p<0.05,
++
p<0.005.
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5.4.2 Myogenic Regulatory Factors (MRFs)
Continuous LPS infusion for 24hr tendentially reduced pax7 mRNA expression
(figure 5.5). Dex also significantly suppressed pax7 mRNA and co-infusion of
both demonstrated an additive effect; the combination of both substances
suppressed pax7 mRNA more than either alone. This decrease in mRNA was
replicated in pax7 protein expression, which showed a tendency toward
decreased protein expression relative to saline control across all three treated
groups.
Likewise, myoD mRNA was significantly reduced by LPS, Dex and LPS+Dex
administration (figure 5.6). Dex had a greater suppressive effect on myoD than
LPS and co-infusion of both did not alter LPS or Dex-induced myoD
suppression. The protein expression followed a similar pattern to its mRNA;
myoD protein was significantly lower in the treated groups relative to saline
control. Interestingly, while myoD protein was reduced to similar levels in LPS
and Dex treated samples; co-infusion of both substances caused a further
reduction in myoD protein, thus further demonstrating the additive effect
described above.
Myogenin mRNA expression was significantly increased in the LPS group
compared to control (figure 5.7). The Dex group showed a significant
reduction in myogenin mRNA, which was not significantly altered by co-
administration with LPS, although there was a tendency toward basal levels of
myogenin mRNA expression. The protein expression showed a similar trend;
there was a tendency toward increased myogenin protein in the LPS group. The
Dex and Dex+LPS treated groups showed significant reductions in myogenin
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protein compared to the saline group. Co-administration of Dex with LPS did
not improve Dex-induced suppression of myogenin protein expression.
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Figure 5.5: Expression of Pax7 a) mRNA and b) protein in EDL muscle following 24hr
continuous intravenous infusion of either saline, LPS, Dex or both (Dex/LPS). a) Relative
mRNA expression of saline controls was set at 1; bars denote fold change in mRNA expression
from saline control with values >1 = increased mRNA expression and <1 = decreased mRNA
expression. Values are means ±S.E.M. b) The densities of ~55kDa pax7 immunoreactive bands
were measured by western blotting and representative bands for each treatment group are
shown above their corresponding bar. n=7-8 per group. By Kruskal-Wallis 1-way ANOVA:
significantly different from saline group:
***
p<0.0005. Significantly different from LPS-treated
group:
+
p<0.05,
++
p<0.005.
a) Pax7 mRNA expression
a) Pax7 protein expression
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Figure 5.6: Expression of MyoD a) mRNA and b) protein EDL muscle following 24hr
continuous intravenous infusion of either saline, LPS, Dex or both (Dex/LPS). a) Relative
mRNA expression of saline controls was set at 1; bars denote fold change in mRNA expression
from saline control with values >1 = increased mRNA expression and <1 = decreased mRNA
expression. Values are means ±S.E.M. b) The densities of ~34kDa MyoD immunoreactive
bands were measured by western blotting and representative bands for each treatment group
are shown above their corresponding bar. n=7-8 per group. By Kruskal-Wallis 1-way ANOVA:
significantly different from saline group:
*
p<0.05,
**
p<0.005.
a) MyoD mRNA expression
b) MyoD protein expression
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Figure 5.7: Expression of Myogenin a) mRNA and b) protein EDL muscle following 24hr
continuous intravenous infusion of either saline, LPS, Dex or both (Dex/LPS). a) Relative
mRNA expression of saline controls was set at 1; bars denote fold change in mRNA expression
from saline control with values >1 = increased mRNA expression and <1 = decreased mRNA
expression. Values are means ±S.E.M. b) The densities of ~25kDa MyoD immunoreactive
bands were measured by western blotting and representative bands for each treatment group
are shown above their corresponding bar. n=7-8 per group. By Kruskal-Wallis 1-way ANOVA:
significantly different from saline group:
*
p<0.05. Significantly different from LPS-treated
group:
+
p<0.05,
++
p<0.005. Significantly different from Dex-treated group:
#
p<0.05.
a) Myogenin protein expression
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5.4.3 Myostatin
There was a tendency toward a reduction in myostatin mRNA expression in
response to LPS infusion (figure 5.8). Dex significantly reduced myostatin
mRNA relative to saline control. Simultaneous Dex+LPS-infusion also
suppressed myostatin mRNA; although mRNA expression trended toward LPS
only levels of suppression. The magnitude of mRNA suppression was greater
in the Dex group, which suggests myostatin mRNA is perhaps more affected
by dexamethasone relative to LPS, at the doses administered.
We detected the ~26kDa and ~12.5kDa immuno-reactive forms of myostatin
protein in crude cytosolic fractions by Western blotting. We did not detect any
immuno-reactive myostatin bands in Dex or LPS+Dex treated nuclear fractions
(after 30 minutes exposure), so results shown represent myostatin expression in
cytosolic protein fractions only (figure 5.8b). LPS caused a reduction in both
forms of myostatin protein; similarly to myostatin mRNA, Dex infusion caused
a greater suppression of both forms of myostatin protein, relative to LPS-only
group. Co-infusion of LPS and Dex elicited a statistically significant reduction
in the ~26kDa myostatin protein expression relative to the saline group, which
trended toward LPS-only levels relative to Dex alone infusion. In contrast,
there was a steep graded reduction in the ~12.5kDa myostatin protein
expression across all three experimental groups, with the lowest reduction in
the co-infused group. Co-infusion of both LPS and Dex demonstrated an
additive effect on mature myostatin protein expression, which appeared to be
independent of the pattern of mRNA and ~26kDa protein expression.
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Figure 5.8: Expression of Myostatin a) mRNA and b) protein EDL muscle following 24hr
continuous intravenous infusion of either saline, LPS, Dex or both (Dex/LPS). a) Relative
mRNA expression of saline controls was set at 1; bars denote fold change in mRNA expression
relative to saline control with values >1 = increased mRNA expression and <1 = decreased
mRNA expression. Values are means ±S.E.M. b) The densities of ~26kDa and ~12.5kDa
myostatin immunoreactive bands were measured by western blotting and representative bands
for each treatment group are shown above their corresponding bar. n=7-8 per group. By
Kruskal-Wallis 1-way ANOVA; significantly different from Saline group:
*
p<0.05,
**
p<0.005.
Significantly different from LPS-treated group:
+
p<0.05. Significantly different from Dex-
treated group:
#
p<0.05.
a) Myostatin mRNA expression
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5.5 DISCUSSION
Results from the study presented in chapter 4 suggested a role for LPS-induced
elevations in inflammatory cytokines, in the suppression of skeletal muscle
myogenesis, via the down-regulation of essential satellite cell markers such as
pax7 and myoD. Strategies aimed at suppressing elevated inflammatory
cytokines, such as low doses of glucocorticoid therapy are beneficial in
increasing survival from severe sepsis (reviewed by Annane 2001). Therefore
we examined whether the administration of low dose dexamethasone
(equivalent to 300Pg/kg/day - less than half the dose reported to induce muscle
atrophy) prevents elevations in inflammatory cytokines and thereby improve
LPS-induced myogenic suppression.
Dexamethasone infusion during endotoxaemia significantly suppressed LPS-
induced elevations in TNF-D, IL-6 and NF-NB mRNA expression in the EDL
muscle. These results are consistent with an anti-inflammatory systemic effect,
similar to that reported by Crossland et al. (2010) and Gardiner et al. (1996).
The inhibition of NF-NB at the transcriptional level is pivotal for inflammatory
suppression, as NF-NB signalling mediates the production and further release
of many inflammatory cytokines including TNF-D and IL-6 (Muller et al.
1993; Guha and Mackman 2001). Dexamethasone did not induce significant
alterations in local muscle TNF-D and IL-6 protein expression; it is unlikely
the dose of dexamethasone administered, whilst able to significantly suppress
local muscle cytokine mRNA expression, is not sufficiently high enough, for
suppressing cytokine expression at the protein level. This is supported in a
study by Myers et al. (2003), where the infusion of a much higher dose of
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dexamethasone in swine (equivalent to 1200Pg/kg/day) was sufficient to
significantly suppress LPS-induced increases in plasma TNF-D and IL-6.
Another potential reason for the discordance between cytokine RNA and
protein levels could be that dexamethasone has limited effects on active
cytokine protein. Indeed, dexamethasone inhibits TNF-D at the transcriptional
and post-transcriptional level but it is incapable of inhibiting it once TNF-D
biosynthesis is initiated (Beutler et al. 1986). The authors also noted
dexamethasone suppression of endotoxin-induced TNF-D mRNA was not
complete and very low levels of mRNA expression could still be detected. A
combination of diminished, but not completely ablated mRNA expression, and
protein resistance to glucocorticoid therapy could explain the limited effects of
dexamethasone on cytokine protein expression.
This inability of low dose dexamethasone to significantly down-regulate the
cytokine protein pool likely accounts for the increased NF-NB p50 protein in
LPS/Dex treated samples relative to saline control. Complete antagonism
between glucocorticoids and active NF-NB may not be universal; the
glucocorticoid receptor escaped antagonism by NF-NB and showed normal
processing and transcriptional activities in L6 muscle cells in a study by
Dekelbab et al. (2007). In short, dexamethasone did not have an effect on NF-
kB p50 protein subunit expression when administered alone and therefore had
limited influence on the LPS-induced increase when administered one hour
before and during LPS infusion. The increase in NF-NB p50 subunit in
LPS/Dex samples suggest NF-NB protein may be up-regulated by other
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mechanisms other than alterations its mRNA pool, for example, vesicular
storage and release.
However, dexamethasone reduced the protein expression of the macrophage
marker Iba-1 and blunted its LPS-induced increase. Glucocorticoids exert anti-
inflammatory action by negatively regulating circulating mononuclear cells;
prednisolone decreased muscle macrophages by about 50% in the soleus and
quadriceps muscles of mdx mice, by down-regulating cellular adhesion
molecules that are required for inflammatory cell infiltration (Wehling-
Henricks et al. 2004). Likewise, Leibovich and Ross (1975), showed that the
recruitment of macrophages and monocytes to sites of inflammation is
impaired by hydrocortisone treatment in guinea pigs. It is believed the rapid,
marked decrease in circulating mononuclear cells following steroid treatment is
likely due to rapid sequestration of macrophages rather than a direct lytic effect
(Thompson and van Furth 1970). Glucocorticoids inhibit macrophages motility
(Gell and Hinde 1953), by altering the tissue environment and permeability
(through down-regulation of cellular adhesion molecules), which may in turn,
interfere with movement of cells to sites of inflammation. Our results suggest
dexamethasone interferes with local cytokine production and release by
suppressing Iba-1 protein expression, a key component for macrophage
membrane ruffling/motility and phagocytosis of infectious particles. Thus, the
degree of macrophage infiltration in EDL muscle in response to LPS was
attenuated by Dex co-infusion.
Continuous LPS infusion suppressed the satellite cell markers pax7 and myoD
and co-infusion with dexamethasone did not improve LPS-induced suppression
of these markers. In fact, co-administration of Dex/LPS appeared to have an
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additive effect on pax7 and myoD suppression. It appears that the dose of
dexamethasone administered, whilst capable of inhibiting the transcription of
inflammatory cytokines, did not improve cytokine mediated suppression of
satellite cell markers. Whether the suppression of satellite cell markers is a
direct consequence of inflammatory suppression (as TNF-Dand IL-6 also have
beneficial dose-dependent effects on satellite cell proliferation and
differentiation (Li 2003; Serrano et al. 2008)), is undetermined. However,
prostaglandins synthesised from arachidonic acid, in response to cytokine
signalling (reviewed by Funk 2001) have been shown to stimulate muscle
growth and satellite cell activity (Horsley and Pavlath 2003; Bondesen et al.
2006). This was blunted by the administration of anti-inflammatory drugs,
which inhibit cyclooxygenase (COX) enzymes (Mendias et al. 2004; Soltow et
al. 2006). Prostaglandins regulate muscle growth by altering the rate of muscle
protein turnover (Rodemann and Goldberg 1982), through modulation of
protein synthesis and degradation (Palmer 1990; Vandenburgh et al. 1990).
Consistent with this is an impairment of satellite cells and myotubes in vivo,
when prostaglandin signalling pathway is dysregulated, for example by COX2
genetic deletion (Shen et al. 2006).
The anti-inflammatory actions of dexamethasone include suppression of
prostaglandin synthesis and release, by inhibition of plasma membrane
phospholipase A2, an enzyme which hydrolyses the bonds releasing
arachidonic acid for prostaglandin synthesis (Blackwell et al. 1980; Hirata et
al. 1980). Dexamethasone-induced alterations in prostaglandin synthesis are
associated with the inhibition of muscle protein synthesis (Reeds and Palmer
1984). Furthermore, inhibition of prostaglandin synthesis is known to reduce
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myoD expression in rat muscle (Monda et al. 2009). The authors found that
administration of the COX inhibiting drug, keptoprofen elicited a very large
decrease in MyoD
+
/M-Cadherin
+
cells in functionally overloaded soleus
muscles. Administration of the synthetic glucocorticoid prednisolone to rats for
eight weeks also reduced the number of mechanically activated myoD
+
satellite
cells, an effect which was rescued with nitric oxide donor supplementation
(Betters et al. 2008). The authors described a role for glucocorticoid-mediated
inhibition of nitric oxide production (a primary signal for satellite cell
activation and myoblast fusion), in glucocorticoid-induced satellite cell
dysfunction. Also, exposure of cultured myotubes to glucocorticoids induced a
rapid degradation of myoD protein, through increased expression of
components of the ubiquitin-proteasome system such as E3 ligases
MAFbx/MuRF1 and N-terminal ubiquitinaion of myoD, which facilitated its
subsequent degradation (Sun et al. 2008). Indeed, high doses of dexamethasone
(>700Pg/kg/day) rapidly up-regulate the E3 ubiquitin ligase MAFbx (Zhao et
al. 2008), which interacts with myoD via an LXXLL sequence motif and
promotes its degradation (Tintignac et al. 2005).
Likewise, local infusion of the COX1/2-inhibiting-NSAID (Non-Steroidal
Anti-inflammatory Drug), indomethacin suppressed the exercise-induced
increase in pax7
+
satellite cells in human vastus lateralis muscle (Mikkelsen et
al. 2009). Clearly satellite cells require correctly balanced inflammatory
signalling (for a review see, Smith et al. 2008), as an excessive elevation of
inflammatory mediators or inflammatory suppression can compromise muscle
homeostasis. Our results support this contention, as demonstrated by the
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additional suppression of myoD and pax7 expression when LPS and
dexamethasone were co-administered, compared to either alone.
Dexamethasone infusion suppressed myogenin expression at the mRNA and
protein level and blunted its LPS mediated increase. Dexamethasone is known
to reduce the differentiation capacity of cultured C2C12 myoblasts, by dose-
dependently suppressing myogenin mRNA expression (te Pas et al. 2000).
Dex-mediated down-regulation of myogenin is thought to occur indirectly, via
Dex-induced increase in MAFbx expression, which interacts directly with
myogenin (likely via a similar LXXLL sequence motif as with myoD) and
promotes proteasomal degradation (Jogo et al. 2009). Furthermore, MAFbx
overexpression resulted in myogenin protein reduction, an effect blunted by
administration of the proteasome inhibitor MG-132 or MAFbx siRNA
silencing. Inhibition of MRFs is likely a primary mechanism by which
glucocorticoids mediate muscle catabolic effects. A study by Bruscoli et al.
(2010) also found that dexamethasone stimulates a Glucocorticoid-Induced-
Leucine-Zipper (GILZ), which reduces myotube formation in culture, by
inhibiting myoD and myogenin, an effect exacerbated or dampened by GILZ
overexpression or RNA silencing, respectively.
Twenty-four hours of LPS and dexamethasone infusion reduced myostatin
mRNA and protein expression, when administered either independently or both
simultaneously. In chapter 4, we showed that myostatin is increased during the
initial stages of endotoxin insult, followed by a return to basal and a subsequent
reduction in expression, relative to control. This expression trend was
congruent with the elevation in inflammatory cytokines TNF-D, IL-6 and NF-
NB, which were at their highest levels of expression following the initial toxin
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insult (after 2hr of LPS) and gradually declined by 24hr. Possible explanations
for the reduction in myostatin after 24hr of LPS infusion likely include
attenuation of inflammatory signalling, or myostatin negative feedback control.
Indeed, this reduction in myostatin mRNA and protein after 24hr of LPS
infusion is similar to that reported by Smith et al. (2011), who found that
myostatin mRNA was significantly reduced in rats 16hr after induction of
sepsis by cacecal ligation and puncture. The same authors found that
administration of dexamethasone also suppressed myostatin mRNA
expression; this supports our contention, that myostatin expression is increased
in response to elevated inflammatory cytokine signalling and dexamethasone
induced suppression of these cytokines likely attenuates the increased
myostatin expression.
The reduction in myostatin expression after 24hr of LPS contrasts with
previous studies suggesting that conditions depicting muscle atrophy such as
cancer, HIV infection, burn injury or ageing are associated with myostatin up-
regulation (Gonzalez-Cadavid et al. 1998; Lang et al. 2001; Baumann et al.
2003; Liu et al. 2008). As mentioned in chapter 3, sections 3.3.4 and 3.5,
although increased expression of myostatin mRNA or protein activity has been
noted in these muscle wasting conditions, conflicting results have also been
reported. Studies by Carlson et al. (1999), Sakuma et al. (2000) and Wehling et
al. (2000), report a lack of correlation between muscle regulation and
myostatin expression. For example the study by Baumann et al. (2003), found
that myostatin mRNA was significantly reduced, rather than increased in aged
rats despite a ~50% reduction in gastrocnemius muscle mass. It is tempting to
speculate that the tight mechanisms regulating myostatin expression (for
217
example, myostatin is naturally inhibited by its own pro-peptide) facilitate
negative feedback and that perhaps, an increase or decrease in myostatin is
dependent on tissue sampling time. This is supported by our results presented
in chapter 4 (see section 4.4.5), where an early increase is myostatin is noted
after 2 and 6hr of LPS infusion but attenuated by 24 hr.
The reduction in myostatin mRNA and protein following dexamethasone
treatment was lower than that elicited by LPS alone. This is similar to the
findings of Song et al. (2011), where administration of dexamethasone to
broiler chickens for 3 days resulted in significantly decreased myostatin mRNA
expression. Myostatin was also suppressed by glucocorticoid treatment in fish
(Rodgers et al. 2003; Weber et al. 2005). This contrasts with studies by Ma et
al. (2003) and Lang et al. (2001), in which dexamethasone treatment resulted
in myostatin mRNA up-regulation. The 5 regulatory region of the myostatin
gene contains putative GREs (Ma et al. 2001), so glucocorticoids likely
regulate myostatin expression directly. Further evidence of myostatin
regulation by glucocorticoids was presented by Lang et al. (2001) and Gilson
et al. (2007), who found that pre-treatment with a glucocorticoid receptor
antagonist, prevented glucocorticoid-mediated increase in myostatin mRNA
and myostatin gene deletion prevented dexamethasone-induced muscle
atrophy.
However, the apparent contradiction to our results may be explained by the
dexamethasone dosage used; dexamethasone dose dependently increased
myostatin promoter activity in vitro (Ma et al. 2001) and the studies by Gilson
et al. (2007), Lang et al. (2001) and Ma et al. (2003), used much higher doses
of dexamethasone (ranging from 600-1200Pg/kg/day) compared to the present
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study (300Pg/kg/day). Intriguingly, a study by Carraro et al. (2009) found that
the myostatin gene was down-regulated when very low, sub-therapeutic doses
of dexamethasone (equivalent to 1.6Pg/kg/day) were administered to cattle;
notably a much lower dose than that used in the present study, but it appears
the ability of ligand bound glucocorticoid receptors to trans-activate or repress
GREs on the myostatin promoter may be dependent (in part) on the
concentration of the ligand.
In summary, skeletal muscle regeneration can profit or suffer from an
inflammatory process, therefore, administration of anti-inflammatory
substances, as a means to combat or reverse inflammatory-mediated muscle
wasting, needs to be carefully calibrated. Our results suggest that the
administration of a lower dose of dexamethasone (less than half that reported to
have catabolic effects on rat skeletal muscle) suppressed LPS-induced
transcription of inflammatory cytokines and reduced excessive muscle
macrophage infiltration. However, the ablation of such inflammatory signals
by dexamethasone implicated consequences for muscle regenerative capacity,
because suppressive effects on myogenic regulatory factors were elicited.
Pax7, myoD and myogenin have pivotal roles in satellite cell activation,
proliferation and differentiation and their down-regulation suggested inhibited
satellite cell activity, likely a key mechanism for dexamethasone-induced
muscle atrophy. Dysregulation of satellite cell activity introduces a functional
deficit in skeletal muscle where-by its ability to adapt to altered load, recover
from acute injury or insult, is interrupted or delayed. The negative effects of
glucocorticoids on satellite cell activity may supersede their efficacy in the
treatment of inflammatory muscle disorders depicting muscle wasting. Despite
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their anti-inflammatory actions, the debilitating muscle wasting effects of
glucocorticoids and the potential to cause long term muscle repair deficit with
prolonged use could hinder therapeutic benefits. Therefore, further elucidation
of the mechanisms underlying muscle atrophy and loss of regenerative
potential, in response to glucocorticoid treatment, is required in order to fully
utilize their net therapeutic potential.
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CHAPTER 6
General Discussion
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6.1 OVERVIEW OF THESIS
The original aims of this thesis were to assess the activity of skeletal muscle
satellite cells (based on the gene expression profiles of specific markers) in
rodent models of hypertrophy and atrophy. Satellite cells are known to
contribute to muscle hypertrophy (predominantly by nuclear addition) and
atrophy (because of an opposing deficit in nuclear supplementation) but their
activity status has not been not routinely addressed in such studies.
In chapter 3, we examined satellite cell specific signalling events in
hypertrophic muscle induced by chronic administration and an anabolic agent 
the clenbuterol pro-drug BRL-47262. Eight weeks of daily administration of
the drug caused statistically significantly (p<0.05) increases in the mRNA
expression of key satellite cell markers pax7 and myoD, accompanied by a
tendential increase in protein expression relative to control animals. There was
also a significant increase (p<0.05) in myostatin mRNA and protein
expression. The mRNA expression of the proliferation marker, ki-67 was also
increased compared to control. No significant alterations in the expression of
myogenin or the myostatin inhibitor follistatin were noted.
Taken together, these results provide evidence for increased satellite cell
activity in hypertrophying muscle. Maintaining increased levels of pax7 and
myoD is compatible with continuous activation/proliferation of satellite cells in
a state of preparedness for subsequent recruitment into myofibres to maintain
nuclear domain size and allow fibre hypertrophy. We interpret the induction of
myostatin, with its inhibitory activity towards satellite cell activation, as an
antagonistic action in a balanced system which enables increased precision in
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the control of myonuclear and satellite cell numbers. Similar roles have
recently been attributed to microRNAs, which are thought to level out
fluctuations in mRNA transcription (reviewed by Ebert and Sharp 2012). We
hypothesised that chronic administration of the pro-drug lead to the stimulation
of compensatory pathways, which may include myostatin, and were likely
concomitant with a levelling out of muscle growth. Intermittent pro-drug
administration coupled with myostatin suppression (e.g., via neutralising
antibody) may represent an effective method for preventing or reversing
muscle atrophy.
Chapter 4 described the gene expression profiles of satellite cell specific
markers in an animal model of sepsis. Muscles from animals continuously
infused with the bacterial toxin lipopolysaccharide demonstrate a propensity
for muscle wasting due to dysregulation of their protein synthesis/degradation
balance and derangements in carbohydrate oxidation and insulin resistance
(reviewed in chapter 4, section 4.2). It is thought early events, such as a
massive elevation in mediators of systemic inflammation may lead to the
induction of cachetic muscle wasting during sepsis. We measured the
mRNA/protein expression patterns of key cytokine markers implicated in
sepsis and components of the satellite cell myogenic program at three sampling
points during the first 24 hours of endotoxaemia.
Continuous LPS infusion caused significant, transient elevations in TNF-D, IL-
6 and NF-NB in the EDL and gastrocnemius muscles, with the most dramatic
magnitude of change occurring after 2 hours, an effect which was attenuated by
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24 hours. Excessive cytokine expression was attributed to increase macrophage
infiltration in the two muscles analysed and TNF-D protein expression was
localised to the macrophage infiltrate. LPS-induced up-regulation of
inflammatory cytokines demonstrated a time and dose-dependent effect on
myogenic markers. Pax7 and myoD mRNA were suppressed by continuous
LPS infusion in both muscles, with the protein expression showing a similar
trend. Furthermore, quantitative immunohistochemical analyses of pax7
+
and
myoD
+
satellite cells showed an apparent reduction in number of quiescent and
activated satellite cells. Activated myoD
+
satellite cells were suppressed at all
time points whilst pax7
+
satellite cells showed a tendency to a return to basal
levels. It is unknown whether the decrease in satellite cell numbers was a result
of apoptosis or a down-regulation of both markers. Accordingly, myostatin was
up-regulated at the early sampling time point, when cytokine expression was
highest and showed a reduction in expression after 24 hours. It is likely that
early up-regulation of myostatin on may have been responsible for pax7 and
myoD suppression.
Taken together, these findings suggested that LPS induced transient elevations
in inflammatory cytokines, which altered the satellite cell myogenic program.
Although some markers (notably pax7) showed a tendency of returning to
basal expression relative to control, others (e.g., myoD) remained suppressed
throughout all sampling points and it will be interesting to discover what the
consequences (if any) are of chronic LPS-mediated suppression of satellite
cells. Given the proposed role of satellite cells in muscle homeostasis, it is
tempting to speculate their continuous impairment should have consequences
for long-term muscle maintenance.
224
In chapter 5, we examined the effect of continuous infusion of an anti-
inflammatory agent, dexamethasone, independently and 1 hour before and
during LPS infusion to determine whether suppression of LPS-induced
inflammatory cytokines would counter myogenic suppression. Co-infusion of
dexamethasone blunted cytokine elevation but had an additive effect on
myogenic suppression and did not improve LPS-induced suppression of pax7
or myoD. Since (modest) inflammatory signalling via cytokines such as TNF-
D, IL-6 and NF-NB is beneficial for muscle regeneration under normal
physiological conditions, it seems pertinent that the suppression of these
factors could impact on satellite cell myogenesis. This was evident by the
additive inhibition of pax7 and myoD when LPS and dexamethasone were co-
administered.
6.2 CONCLUSIONS
Taken together, the studies described within this thesis emphasise satellites are
important for maintenance of muscle homeostasis and their activation /
inhibition may determine the magnitude of muscle loss or gain. This was
demonstrated by the pattern of pax7 and myoD expression in hypertrophying
muscle, where both markers were up-regulated and in atrophying muscle,
where they were down-regulated. We believe the down-regulation of these
markers in atrophy could have implications for muscle regenerative capacity,
especially myoD, whose expression was continuously inhibited across all time-
points sampled in septic muscles. Future studies should be directed at
examining the effects of chronic infusion of LPS (longer than just 24 hours) to
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determine if markers like myoD do stay suppressed. Recent studies by several
groups show that pax7 and myoD are essential for satellite cell function and
their continuous inhibition introduces aberrant behaviour in satellite cells,
ultimately contributing to a muscle regenerative deficit (reviewed by Mansouri
et al. 1996; Sabourin et al. 1999; Cornelison et al. 2000; Seale et al. 2000). For
example, loss of myoD by genetic ablation delays muscle regeneration and
myoblasts lacking myoD fail to fuse (Knapp et al. 2006). Similarly, loss of
pax7 reduces the number of functioning satellite cells in adult muscle (Kuang
et al. 2006), which displayed reduced growth and marked muscle wasting
coupled with a regenerative deficit following muscle injury.
In summary, satellite cells are a major source of compensatory action in
skeletal muscle, their activation and subsequent myogenesis represents an
auxiliary mechanism by which muscle responds to damaging stimuli; therefore
their dysregulation (through the alteration of key myogenic markers or
increased apoptosis) results in an alteration in normal function. A recent
publication by Bruusgaard et al. (2010) highlighted this link between satellite
cells and hypertrophy quite well, using an in vivo time-course analysis, they
showed that increased number of myonuclei is a major cause of hypertrophy in
rodents. New myonuclei were added before any discernable increase in muscle
fibre size during muscle overload. However, the authors also challenged the
concept of fixed nuclear domain sizes, which theorises that the increase in
muscle size is due to satellite cell related nuclear addition and the selective
apoptosis of some myonuclei during atrophy/disuse. The authors observed that
newly acquired myonuclei were retained during subsequent denervation-
induced muscle atrophy and for a considerable period thereafter. This
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protection of some myonuclei from apoptosis could be beneficial for
sarcopenia; strength training at an earlier age could improve myonuclear
retention since the ability to create new myonuclei in the elderly is impaired.
However, it is possible that dysregulation of satellite cells limits the efficacy of
muscle compensatory processes (i.e. satellite cell activation/proliferative or
differentiation potential), thereby contributing to the progression of muscle
atrophy and myopathy. Failure of satellite cell compensatory action is more
prominent in cases of progressive muscle diseases and in old age. It is thought
that alteration of the anti-oxidative potential of satellite cells, as a result of
increased reactive oxygen species (ROS) accumulated over ones lifetime
decreases the regenerative potential of satellite cells in sarcopenia (reviewed by
Fulle et al. 2005). Reduced muscle regenerative capacity, as a result of reduced
number of satellite cells, due to repeated bouts of muscle repair in DMD is also
considered a key factor in determining the severity of the dystrophy phenotype.
In both ageing and DMD, repeated bouts of regeneration, accumulation of
epigenetic mutations in key satellite cell regulatory genes as well as telomere
shortening, lead to loss of satellite cell self-renewal activity and impaired
myogenicity.
6.3 LIMITATIONS AND FUTURE DIRECTIONS
It would be beneficial to our studies to determine whether the increased pax7
and myoD expression relative to control noted in chapter 3 is consistent with
increased numbers of activated/proliferating satellite cells in soleus muscle by
227
quantitative immunohistochemistry. By use of the Duolink
®
proximity ligation
assay, which co-localises complexed protein targets as a single signal
visualised by immuno-microscopy, the proportion of activated/proliferating
(pax7
+
/myoD
+
) satellite cells could be estimated from the total number of
pax7
+
or myoD
+
only cells, thus providing an estimate of the degree of
activation elicited by BRL-47262. Additionally, localisation of the myostatin
mRNA message (for example, by in-situ hybridisation) within the same study
should have provided an interesting avenue of investigation. We tried this
using a modification of the method by Braissant et al. (1996) for in-situ
hybridisation (Tellez 2005; Tellez et al. 2006), using specific probes for
myostatin, but could not get a clearly interpretable signal. The source of the
increased myostatin mRNA expression is unknown, it is undetermined if its
expression was global or localised to specific entities, e.g., satellite cells or
myofibres. Our studies were also limited by the lack of a sensitive commercial
antibody for myostatin. None of the antibodies mentioned within this thesis
produced a convincing myostatin signal by immunohistochemistry. Discovery
and optimisation of a suitable antibody should enable localisation of myostatin
protein expression. Myostatin protein is a secreted protein thought to function
in an autocrine/paracrine manner and it would be beneficial to clarify the
predominant source of myostatin synthesis.
In chapter 4, we observed a decrease in the number of pax7
+
and myoD
+
cells
in LPS samples compared to control. This could have been as a result of
increased satellite cell apoptosis or of significant down-regulation of pax7 and
myoD, below the limit of detection by immunohistochemistry. The
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incorporation of a TUNEL (terminal deoxynucleotidyl transferase dUTP nick
end labelling) assay, along with measurements for markers of apoptosis (e.g.
caspase-3) should clarify whether LPS indeed led to sudden and frequent
apoptosis of satellite cells.
LPS is known to induce apoptosis of myonuclei in rat skeletal muscle (Gierer
et al. 2007) and in rat cardiomyocytes via TNF-D-mediated mechanisms
(Comstock et al. 1998). However, a frequent finding in studies indicating
muscle nuclei loss from atrophy is the lack of distinction between TUNEL-
positive myonuclei and TUNEL-positive satellite cells (reviewed by Gundersen
and Bruusgaard 2008). Using a flipped sectioning technique (described in the
appendix), which identifies the same cells spanning across the plane of a series
of muscle cross-sections; with roughly one half being in each section, should
identify TUNEL-positive nuclei on one section, whilst utilising the adjacent
section to identify the other half of these cells using satellite cell specific
markers. This should provide an estimate of the proportion of satellite cells
undergoing apoptosis.
In chapter 5, dexamethasone infusion was found to suppress pax7, myoD and
myogenin expression relative to control. It would enhance our findings to
correlate the suppression of these markers with a decrease in the number of
pax7
+
, myoD
+
or myogenin
+
satellite cells in these muscles by quantitative
immunocytochemistry. Unfortunately, muscle samples were shared with group
colleagues interested in muscle metabolic derangements and the small nature of
the rat EDL muscle meant there were insufficient muscle samples available for
cryo-sectioning.
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In both chapters 4 and 5, the inflammatory cytokines TNF-D, IL-6 and NF-NB
were implicated in satellite cell impairment; however the exact contribution of
them was not examined. The interactions between cytokines and the signalling
pathways they regulate paint a very complex picture. With all three cytokines
measured reported to contribute to the aetiology of muscle wasting, it would
enhance our studies further to outline the specific roles attributed to each, for
e.g. via use of cytokine inhibitors or continuous infusion of specific cytokines
to measure and compare LPS-mediated and specific cytokine-mediated
responses.
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METHOD DEVELOPMENT APPENDICES
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APPENDIX I
Myostatin Antibody Validation
232
1. Rationale
Some discrepancies still exist regarding the precise molecular weight of the full
length myostatin protein and its processed forms (Mendler et al. 2000; Matsakas
et al. 2006; Smith et al. 2011). The consensus from the literature is that the most
prominent myostatin bands detected by western blotting migrate at ~52-55kDa
(often referred to as myostatin precursor or pro-myostatin), at ~40kDa (referred
to as LAP myostatin), at ~26kDa (deemed to be a myostatin dimer) and at
~12.5kDa (which is the fully processed, mature myostatin peptide). However
some authors have also reported bands varying between ~15kDa and ~42kDa,
using either in-house or commercial antibodies.
Therefore, we carried out a series of preliminary western blotting experiments to
determine the specificity of three commercially available antibodies for the
various reported forms of myostatin protein; rabbit anti-GDF8 (A300-401A,
Bethly Labs, Montgomery, TX, USA), rabbit anti-myostatin near c-terminus
(Ab3239, Millipore, Billerica, MA, USA) and goat anti-GDF8 C-20 (sc-6884,
Santa Cruz Biotechnology CA, USA). These antibodies have been shown to
detect the 12.5kDa fully processed monomeric myostatin peptide (Rios et al.
2004; Bish et al. 2010), the ~26kDa immuno-reactive myostatin band, suspected
to represent a myostatin homodimer (Gonzalez-Cadavid et al. 1998; Sakuma et
al. 2000; Hittel et al. 2010), the ~40kDa LAP (McFarlane et al. 2005) and the
~55kDa myostatin protein precursor (Taylor et al. 2001; Wojcik et al. 2005;
Chandraskeharan and Martin 2009). All three antibodies were raised against an
epitope specific for the C-terminal portion of myostatin, which forms part of the
mature fully processed form and the precursor proteins, and thus all antibodies
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should be able to detect the unprocessed precursor, myostatin intermediates and
the mature peptide.
2. Methods
Anti-myostatin near c-terminus (diluted 1:250 in 5% (w/v) non-fat milk powder
in TBS-T), rabbit anti-GDF-8 (1:400 in 5% (w/v) non-fat milk powder in TBS-
T) and goat anti-GDF-8 sc-6884 (diluted 1:500 in 5% BSA-TBS) were used as
described in chapter 3, section 3.3.3. 100Pg of cytosolic and nuclear muscle
proteins from untreated adult male Wistar rats were loaded per lane. A
recombinant myostatin peptide (100ng/Pl, R & D System, Mineapolis, USA),
which contains a mixture of pro-peptide and active fragments was used as a
positive control.
2.1 Myostatin competitive blocking studies
Antibody specificity was also assessed by pre-incubating with a blocking
peptide (GDF-8 blocking peptide, Bethyl Labs) according to the manufacturers
instructions. Briefly, the amount of antibody (by weight) ordinarily required for
western bloting was mixed with a 5-fold (by weight) excess of blocking peptide
to a total volume of 500Pl with 5% non-fat milk in TBS-T blocker. Antibody
stock was 1Pg/Pl, thus 25Pg of blocking peptide was added to 5Pg of antibody.
Studies by Gonzalez-Cadavid (1998) showed that 7ng/Pl of blocking peptide
was sufficient to block myostatin antibody activity by immunohistochemistry.
Solutions were incubated for 2hr at room temperature, made up to 2ml with milk
blocker and western blotting was carried out, as above.
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2.2 Minimum myostatin protein concentration for western blotting
To determine the minimum concentration of myostatin that can be detected by
western blotting, serial dilutions of a recombinant myostatin peptide (R & D
System, Mineapolis, USA) were prepared in reconstitution buffer (4mM HCl
containing 0.3% (w/v) BSA) and were loaded onto 5-20% SDS-PAGE, as
described above. Untreated adult muscle homogenate (50Pg) from male Wistar
rats was used as a positive control. All three anti-myostatin antibodieswere
tested to determine their specificity for recombinant myostatin; rabbit anti-GDF-
8(1:400, Bethyl Labs, Montgomery, TX, USA) and goat anti-GDF-8 sc-6884
(diluted 1:400 in 5% BSA-TBS, Santa Cruz Biotechnology, CA, USA).
3. Observations and conclusions
All three antibodies detected the 12.5kDa mature recombinant myostatin peptide
positive control and a ~26kDa immunoreactive myostatin protein band (figure
1). The Santa Cruz antibody appears to be less specific as it bound to several
other species in the muscle samples in three separate experiments. The natures of
these bands are unknown. This antibody also bound to a <75kDa band that was
not recognised by the other two; the nature of this band is also unknown
although it is tempting to speculate it is the BSA in the reconstitution buffer. It is
possible the Santa Cruz antibody may not recognise any myostatin; the fact that
the soleus sample in figure 1 contains a more intense protein band about 26kDa
by Ponceau staining, which is replicated in the Santa Cruz blot, indicates this
antibody may bind to proteins non-specifically. In addition, using Duolink
®
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Figure .1: Myostatin antibody validation by western blotting. The specificity of three commercially available antibodies was tested using muscle homogenate from
untreated adult male Wistar rats. Top: Ponceau stain to confirm protein transfer and equal loading, Bottom: Immunoblots (A-Bethyl D-GDF8, B-Santa Cruz D-GDF8, C-
Millipore D-myostatin near C-terminus). Loading order:M-marker, 1-Recombinant myostatin peptide (100ng/Pl), 2-EDL cytosolic fraction, 3-Gastrocnemius cytosolic, 4-
Soleus cytosolic, 5-EDL nuclear fraction, 6-Gastrocnemius nuclear, 7-Soleus nuclear (all at 100Pg total protein). Blots A+C were exposed to hyperfilm for 5minutes
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PLA, which increases the specificity of immuno-detection by using two targeted
secondary antibodies (see chapter 2, section 2.2.6.3), no bands were detected in
that region. We deemed this non-specificity sufficient to eliminate this antibody
from further study.
The specificity of the remaining two antibodies was further tested by incubating
with an excess of blocking peptide containing portions of the myostatin c-
terminal. The blocking peptide completely eliminated the Millipore antibodys
ability to recognise any of the myostatin species after long exposure to hyperfilm
(>10 minutes), which is usually sufficient to pick up any rare species of
myostatin that are on the brink of detection via western blotting (figure 2).
Interestingly, the longer exposure of the control blot to film revealed some rare
species of myostatin in the recombinant peptide mix. These are bands of
~17kDa, ~19kDa and ~25kDa previously reported by Lalani et al. (2000),
Mendler et al. (2000) and Baumann et al. (2003), respectively. These bands are
thought to be rare in skeletal muscle homogenate (Lalani et al. 2000) and could
represent differentially glycosylated forms of myostatin that are of low
abundance, detectable after long exposure to hyperfilm (Gonzalez-Cadavid et al.
1998; Rios et al. 2004).
The activity of the Bethyl antibody was not completely eliminated by its
blocking peptide; the ~40kDa LAP myostatin peptide seen in the control blot
could still be detected. It is possible the Bethyl antibody requires a higher
concentration of blocking peptide to completely inhibit its activity. In summary,
although the blocking peptide eliminated both antibodies affinity for the
recombinant mature myostatin peptide, the Bethyl antibody was more resistant
to inhibition by its blocking peptide. Thus we surmised that the Millipore
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Figure 2: Assessment of Myostatin antibody specificity by competitive
blocking and western blotting. The specificity of two commercially available
antibodies was tested using muscle homogenate from untreated adult male
Wistar rats. Top: Ponceau stain to confirm protein transfer and equal loading,
Bottom: Immunoblots (A-Control (No blocking): Millipore D-myostatin, B-
Millipore D-myostatin , C-Bethyl D-myostatin). Loading order:M-marker, 1-
Recombinant myostatin peptide (100ng/Pl), 1-EDL cytosolic fraction, 2-
Gastrocnemius cytosolic, 3- Recombinant myostatin peptide (100ng/Pl), 4-
Recombinant myostatin peptide (1ng/Pl). All blots were exposed to hyperfilm
for 10 minutes to enable detection of any protein bands resulting from inefficient
antibody blocking.
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antibody was more specific and was therefore used to quantify myostatin protein
expression in control and treated tissues in our studies (see chapters 3-5).
Some authors such as Wehling et al. (2000) have observed a 2kDa difference in
myostatin protein in two different types of muscles within the same animal. To
rule out such a possibility, we ran a high concentration of total protein (200Pg)
of cytosolic and nuclear protein fractions from four different skeletal muscles to
verify the nature of all the myostatin bands that could be detected using the
Millipore antibody (figure 3). Since myostatin protein expression is measured in
other muscle types elsewhere in this thesis, it was essential to verify the presence
of unprocessed and processed forms within these tissues and rule out any
discrepancies regarding molecular size. Three prominent forms of myostatin
were detected; pro-myostatin (~55kDa), LAP (~40kDa) and the myostatin dimer
(~26kDa), the latter of which was the only species detected in the nuclear
fraction. The mature monomeric form was not detected, which confirms reports
that active myostatin predominantly exist in its dimeric form in normal adult
skeletal muscle. This form of myostatin seemed resistant to the extreme
denaturing and reducing conditions used by us (8M Urea) and Gonzalez-
Cadavid et al. (1998) and Lalani et al. (2000), where up to 6M Urea was used.
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Figure 3: Myostatin protein detected in cytosolic and nuclear fractions of
untreated adult male Wistar rat muscles by western blotting. 200Pg of
protein sample was loaded per lane in the following order: 1- EDL, 2-
Gastrocnemius, 3- Soleus, and 4- Tibilais Anterior. (A) Ponceau.stain to
confirm protein transfer. (B) Immunoblot of protein bands present in untreated
adult skeletal muscle extracts. Blot was exposed to hyperfilm for 1 minute and
developed.
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APPENDIX II
Estimating satellite cell size in situ
241
1. Summary
Satellite cell nuclei are between 8 and 12Pm long in human and rat muscle.
Based on the observation that theyre often cut in half on muscle cryos-
sections, we reasoned that identifying those cells that are in the cutting plane of
two adjacent sections would provide a means of running multiple analysis on
the same cell without compromising the cell activation status. In order to be
able to use this approach on a series of frozen cross-sections, one needs to
establish the proportion of satellite cells that span the cutting plane between a
given pair of sections.
Consecutive muscle cross-section pairs were cryo-sectioned, of which the
second one was flipped to expose the same cutting surface between the two
sections. They were stained using well established satellite cell markers (pax7
or CD56) and imaged. The images of the second (flipped) section were then
flipped back in silico, which allowed identification of those nuclei that spanned
across the two sections to be counted by light microscopy.
In 8 Pm thick sections of rat muscles, approximately 24% of pax7+ satellite
cells were identified by position across two consecutive cross-sections. Pax7 is
a nuclear antigen, staining with a membrane antigen (CD56/NCAM, a cell-cell
recognition glycoprotein) yielded a higher percentage of matched cells across
both sections (~36%).
From our observations of the frequency of the same satellite cell spanning the
cutting plane of two consecutive cross sections, we devised a mathematical
model, which enabled an estimate of the in-situ satellite cell size, if the
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proportion of satellite cells spanning the cutting plane is known. This could, for
example, enable estimation of satellite cell activity status (based on size),
following exercise, or in pathological conditions such as DMD or polymyositis,
where satellite cell alterations have been reported.
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2. Background
As briefly reviewed in Chapter 1, satellite cells are a rare population of
progenitor cells in adult skeletal muscle constituting approximately 2-7% of
total muscle nuclei within adult muscle (Allbrook et al. 1971; Schultz 1974;
Schmalbruch and Hellhammer 1976; Halevy et al. 2004). The behaviour of
satellite cells in vivo is poorly understood; it appears that disturbances to the
basal lamina (e.g., from exercise-induced myotrauma), activates satellite cells.
They subsequently migrate to the source of disturbance using tissue bridges
(Watt et al. 1987) and participate in repair process, which may include nuclear
supplementation or secretion of MRFs.
The close association between satellite cells and the basal lamina creates a
sense of immediacy between satellite cells and their associated myofibres. This
enables satellite cells to function as sensors for muscle mechanical or structural
damage. Thus, studying satellite cell activity in vivo is quite difficult; isolation
of satellite cells disrupts muscle structural integrity, often resulting in
activation and alteration of gene expression. As a result, the gene expression
profiles of quiescent satellite cells have remained, largely unknown. Therefore,
defining the molecular events/mechanisms regulating satellite cell quiescence,
under normal physiological conditions and those regulating activation under
pathological conditions in vivo remains a challenge.
Ultra-structural and immunohistochemical techniques are useful for satellite
cell identification, assessing distribution and activity status. However,
immunohistochemical approaches are limited by the discovery of satellite cell
specific markers and the availability of antibodies. Furthermore, interpretation
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of satellite cell specific signalling events derived from crushed muscle extract
is made more difficult, since satellite cells represent a relatively small fraction
of total tissue volume. With this in mind we sought to explore an alternative
method to identify satellite cells in their native environment in the muscle that
does not compromise activation status.
Based on the observation that satellite cells are often cut in half in muscle cryo-
sections, we reasoned that flipping the second of two adjacent cross-sections,
will expose the same cutting surface, and enable the identification of those
satellite cells within the cutting plane of two consecutive sections by position
(summarised in figure 1), after optically re-flipping images of the second
section, such that images of both sections are super-imposable. Thus, satellite
cells on one section can be identified by immunohistochemistry using well
established satellite cell markers (e.g., pax7 or CD56), whilst utilising the
second section as a template. The second section could also be used to
determine satellite cell biomarkers with techniques that may be incompatible
with the first section. For example, a Duolink
®
PLA assay for rabbit and mouse
primary antibodies (as described in chapter 2, section 2.2.6.3), or in-situ
hybridisation, which requires uncompromised RNA. Another approach could
identify satellite cells on the first sections and use the adjacent sections to
enrich for satellite cells via laser capture micro-dissection. Theoretically, this
should allow multiple molecular analyses to be conducted on the same satellite
cell, without compromising its native state. However there is a need to
establish the numbers of satellite cells that span the cutting plane of a given
pair of sections, i.e., the number of satellite cells that can be identified, using
specific markers on both sections.
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Fig. 1: Schematic representation of Method. Two consecutive 8-10Pm muscle sections are cut on the cryostat. The second section is flipped to
reveal the same cutting surface as the first. This exposes cut satellite cells for immunohistochemical analysis on the first section and allows the
second section to be used as a template for other investigations.
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3. Methods
Soleus and TA muscles were obtained from sedentary young female Spraque-
Dawley rats (200-250g). Human muscle samples were obtained post-mortem,
from the vastus lateralis muscle of a healthy fit 24year old male. Tissue
samples were directly frozen in isopentane cooled by liquid nitrogen, then
stored at -80ͼC for later analysis.
Frozen 8-10Pm serial or flipped sections were cut in a cryostat (C1900
microtome, Leica Microsystems, Wetzler, Germany) at -25°C (chamber
temperature) and -17ͼC (chuck temperature). Sections were mounted onto
Superfrost® Plus slides (Thermo Fisher, Loughborough, UK) and fixed in 4%
Paraformaldehyde (PFA/PBS: 4% (w/v) PFA, 137mM NaCl, 2.7mM KCl,
4.3mM KH2PO4 5mM MgCl2pH 7.4) for 3 minutes. Sections were washed in
tris-buffered saline (TBS; 0.05M Tris, 0.15M NaCl, pH 7.4) for 3 x 5minutes
and blocked with 5% normal horse serum (Vector Laboratories, Burligame,
CA, USA). Sections were incubated in primary antibody for 1-2hr at either
room temperature (anti-pax7 monoclonal antibody 1:20  Developmental
Studies Hybridoma Bank, Iowa, USA) or at 37°C (anti-CD56 monoclonal
antibody 1:30  BD Biosciences, NJ, USA). Control sections were incubated in
blocker only.
Primary antibodies were visualised with Vectastain
®
anti-mouse kit
(biotinylated anti-mouse IgG secondary antibodies 1:300, ABC reagent and
DAB substrate kit for peroxidise  Vector Labs). Rat muscle sections were
incubated with a rat adsorbed secondary antibody (Vector Labs) to improve
signal-to-noise ratio. Optimal antibody dilutions were determined in
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preliminary optimisation experiments and DAB staining was controlled
visually (minimum, 2 min and maximum, 5 min). Slides were immediately
rinsed in double distilled water for at least 5 minutes to stop the reaction, air
dried and mounted in glycerol gelatine (Merck, Darmstadt, Germany) for
microscopy. Satellite cells were counted with light microscopy and images
acquired using a Micropublisher 3.3 RTV digital camera (Q-Imaging, British
Columbia, Canada) attached to a Leica DM4000B light microscope.
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4. Results
To determine the incidence of a cut satellite cell spanning across two 8Pm
sections of a pair, adjacent/flipped cross-sections from rat soleus and tibialis
anterior muscles were stained with pax7. Section 1 and section 2 (the flipped
section) were stained with anti-pax7 antibody only. For human vastus lateralis
muscle, 10Pm adjacent cross-sections were stained with anti-CD56 only, or
pax7 and CD56; i.e. section 1 was stained against pax7 and section 2 against
CD56 (see examples in figure 2). CD56, also known as neural cell adhesion
molecule (NCAM) is a cell surface glycoprotein involved in cell-cell
interaction (Schubert et al. 1989). It is expressed in quiescent and activated
satellite cells and has been used in a number of human studies to identify and
quantify satellite cells (Kadi et al. 2004; Mackey et al. 2007; O'Reilly et al.
2008; Mackey et al. 2009).
The number of pax7
+
/pax7
+
and pax7
+
/CD56
+
satellite cells identified in the
same position across both sections, were counted and expressed as a percentage
of the total number of satellite cells identified on both sections (% match). The
percentages of matched cells on different muscles, using either one or a
combination of both antibodies are presented in figure 3. The numbers of
satellite cells matched on adjacently paired sections stained with CD56 only
were slightly higher than those stained with CD56/Pax7 or pax7 only.
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Figure 2A: Photomicrograph showing CD56
+
satellite cells identified on
adjacent cross-sections of human vastus lateralis muscle. One section (panel
A) was flipped to reveal the same cutting surface as the adjacent sections and
both stained against CD56. The photomicrographs are mirror images of each
other. Arrows indicate those cells that are CD56
+
, with the white ones showing
those cut cells present on both sections.
Fig 2B: Pax7
+
and NCAM
+
satellite cells identified on adjacent cross-
sections of human vastus lateralis muscle. Panel A represents the flipped
section, stained against CD56 whilst panel B shows the un-flipped section,
which was stained against Pax7
+
. Both images mirror each other and are
representative of the entire section. The arrows show those cells that were
positive for either antigen in the respective sections; the red arrows show only
those cells that are positive on both
A B
A B
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Figure 3: Average % match of satellite cells at the cutting surface of
adjacent cross sections of rat and human muscle. Values are means and
vertical bars represent S.E.M (n=5). Comparisons between Pax/Pax, Pax/CD56
and CD56/CD56 by 1-way ANOVA: p=0.04. Rat muscles: Tibialis Anterior
(TA), Soleus (SOL). Human: Vastus Lateralis (VA).
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5. Discussion
From observations of the frequency of cut satellite cells spanning across a pair
of adjacent cross-sections and published information on satellite cell length
(Muir et al. 1965; Tome and Fardeau 1986), we devised a mathematical model,
to estimate the expected proportion of matched cells given the length of a
satellite cell and section thickness (figure 4). The model is consistent with the
hypothesis that the proportion of matched cells increases with thinner sections
and decreases with thicker sections (see figure 5). The larger the satellite cell,
the greater the incidence of it spanning the cutting plane.
Given an average satellite cell length of 8Pm on 10Pm thick sections: using P =
a / (2a + 2b) x 100, as shown in figure 3, the theoretical proportion of matched
cells expected would be ~22%. Using the same satellite cell length to calculate
the proportion of matched cells on 5Pm thick sections estimates a 30% match,
compared to a 10Pm section. It appears the hypothesis that the larger the cell or
thinner the section, the larger the percentage match, is only valid to a certain
extent. This is demonstrated in figure 4; doubling the theoretical satellite cell
length or halving the section thickness does not double the percentage match.
Electron microscopy studies on normal, disease-free human and rat muscles
have reported the average length of a satellite cell nuclei varies between 8 and
12Pm (Schmalbruch 1977; Snow 1977b; Snow 1977a; Watkins and Cullen
1988). Using the model and the formula presented in figure 3, the average
length of satellite cells in a cross section can be estimated, when the percentage
match is known. Reversing the formula should enable estimation of satellite
cell length, given:
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Figure 4: Schematic diagram of theoretical limitations of the method. The red line depicts the cutting surface with a pair of 8Pm sections of interest on
either side, one of which is flipped. Assuming a linear distribution of satellite cells in a block of muscle, the proportion of satellite cells spanning across both
sections can be estimated using a formula. Based on this model, the theoretical % of identified satellite cells spanning across both sections, P, can be
estimated, given a cell length of 8Pm and 8Pm sections = 8/[(2x8)+(2x8)] = 25%,this is close to our observation of ~24% in rat soleus and TA muscles. By
reversing the formula to solve for a, the satellite cell length can also be estimated.
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Figure 5: Expected % of satellite cells matched based on theorectical
distribution of satellite cells in a muscle. Using the formula P = a / (2a +2b) x
100, see figure. 3, calculating the theoretical percentage of satellite cells
expected given the thickness of cryostat sections and the average satellite cell
length, shows a decrease with section thickness and vice versa. The trend
favours an increase in % matches with increased satellite cell length.
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the proportion of matched cells. For example given, P ~ 24% on adjacent 8Pm
sections of rat muscle, the average length of a satellite cell,a can be estimated
thus
P= 24/100 = 0.24
a = (P x 2b) / (1-2P)
=> (0.24 x16) / (1-0.48) = 7.4Pm.
This is quite close to published reports of satellite cell nuclear length, which
has been found to vary between 8-12Pm. This model could provide a novel
approach for quantitative study of satellite cell nuclear changes in muscle
disorders, as an alternative to electron microscopy. Pax7 is a nuclear antigen
(Gnocchi et al, 2009); hence positive matches show those satellite cells cut at
the level of the cell nuclei; a lower frequency than using a membrane antigen
such as CD56, which increases the proportion of satellite cell identified
spanning the cutting plane, since the probability identifying cut satellite cell
cytoplasm is greater compared to the nucleus. This explains the higher
proportion of matched cells seen in the CD56-only stained sections. Solving
the formula for a as above, using the average proportion of matched cells on
CD56 only stained sections (~36%) estimates an average length of 22Pm.
This likely explains the modest numbers of pax7 only satellite cells identified
across adjacent cross-sections; since pax7 is confined to the nucleus, in contrast
to the membrane staining of CD56, which stains the longer lamellipodia
satellite cell extensions. In a satellite cell profile tracing study by Mackey et al.
(2009), comparisons between pax7 and CD56 stained satellite cells across
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multiple consecutive 7Pm cross sections, showed the same pax7+ satellite cell
could not be seen in more than two consecutive cross-sections, a depth of
14Pm. This was in contrast to CD56+ satellite cells, which could be traced over
5 consecutive sections, a depth of 35Pm.
Quiescent satellite cells have scant cytoplasm, a high nuclear-to-cytoplasmic
ratio with large amounts of heterochromatin relative to activated satellite cells,
which undergo cytoplasmic expansion due to increased size and number of
organelles (reviewed by Schultz and McCormick 1994). Therefore, the
frequency of satellite cells spanning the cutting plane should improve with
activated satellite cells.
The mathematical analysis presented show results obtained are close to the
theoretical optimum; we sought to identify satellite cells in the cutting plane of
two adjacent muscle cross sections, in order to test the feasibility of developing
a method, which extracts maximum information from a series of cryo-sections,
without compromising satellite cell activation status. In summary,
establishment of the proportion of satellite cells spanning the cutting plane
facilitated the formulation of a mathematical model, which enabled estimation
of satellite cell size, when the proportion of satellite cells on either side of the
cutting plane is known. Estimation of satellite cell nuclear and cytoplasmic
size, using the model revealed in lengths of ~7Pm and ~22Pm, respectively 
similarly to published reports.
Further development of the model could be useful for estimating satellite cell
size in various pathological conditions such as polymyositis, and muscular
dystrophies, where satellite cell nuclear alterations are markers of disease
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severity (reviewed by Tome and Fardeau 1986; Watkins and Cullen 1988; Park
et al. 2009). Using this method, a more complete picture of satellite cell
activity status could be determined; based on the size and gene expression
profile (using established markers) of satellite cells from muscle biopsies,
following an exercise regime or drug intervention for example. Future work
aimed at developing this method further should compare pax7/pax7 and
CD56/CD56 results in the same species (since the CD56 antibody used here
was specific for human NCAM). It would also be useful to determine the
proportion of that could be identified on the adjacent section when a non-
specific satellite cell marker is used such as ki-67. Additionally, it would be
beneficial to test the feasibility of the method further, by estimating satellite
cell size in different muscles/species, under different conditions (e.g. atrophy,
hypertrophy, etc).
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